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ABSTRACT
Histidine-rich glycoprotein (HRG) is a relatively abundant plasm a protein 
whose function is unclear, although it has been proposed that HRG may 
regulate processes as diverse as cell adhesion, coagulation and complement 
activation. This thesis will describe studies which indicate an im portant new 
functional role for HRG, namely the regulation of the size of im m une 
complexes (ICs) and their subsequent uptake by monocytes. Prelim inary 
studies prior to my PhD demonstrated that HRG co-purifies with C lq, based 
on enzyme linked im m unosorbent assay (ELISA) results binds to purified 
C lq  and immunoglobulin G (IgG) and can inhibit the formation of insoluble 
ICs. The aim of this thesis was to initially verify these preliminary findings 
and to further examine the functional significance of the interaction of HRG 
with ICs.
Studies outlined in Chapter 3 used the IAsys biosensor to verify that HRG 
interacts w ith C lq  and IgG and established the kinetics of the interaction. 
Kinetic analyses of the HRG-Clq and HRG-IgG interactions revealed two 
distinct binding sites w ith dissociation constants (Kd) K dl 7.8 nM and Kd2 
37.3 nM for C lq, and one binding site with Kd 85 nM for IgG. The IgG and 
C lq  binding regions on HRG were found to be located in the 30 kDa N- 
term inal region of the HRG molecule. The Fab region of IgG is likely to be 
involved in the HRG-IgG interaction since HRG also bound to F(ab')2 
fragm ents w ith an affinity similar to that seen w ith the com plete IgG 
molecule. Interestingly, the binding between HRG and IgG was significantly 
p o ten tia ted  (Kd reduced from 85.0 to 18.9 nM) by the presence of 
physiological concentrations of Zn2+ (20 p.M). Conversely, the presence of 
Z n 2+ weakened the binding of HRG to C lq  (Kd increased from 7.80 to 29.3 
nM). M odulation of these interactions by other divalent metal cations was 
less effective w ith  relative potencies being Zn2+> N i 2+> C u 2 + . An 
exam ination of the effect of native and 30 kDa HRG on the form ation of 
insoluble ICs between ovalbumin and polyclonal rabbit anti-ovalbumin IgG, 
revealed that physiological concentrations of HRG can m arkedly inhibit 
insoluble immune complex (IC) formation in vitro. The results show that 
hum an HRG binds to C lq  and to IgG in a Zn2+-modulated fashion, and that 
HRG can regulate the formation of insoluble ICs in vitro, thus indicating a 
new functional role for HRG in vivo.
Experiments described in Chapter 4 show that changing the heavy chain
xii
isotype and the light chain type of IgG from k to X has a profound effect on 
the kinetics of the interaction of HRG with all IgG subclasses, the latter 
finding possibly providing a functional role for the k and X light chains of 
immunoglobulins (Igs). The binding of HRG to IgG subclasses was also 
modulated by the presence of Zn2+. Interestingly, Zn2+ potentiated the 
binding of HRG to all IgG subclasses possessing k light chain, whereas Zn2+ 
slightly inhibited the binding of HRG to IgG subclasses possessing the X light 
chain. Thus, it was hypothesised that the ability of IgG molecules to interact 
with HRG and, consequently, form soluble versus insoluble ICs is dependent 
on the the IgG isotype and light chain type they express.
Since HRG has the ability to regulate the size of ICs and keeps ICs in a soluble 
form, this raised the intriguing question whether HRG, when incorporated 
in ICs, can regulate the binding of ICs to monocytes. Studies described in 
Chapter 5 of this thesis examined the ability of HRG to regulate the binding of 
monomeric IgG and ICs to monocytes. Initial studies demonstrated that HRG 
blocks the binding of monomeric IgG to the monocytic cell line THP1 but had 
no effect on the binding of ICs to these cells. Interestingly, under certain 
highly defined conditions, incorporation of HRG in IgG containing ICs 
potentiated the binding of ICs to THP1 cells in a Zn2+ dependent manner. 
Based on these observations it was hypothesised that the IgG binding domain 
of HRG can interact with Fc gamma receptor type I (FcyRI) on monocytes and 
block monomeric IgG binding. In contrast, if HRG interacts with monomeric 
IgG or IgG containing ICs the FcyRI binding site on HRG is masked and HRG 
enhances IC binding to monocytes, probably via its heparan sulfate binding 
domain.
Finally, the results described in Chapter 6 show that HRG, when incorporated 
in ICs, blocks the binding of rheumatoid factor (RF) to ICs and inhibits the 
subsequent insolubilisation of ICs by RF. These experiments provide the first 
report that a plasma protein, HRG, can block the binding of RF to ICs. Based 
on these data it is proposed that HRG may control the production of RF and 
the pathogenic effects arising from excessive production of RF in vivo. 
Chapter 6 also provides evidence that HRG can solubilise already formed 
insoluble ICs, a phenomenon which may be important in preventing the 
pathogenic effects of insoluble ICs deposited in tissues. In summary, these 
data imply that the presence of HRG in plasma is necessary for the effective 
clearance of ICs from the circulation in vivo.
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LITERATURE REVIEW
Chapter 1 Literature Review
GENERAL INTRODUCTION
1
A key feature of the adaptive immune response to a pathogen is the secretion of 
pathogen-specific antibodies (Abs) by differentiated B lymphocytes. These 
secreted Abs then bind to their cognate antigens (Ags) to form soluble ICs 
which rapidly can become insolubilised. Under normal conditions, the ICs are 
cleared by the reticuloendothelial system (RES) with their clearance from the 
circulation being largely dependent on Fc receptors (FcR) and complement 
proteins/receptors. Prior to the commencement of my PhD studies, my preliminary 
research suggested that HRG may bind to human IgG and Clq, a result which 
allowed me to hypothesise that HRG may be another endogenous regulator of 
the formation and clearance of ICs. Thus, the aim of this thesis was to 
characterise the interaction of HRG with IgG subclasses and clarify the role of 
HRG in the formation and clearance of ICs, and the solubilisation of already 
formed insoluble ICs. Consequently, as background to the research work 
described in this thesis, Part I of this Chapter will describe general features and 
properties of HRG and Part II will address issues related to the insolubilisation 
and clearance of ICs and pathological conditions associated with the 
inappropriate deposition of ICs in tissues.
1.1 PART I HISTIDINE-RICH GLYCOPROTEIN
1.1.1 Introduction
HRG is a protein found in the plasma of many vertebrate species including 
human, cow, chicken, rabbit and mouse. HRG is synthesised by the liver at a 
relatively high rate, with the concentration of HRG in plasma being relatively 
high (~2 (iM), suggesting that the protein could play important functional roles. 
Although a number of biological properties have been reported, namely 
binding to divalent metal ions (Morgan, 1978,1981,1985), heparin (Heimburger 
et al., 1972), heparan sulfate (Brown and Parish, 1994), thrombospondin (TSP) 
(Leung et al., 1984), fibrinogen (FBG) (Leung, 1986), and certain complement 
proteins (Chang et al., 1992a), hitherto the precise physiological function(s) of 
HRG remain to be determined. The aim of this review is to summarise recent 
findings on the structure, biological properties and clinical significance of HRG, 
and to highlight issues that appear crucial for a better understanding of the 
mechanisms by which HRG can regulate blood clotting and immune function.
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1.1.2 Structure and biological properties of HRG
1.1.2.1 Structure of HRG
HRG, also known as histidine-proline-rich glycoprotein (HPRG), is a ~ 75 kDa 
plasma glycoprotein which was first discovered and isolated from human 
serum as a ~ 60 kDa a2-glycoprotein by Heimburger et al in 1972. Native 
human HRG has since been shown to be a glycoprotein which migrates at ~ 75- 
77 kDa on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS- 
PAGE) gels (Rylatt et al., 1981). Evidence suggests that in humans the majority 
of HRG is synthesised by parenchymal cells of the liver for release into the 
blood stream (Koide et al., 1986; Corrigan et al., 1990; Hertnis et al., 1991). This 
is also supported by the fact that patients with liver insufficiency show reduced 
levels of HRG (Saito et al., 1982). A small proportion of plasma HRG (0.14 %) 
has been shown to exist on the surface of platelets (Leung et al., 1983). It also 
has been suggested that HRG is present in the a-granules of platelets and is 
released following thrombin stimulation (Leung et al., 1983). However, both 
plasma and platelet HRG have been shown to react with Abs specific for human 
HRG indicating that the HRG from these two sources is immunochemically 
identical (Leung et al., 1983). Using anti-HRG Abs, HRG also was detected in 
human megakaryocytes isolated from normal marrow tissue (Leung et al., 
1983). In mice, evidence also suggests that HRG may be produced by 
monocytes and macrophages (Sia et al., 1982). Blood clearance studies indicate 
that HRG in human plasma has a half life of approximately three days, thereby 
suggesting a rapid turn over of HRG in vivo (Lijnen et al, 1981a).
The primary structure of human HRG, as determined from the nucleotide 
sequence of its complementary DNA (cDNA), shows that HRG consists of 507 
amino acids. Studies using circular dichroism, limited proteolysis, amino acid 
sequencing and cDNA sequencing have revealed that human HRG consists of a 
N-terminal region containing two cystatin-like domains (N1 and N2), a C- 
terminal domain and a histidine-proline-rich (HPR) domain (Figure 1.1 A). The 
HPR domain contains a central histidine-rich region (HRR) which contains 12 
tandem repeats of the 5 amino acid sequence Gly-His-His-Pro-His sandwiched 
between two proline-rich regions (PRR) (Koide et al., 1986). Histidines (His) are 
highly concentrated in the HRR (between residues 330 and 389), but proline 
(Pro) residues are more widely distributed with many being concentrated 
before and after the HRR. The high level of histidines in the HRR is most likely 
responsible for the highly hydrophilic nature of both the HRR, and native HRG
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FIGURE 1.1 Gene and structure of HRG
The structure of native hum an HRG is depicted in (A). HRG is comprised 
of three dom ains namely the N1 and N2 amino-terminal domains, the 
HPR dom ain (binds heparin  and heparan sulfates) which contains a 
central HRR and flanking PRR, and a C -term inal dom ain (binds 
plasm inongen and plasmin). Residue 6 of the N1 dom ain is linked to 
residue 497 of the C-terminal dom ain by a disulfide bond. There are 
several disulfide bonds, as indicated, within domains N1 (60-71, 87-108) 
and N2 (199-222) and the PRR (264-294) which may render these domains 
resistant to cleavage by plasmin. The HRR is readily released into the 
su rround ing  m edium  upon cleavage by plasm in or kallikrein. As 
depicted, the N I, N2 and HRR domains contain three, one and two 
a ttached  carbohydrates, respectively. In m ost hum ans, the six 
glycosylation sites are conserved (HRG-1) but a HRG polymorphism exists 
in which, due to Ser 186 being substituted with Pro 186, the glycosylation 
site in domain N2 is lost (HRG-2). Based on rabbit HRG structure, the two 
major plasm in cleavage sites flanking the HRR are indicated. As depicted 
in (B) the hum an HRG gene is composed of eight exon and seven intron. 
In terms of gene structure the first I occurs in the 5' untranslated region 
(B). The leader sequence of HRG (residues -18 to -1) is encoded by the 
second exon, Ex2 - The N1 amino-terminal domain of HRG (residues 1- 
112) is encoded by three exons namely Ex2 , Ex3 and Ex4 , and the N2 
amino-terminal domain (residues 113-229) is also encoded by three exons 
nam ely Exs, Ex6 and Ex7 , whereas the PRRi (residues 255-314), HRR 
(residues 330-389), PRR2 (residues 398-439) and C-term inal dom ains 
(residues 440-507) are all encoded by a single exon, Exs (B).
Aplasmin(ogen) binding site
/ / /\ N \ A tta c h e d  C a r b o h y d r a te
s ----s1 1 D is u lp h id e  B o n d s
P R R P ro lin e-R ich  R eg ion
H R R H istid in e-R ich  R eg ion
N 1 N1 a m in o -term in a l d om ain
N 2 N 2 a m in o -term in a l d om ain
C C -term in a l d o m a in
N1 -
330
HRR
389
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(Kyte and Doolittle, 1982). On the other hand, the presence of prolines may 
form bending and twisting conformations, providing a framework for the 
structure of the HRR of HRG (Figure 1.1A). The unusually high proportion of 
histidines and prolines, each of which exceeds 12% of the total amino acid 
content, is perhaps the most characteristic feature of the HRG sequence. The 
isoelectric point of HRG is approximately 6.45 suggesting that at physiological 
pH HRG is negatively charged.
The human HRG gene spans approximately 11 kb on chromosome 3q28-q29 
and consists of eight exons (Ex) and seven introns (I) (Koide, 1988; Van Den 
Berg et al., 1990; Hennis et al., 1994) (Figure 1.1B). The HRG gene consists of 
2067 nucleotides which includes 121 nucleotides of 5'-noncoding sequence, 54 
nucleotides coding for a leader sequence of 18 amino acids, 1521 nucleotides 
coding for the mature protein of 507 amino acids, a stop codon of TTA , and 352 
nucleotides of 3 -noncodingsequence followed by a polyA-tail of 16nucleotides 
(Koide, 1988). The leader sequence of 18 amino acids in HRG contains a region 
rich in hydrophobic amino acids which is removed by the cleavage of an Ala- 
Val peptide bond by signal peptidase (Blobel et al., 1979) (Figure 1.1A and B). 
The Ii occurs in the 5' untranslated region of the gene and the I2 and I3 are 
present within the N1 amino-terminal domain separating this domain into three 
exons (Ex2, EX3, and EX4). I4 occurs at the boundary between the N1 and N2 
amino-terminal domains. The N2 amino-terminal domain is also encoded for 
by three exons (Exs, Ex6, and EX7) separated by two I, I5 and le. Intron 7 (I7) 
separates the N2 amino-terminal domain from the HPR domain (Figure 1.1B). 
The HPR and C-terminal domains are encoded by exon 8 (Exs) which does not 
contain any I (Hennis et al., 1994) (Figure 1.1B).
Interestingly, the HRR of HRG has considerable homology (~50 %) with the 
HRR of higher molecular weight kininogen (HMWK), suggesting that the HRR 
of HRG and HMWK are evolutionally and functionally related (Koide et al., 
1986; Koide, 1988). Furthermore, apart from the high level of homology in the 
HRR, the amino acid sequence of the N-terminal domain of HRG (between 
residues 30-75) is homologous (~ 43 %) to the amino acid sequence of the N- 
terminal domain of HMWK (between residues 54-98) (Koide et al., 1986; Koide, 
1988). This homology is further strengthened by the demonstration that the 
disulfide bridge arrangement located at the N-terminal region of HRG is similar 
to that observed in cystatins, a family of cysteine proteinase inhibitors. This has 
led to the suggestion that HRG is a member of the cystatin superfamily which 
includes HMWK, a2-HS glycoprotein, and human cystatin C (Sorensen et al.,
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1993). Hitherto, however, no proteinase inhibitory activity has been ascribed to 
HRG.
The secondary structure of HRG has not been completely solved, but 
predictions from the primary sequence show that human HRG may consist of 
8% a-helices, 14% ß-sheets, 46% ß-turns and 32% random coils. The primary 
sequence of HRR suggests that this region only contains ß-turn and random coil 
structures (Koide et al., 1986). Human HRG contains sixteen half-cystine 
residues, and twelve of these are involved in the formation of disulphide 
bridges (see Figure 1.1 A) (Sorensen et al., 1993). As well as providing structural 
links for tertiary structure the six disulphide bridges can keep regions of the 
HRG molecule together after its cleavage by plasmin (see below). HRG has a 
number of potential N-linked glycosylation sites: namely asparagine-45 (Asn- 
45), Asn-69, Asn-107, Asn-326 and Asn-327; these account for some 14 % of the 
molecular mass of HRG being due to carbohydrate (Heimburger et al., 1972) 
(Figure 1.1 A). These characteristics, coupled with its modular architecture, 
suggest that HRG possesses several independent binding sites, perhaps 
allowing it to bind several ligands simultaneously (Borza et al., 1996).
1.1.2.2 Proteolytic cleavage of HRG
Evidence suggesting that HRG can be cleaved by serum proteases like plasmin 
was first obtained by studies showing a lower recovery of native HRG from 
serum, than from plasma (Rylatt et al. 1981). More detailed studies using 
purified components in vitro indicate that native HRG ( ~ 75 kDa) is not cleaved 
by thrombin, but can be cleaved into polypeptides ranging from 9 to 67 kDa by 
treatment with serine (Ser) proteases like plasmin or kallikrein (Smith et al. 
1985). Recent evidence suggests that arginine-295 (Arg-295) and lysine-413 
(Lys-413) in the HPR region of HRG are the sites most susceptible to cleavage 
by plasmin, resulting in the release of the HPR region from the HRG molecule 
(Figure 1.1 A) (Borza et al., 1996). The remaining fragment of HRG (termed the 
N /C fragment) comprises the 30 kDa N-terminal region connected to the C- 
terminal fragment by a buried disulphide bond with the separation of these two 
regions requiring further denaturation and reduction (Borza et al., 1996). While 
the C-terminal fragment of HRG can be readily cleaved into short peptides, the 
cystatin-like disulphide bonds within the 30 kDa N-terminal portion (see above) 
apparently stabilizes this portion making it resistant to further proteolysis by 
plasmin (Figure 1.1 A) (Sorensen et al., 1993).
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Cleavage of HRG by plasmin was demonstrated in vivo following streptokinase 
(SK) or urokinase therapy in patients with venous thrombosis (Smith et aL, 
1985). In these studies no intact HRG could be found 30 minutes after infusion 
of SK but the HRG fragments remained in the circulation (Smith et al., 1985). 
Interestingly, the cleavage of HRG by serum proteases also is reported to be 
inhibited by the pretreatment of the HRG with heparin, in vitro (Smith et al. 
1985). Collectively, these findings suggest that in some patho(physio)logical 
conditions the regulated cleavage of HRG in the circulation may constitute a 
mechanism for regulating HRG's function in vivo.
1.1.2.3 Polymorphisms and levels of HRG in plasma
The existence of two molecular forms of HRG with a molecular weight 
difference of 2 kDa, namely 77 kDa HRG (form 1, HRG-1) and 75 kDa HRG 
(form 2, HRG-2), has been reported (Hennis et al., 1995). DNA sequencing of 
the HRG gene from homozygous HRG-1 and HRG-2 individuals showed five 
different polymorphisms in Ex 4, 5 and 7 with a Pro/Ser polymorphism at 
position 186 in Ex 5 being related to the two HRG isoforms: HRG-1 contains Ser, 
whereas HRG-2 contains Pro (see Figures 1.1 A and B). The presence of Ser-186 
in HRG-1 introduces an additional potential N-glycosylation site (Asn-184) with 
the consensus sequence Asn-X-Ser/Thr. Thus, the observed difference in the 
molecular size of HRG can be accounted for by differences in glycosylation, 
with HRG-1 (77 kDa) being more highly glycosylated than HRG-2 (75 kDa) 
(Hennis et al., 1995).
Evidence suggests that the level of HRG in human plasma can vary from 47 to 
147 percent of the mean HRG level (Morgan et al., 1978; Saito et al., 1982). This 
variation can be accounted for by age (3%), environmental factors (27 %), and 
genetic influences (70% ). The level of HRG in human plasma is age-dependent 
with HRG levels increasing by approximately 0.41 % per year (Drasin and 
Sahud, 1996). Approximately 85% of the genetic variability can be explained by 
the glycosylation differences observed in HRG-1 and HRG-2 (see above). Thus, 
HRG-1 homozygotes have HRG levels 50% higher, whereas HRG-2 
homozygotes have HRG levels 50% lower, than the mean level of HRG. 
Heterozygotes have an intermediate level of the two forms of HRG, and are 
defined as the 100% level of HRG. It is presently unclear whether the 
differently glycosylated forms of HRG differ in their physiological function.
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The remaining 15% of genetic variability has been attributed to other genetic 
differences (Hennis et al., 1995). It has been suggested that blood group-type 
may contribute to this previously unexplained genetic influence, as in healthy 
human subjects the level of HRG is significantly higher (125 %) in subjects 
possessing the AB blood group, than in subjects possessing either the A (103 %) 
or the O (105 %) blood-groups (Drasin and Sahud, 1996).
Furthermore, a family with congenital low levels of HRG (~20 % of normal) has 
been described, genetic analysis revealing that the low levels of HRG in these 
individuals is caused by a single nucleotide substitution (nucleotide guanine- 
429 (G429) to adenine (A) in Ex 3) of the HRG gene (see Figure 1.1B) which 
changes glycine 85 to glutamine in the first cystastin-like domain (termed 
Tokushima-HRG) of the HRG molecule. This substitution was reported to 
cause a change in the conformation of HRG leading to the degradation of the 
mutant HRG within the cell, and allowing only 20 % of the mutant HRG to be 
secreted into the surrounding medium (Shigekiyo et al., 1998).
1.1.2.4 Plasma levels of HRG in various disease states
Although, as outlined above, plasma HRG levels show considerable variation in 
healthy subjects (47 - 147 percent of the mean HRG level) (Morgan et al., 1978; 
Saito et al., 1982), significant differences in serum HRG levels have been 
observed in some conditions. For example, Morgan et al. (1978) first reported 
that serum HRG levels are decreased (~ 2-fold) in the second trimester of 
pregnancy, which is positively correlated with a known decrease in serum 
levels of the complement inhibitory protein Cl-esterase inhibitor (Halbmayer et 
al., 1991, 1992). Moreover, the use of oestrogen, but not progestin, as an oral 
contraceptive results in a decrease in serum HRG levels (Haukkamaa et al., 
1983). It has also been reported that the serum level of HRG is always low at 
birth (20-30 % of adult HRG) (Morgan et al., 1978), and increases steadily with 
age reaching the adult level at approximately 1 year of age (Corrigan et al., 
1990). These findings suggest that plasma HRG levels are regulated by 
hormone- and age-dependent mechanisms in humans.
Interestingly, it has been reported that serum HRG levels are significantly 
decreased (~ 2-fold) in patients with sepsis and liver insufficiency (Lijnen et al., 
1981a) and that the level of HRG in patients with advanced liver cirrhosis (7.0 ± 
2.5 mg/dl) was decreased by 58% when compared to the HRG levels in healthy 
subjects (11.8 ± 2.7 mg/dl). The decreased serum level of HRG in these patients
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was proportional to a previously described decrease in the level of albumin (~ 
56%), antithrombin III (ATIII) (~ 66%) and a2-antiplasmin (~ 60%), but not to 
the change in levels of FBG and plasminogen (PLG), suggesting that the lower 
serum HRG level is due to a decreased synthesis of HRG by the liver (Saito et 
al., 1982) following liver damage. Moreover, studies on patients suffering from 
mild, moderate and severe liver cirrhosis showed no relationship between the 
level of plasma HRG and enhanced fibrinolysis in these patients. However, the 
level of HRG was found to decrease in both moderate and severe liver cirrhosis, 
but to increase in mild liver cirrhosis (Leebeek et al., 1989). These findings are 
consistent with the notion that the majority of HRG is synthesized by the liver 
(Koide et al., 1986).
Plasma levels of HRG are also lower in some immunological disorders and 
following administration of immunosuppressive steroids. For instance, it was 
reported that compared to healthy subjects (12.5 ± 3.0 mg/dl), the mean serum 
levels of HRG were significantly decreased (~ 40% decrease) in patients with 
asthma and chronic obstructive pulmonary disease receiving high-dose 
immunosuppressive steroid regimens (7.6 ± 2.9 mg/dl). The HRG level was 
found to decrease by ~ 55% (5.7 ± 1.8 mg/dl) in patients with acquired immune 
deficiency syndrome (AIDS) and even by -65% (4.4 ± 1.1 mg/dl) in patients 
with end-stage renal disease after transplantation and steroid therapy. 
Collectively, these findings suggest that serum HRG levels are selectively 
decreased in patients with AIDS and those who are treated with 
immunosuppressive steroids (Morgan, 1986). A decrease in serum HRG levels 
in patients with acute inflammation and after surgical operations provides 
additional evidence that HRG plays some role in the immune system (Saigo et 
al., 1990a). In fact, these findings indicate that HRG is a negative acute phase 
reactant and may play an important role in acute inflammation (Saigo et al., 
1990b). Other studies have shown that plasma HRG levels are dramatically 
decreased in patients with systemic lupus erythematosus (SLE) (Castel et al., 
1983) suggesting an involvement of HRG in IC-associated/mediated diseases 
(ICD).
Interestingly, a family with a history of thrombosis possessed congenital high 
plasma levels of HRG (~ 2-3 fold higher than normal) suggesting that a high 
level of HRG may be a factor that leads to thrombotic disorders (Castaman et 
al., 1993). However, another family was identified with both congenital high 
levels of HRG and tissue PLG activator inhibitor-1 which did not suffer from
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thrombotic disorders suggesting no correlation between venous thrombotic 
disease and high levels of HRG (Angles-Cano et al., 1993).
A family with congenital low levels of HRG (~20 % of normal) did not suffer 
from a higher incidence of thrombotic disorders, suggesting that HRG may not 
be a key regulator of fibrinolysis (Souto et al., 1996). Studies in healthy 
individuals with congenital low levels of HRG (20 - 30 % of normal range) also 
indicated that these levels were not associated with altered hemostatic function, 
immunologic function or levels of trace elements. These data suggest that HRG 
plasma levels are far in excess of those required to mediate HRG’s normal 
physiological functions or other molecules exist which can substitute for HRG 
in its absence (Shigekiyo et al., 1995).
1.1.3 Ligands for HRG
A number of ligands have been described for HRG and Table 1.1 summarizes 
some of the physicochemical properties of the various HRG-ligand interactions. 
The sections below will discuss in more detail five important classes of ligands 
for HRG.
1.1.3.1 H em e and divalent metal cations
Early studies by Morgan (1978) revealed that HRG binds with moderate affinity 
to heme, divalent metal ions and organic ligands like bilirubin (Table 1.1). The 
binding of HRG to heme, although sensitive to inhibition by metal ions, was 
thought not to be of physiological relevance. The affinity of rabbit HRG (which 
is present at a plasma level of ~ 1 mg/ml) for divalent metal ions was found to 
follow the order Cu2+ ~ Hg2+ > Zn2+ ~ heme ~ Ni2+ > Cd2+ > Co2 with no 
binding of Mg2+, Mn2+ or Pb2+ being detected. Only the interaction of HRG 
with Zn2+ and Cd2+ was found to display cooperative binding. Since HRG 
competes with albumin and transferrin in binding divalent metal cations like 
Zn2+, it was proposed that HRG can bind metal ions even in the presence of 
serum proteins, and therefore, that HRG plays an important role in metal ion 
transport and hemostasis (Morgan, 1981). Other studies, however, suggest that 
in normal human plasma, and in the plasma of patients with familial 
hyperzincemia, the majority of Zn2+ is bound to albumin, and not to other 
Zn2+-binding proteins such as HRG and transferrin (Failla et al., 1982). 
Subsequent studies also revealed that albumin and a2-macroglobulin are the 
major transporters of Zn2+ in plasma and that HRG is not quantitatively
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important in the transport of Zn2+ (Cousins, 1989). These findings suggest that 
HRG is unlikely to play a major role in the transport of divalent metal ions in 
vivo.
Following digestion of native rabbit HRG (94 kDa) by plasmin, studies with the 
HRR (30 kDa fragment which is rich in His (29%), Pro (37%), Gly (16%) and 
carbohydrate (9%)) indicated that the HRR of HRG (see Figure 1.1 A) retains 
much of the ability of intact HRG to bind metal ions and is the functional 
domain of HRG which binds Zn and other metal ions in a pH-dependent 
manner (Morgan 1985). This also was consistent with studies showing that 
chemical modification of the His residues of HRG diminishes the binding of 
Zn2+ by HRG (Morgan, 1985). Interestingly, recent studies also have shown 
that protonation of the HPR region (below pH 6) can lead to conformational 
changes which can be transmitted via the disulphide bonds to other parts of the 
HRG molecule (see Figure 1.1A). This indicates that metal ion binding can 
change the conformation of HRG and, thereby, presumably regulate its function 
(Borza and Morgan, 1998).
The ability of HRG to interact with metal ions may be important in regulating
HRG function (Guthans and Morgan, 1982). Despite some conflicting reports,
substantial evidence suggests that metal ions are important modulators of HRG
binding to other molecules, including heparin (see below). A number of in vitro
studies have shown that this binding by human HRG is abolished in the
presence of ethylenediamine tetra acetic acid (EDTA) (Lijnen et al., 1983b; Lane
et al., 1986). On the other hand, it was reported that rabbit HRG can still bind
heparin of different molecular weights in the presence of EDTA, suggesting that
rabbit HRG can bind heparin in the absence of metal ions. This is consistent
with the finding that the ability of HRG from different species to bind heparin is
different (Burch et al., 1987). Other in vitro studies by Kazama and Koide (1992)
reported that 20 pM Zn2+, the amount that they suggested to be a physiological
concentration, enhanced the ability of HRG to bind heparin and neutralize
heparin's anticoagulant activity. Similarly, there is conflicting evidence as to
whether metal ions affect the interaction of HRG with components of the
immune system. For example, the binding of HRG to the complement
component C9 was found to be enhanced in the presence of divalent cations
such as Ca2+ and Mg2+ (Chang et al., 1992a), whereas the binding of [125I]-
labelled HRG to human peripheral blood T lymphocytes was unaffected by
either 2 mM EDTA or 20 |iM Zn2+ (Saigo et al., 1989). A possible explanation for
2+these conflicting observations is the difference in the concentration of free Zn
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available to bind HRG in the assay systems used as in some studies 2% BSA 
2+(which binds Zn ) also was included in the reaction vessel (Saigo et al., 1989).
1.1.3.2 Heparan sulfates and heparin
Heparan sulfate is a sulfated glycosaminoglycan (GAG) which exists on the 
surface of cells as a constituent of proteoglycans or as a component of the 
extracellular matrix (reviewed by Jackson et al., 1991). Heparin, a highly 
sulfated form of heparan sulfate, is restricted to mast cell granules. GAGs 
include chondroitin sulfate, keratan sulfate, dermatan sulfate and hyaluronic 
acid. These GAGs consist of polymers of repeating disaccharide units, in which 
one of the sugars is either N-acetylgalactosamine or N-acetylglucosamine and 
the other a uronic acid. Different patterns of sulfation in the carbohydrate 
moieties gives further diversity to the structure of the GAGs. Heparan sulfate is 
one of the predominant GAGs covalently attached to cell surface proteoglycans. 
In patho(physio)logicai conditions the release of heparan sulfate, by the action 
of heparanases that are produced by a number of cells such as leukocytes and 
platelets (Freeman and Parish, 1998), may play an important role in cell-cell and 
cell-matrix interactions and in cell migration (for review see Jackson et al., 
1991).
The ability of HRG to bind heparin was first reported by Heimburger et al. in 
1972. Subsequently, Koide et al. (1982,1985) showed that HRG can be purified 
using a chromatographic procedure based on the ability of HRG to bind to 
heparin, and that the Kd of this interaction is ~ 7 nM, suggesting that HRG may 
interfere with the blood coagulation cascade during heparin administration in 
vivo (Lijnen et al., 1983b). As HRG is able to bind to many different cell types, 
and the binding is largely inhibitable by pretreatment of HRG with heparin, it 
would appear that heparan sulfates, and other GAGs present on the surface of 
cells may be natural receptors for HRG (Brown and Parish, 1994).
Despite extensive investigations, early studies (Lijnen et al., 1983b, 1984; Burch 
et al., 1987) failed to identify the region of HRG involved in heparin binding. 
Based on the observed similarities between the amino acid sequence of the N- 
terminal region of HRG and that of the N-terminal region of antithrombin III 
(ATIII) (~ 40 % homology), Koide et al. (1982) proposed that the N-terminal 
region of HRG is the domain involved in binding to heparin. This was in 
contrast to other studies showing that the pretreatment of HRG with 
deoxypyrocarboxylate, which modifies His residues, diminishes the heparin
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binding ability of HRG, thereby suggesting an involvement of the His residues 
of HRG in heparin binding (Burch et al., 1987). Recent studies have, however, 
supported the view that the HRR of HRG is the domain involved in heparin 
binding (Figure 1.1 A, Table 1.1) (Borza et al., 1996; Borza and Morgan 1998). 
Moreover, a study of the binding of HRG to immobilized GAGs revealed that 
HRG binds to GAGs only when the HRR of HRG is protonated and/or bound 
to metals ions like Zn2+ (Borza and Morgan, 1998). It was proposed that under 
conditions of local acidosis (eg. ischemia, hypoxia or inflammation), when the 
local pH is decreased by 1 to 1.5 unit below the physiological pH, or under 
conditions where the local metal ion concentration is increased (eg. upon the 
release of Zn2+ by activated platelets), HRG can bind to cell surface and 
extracellular matrix GAGs and co-immobilize other ligands such as PLG (Borza 
and Morgan, 1998).
1.1.3.3 Plasminogen/plasmin and fibrinogen/fibrin
Studies by Lijnen et al. (1980) revealed that HRG binds to both PLG and 
plasmin with moderate affinity having KdS of 1.1 and 0.9 pM, respectively 
(Table 1.1). Subsequently it was proposed that HRG interacts with the high 
affinity Lys binding site of PLG (a triple loop structural (kringles) domain of 
plasmin(ogen) involved in Lys recognition which binds a 2-antiplasmin and 
fibrin) and can inhibit the interaction of plasmin(ogen) with a 2-antiplasmin and 
fibrin (Lijnen et al., 1980). Further studies of the interaction of HRG with PLG 
revealed that PLG interacts with the C- and N-terminal regions of HRG, and 
that both interactions are affected by ionic strength, but not by pH or Zn2+. In 
particular, Lys residues in the C-terminal region of HRG were found to be 
essential for PLG binding (Figure 1.1A) (Sorensen et al., 1993; Borza and 
Morgan, 1997). However, PLG and heparin bound HRG independently, 
indicating that the PLG and heparin binding sites on HRG are distinct (Saez et 
al., 1995). Consistent with previous studies, HRG and PLG were found to 
interact with a Kd of ~ 0.75 pM and a stoichiometry of 1 : 1 (Table 1.1). Further 
studies revealed that immobilization of HRG onto a solid surface increases its 
affinity for native PLG and plasmin some 50-100 fold, giving K^s of 60.7 nM 
and 13.7 nM, respectively (Table 1.1) (Silverstein et al., 1985b; Borza and 
Morgan, 1997). These findings suggest that HRG is likely to bind stronger to 
PLG when it is immobilized on cells through the interaction of its heparin 
binding (HRR) region with GAGs on cell surfaces.
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In a related study Leung (1986) reported that HRG also binds strongly to FBG 
(Kd = 6.7 nM, Table 1.1), a finding which suggests that HRG can regulate the 
formation of fibrin clots (this point will be discussed later in section 1.1.5.1.1). 
However, the region(s) of HRG which interacts with FBG has not been defined.
1.1.3.4 Thrombospondin
Evidence indicates that a substantial amount of HRG (~ 0.14 % of the total HRG 
in plasma) exists on the surface of platelets (~ 370 ng/109 platelets) and can be 
released by stimulation of the platelets with thrombin (Leung et al., 1983). 
Moreover, HRG was found to bind with high affinity (Kd ~ 7 nM) to TSP (Table 
1.1), a 450 kDa protein present in the a-granules of platelets, which is also 
released following stimulation of platelets with thrombin (Jaffe et al., 1982; 
Leung and Nachman, 1982). Interestingly, the binding of HRG to TSP did not 
interfere with the ability of TSP to bind FBG, and the HRG-TSP complex was 
still able to bind heparin and PLG (Leung et al., 1984). Each TSP molecule can 
form a complex with three molecules of HRG and three molecules of PLG, 
thereby creating a complex with the ability to bind cell surface heparan sulfates 
and to potentiate the generation of plasmin by tissue PLG activator. 
Furthermore, the binding to HRG of a first ligand (TSP or PLG) augments the 
binding of the second ligand (PLG or TSP), respectively (Silverstein et al., 
1985a).
1.1.3.5 Complement components
Preliminary studies suggest that HRG immobilized on a nylon membrane, 
when incubated with normal human serum, interacts with factor D and 
components of the membrane attack complex (MAC) of complement, namely 
C8, C9 and S-protein (Chang et al., 1992a). The molecular basis of these 
interactions with HRG is unclear and the functional significance is unknown. 
Recently, it was also demonstrated that HRG interacts with the purified first 
component of complement, Clq, with high affinity (Kd ~ 10 nM) and that the 30 
kDa N-terminal fragment of HRG was found to contain the Clq binding site 
(Gorgani et al., 1997; Chapter 3 of this thesis). However, the functional 
relevance of the interaction of HRG with Clq awaits further study.
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1.1.4 Cell Surface Receptors for HRG
The ability of human HRG to interact with cell surface receptors was first 
demonstrated by Rylatt et al. (1981) who showed that HRG from the sera of 
many vertebrates can inhibit the autorosetting of murine lymphocytes and 
erythrocytes. Subsequent studies showed that HRG can bind to a number of 
different cell types including murine macrophages, erythrocytes, 3T3 
fibroblasts, human peripheral blood T cells, the human monocytoid cell line 
U937, and Epstein Bar virus-transformed B cell lines. Despite the ability of 
HRG to bind to diverse cell types, the cell surface receptor(s) responsible for 
HRG binding have not been identified and it is unclear whether HRG interacts 
with these cells via similar receptors.
Interestingly, studies by Parish et al. (1984) demonstrated that native human 
HRG interacts with anionic carbohydrates, possibly sulfated polysaccharides, 
on murine erythrocytes. Furthermore, additional studies revealed that a 60 kDa 
fragment of HRG lacking the HRR is unable to bind to murine erythrocytes. 
These findings suggest that heparan sulfates on the erythrocyte surface are 
binding sites for HRG, although other anionic carbohydrates could be involved, 
and that the HRR of human HRG is the major functional domain which 
interacts with these sites on erythrocytes (Lijnen et al., 1983a).
Following the initial observation that native human HRG binds to murine 
macrophages (Sia et al., 1982), studies by Chang et al. (1992b) demonstrated that 
HRG binds to inflammatory peritoneal macrophages, and that the 40 kDa N- 
terminal cystatin-like domain of HRG plays an important role in this binding 
(Chang et al., 1994). Moreover, since the pretreatment of HRG with heparin did 
not change the ability of HRG to bind to macrophages, the studies imply that 
HRG binds to a receptor on macrophages which is distinct from cell surface 
heparan sulfates. Additional studies using Abs provided evidence that HRG 
modulates Fc gamma receptor type 2 (FcyRII) expression on the surface of 
mouse inflammatory peritoneal macrophages (Chang et al., 1994), thus 
suggesting that HRG may interact with FcyRII on macrophages.
Studies on the interaction of HRG with human peripheral blood T lymphocytes 
indicated that HRG interacts with a 56 kDa cell surface protein which is 
immunochemically distinct from CD2 despite having a similar molecular 
weight (Saigo et al. 1989). Furthermore, kinetic analysis of the interaction of 
HRG with these cells indicated two distinct binding sites for HRG, namely a
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high affinity binding site with a Kd of ~ 19 nM and a low affinity binding site 
with a Kd of ~ 500 nM (Saigo et al., 1989). Heparin at a 50-fold molar excess or 
bacterial heparinase pretreatment of the T cells did not inhibit HRG binding to 
the cells, suggesting that HRG does not interact with cell surface heparan 
sulfates. More recent studies employing flow cytometry, however, showed that 
the binding of human HRG to murine and human T cell lines is potentiated in 
the presence of physiological concentrations of Zn2+ and is largely inhibited by 
heparin (Olsen et al., 1996). The reason for this discrepancy is unclear although 
heparan sulfate may be a more important ligand on activated and/or 
transformed T cells than on resting, peripheral blood T cells. Similarly, it was 
reported that the binding of HRG to the monocytic cell line U937 and to Epstein 
Barr virus-transformed B cells is abolished by pretreatment with heparin (Saigo 
et al., 1989). HRG also was found to bind to heparan sulfate moieties on 3T3 
fibroblasts and inhibit the binding of acidic fibroblast growth factor (FGF) and 
basic FGF to the heparan sulfates on these cells (Brown and Parish, 1994). The 
fact that HRG binding to these cell lines was inhibitable with heparin and other 
sulfated polysaccharides suggests that, similar to the erythrocyte cell surface, 
GAGs are a major receptor for HRG on many nucleated cells.
In summary, these findings suggest that HRG binds to at least three classes of 
cell surface receptors: GAGs, such as heparan sulfate, that exist on the surface of 
the majority of cells (eg. erythrocytes, T cells, monocytes, macrophages, 
fibroblasts), FcRs on macrophages, and a 56 kDa protein on the surface of 
human peripheral blood T lymphocytes.
1.1.5 Involvement of HRG in non-immune physiological
processes
The ability of HRG to bind to several different plasma proteins and to interact 
with several different cell types (as outlined above) suggests it can potentially 
regulate a diverse range of physiological processes including blood clotting and 
aspects of immune function. The interaction of HRG with several physiological 
processes including the blood clotting system (fibrinolysis and coagulation) and 
regulation of apatite formation and muscle function are discussed in more 
detail below (section 1.1.5). The interaction of HRG with immune cells and 
other components of the immune system will be discussed in the next section 
(section 1.1.6).
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1.1.5.1 Regulation of blood clotting by HRG
The plasma concentration of HRG deviates from the average normal level in 
various hematological disorders suggesting that HRG may play a role in the 
physiology of blood clotting. For example, individuals with genetically 
determined elevated levels of HRG have been shown to develop prothrombotic 
(increased clotting) abnormalities (Angles-Cano et al., 1993), whereas some 
patients with liver cirrhosis, who possess lower levels of plasma HRG, exhibit 
excessive bleeding and elevated fibrinolysis (Saito et al., 1982). The role of HRG 
in two aspects of the blood clotting system, namely fibrinolysis and coagulation, 
is discussed below.
1.1.5.1.1 Fibrinolysis
The notion that HRG can act as an antifibrinolytic agent followed from the 
observation that it can interact with moderate affinity with PLG (Kd = 1.1 JiM) 
and plasmin (Kd = 0.9 |iM). HRG is reported to be able to bind to the high 
affinity Lys binding site of plasmin(ogen) (similar to the interaction of 6- 
aminohexanoic acid with PLG) in normal human plasma and to inhibit the 
interaction of plasmin(ogen) with a 2-antiplasmin and fibrin. Thus it has been 
proposed that HRG, when bound to PLG, inhibits the interaction of PLG with 
fibrin clots and thus indirectly inhibits plasmin-mediated fibrinolysis (Lijnen et 
al., 1980). This antifibrinolytic effect of HRG would be expected to potentiate 
clotting in the microenvironment of fibrinogenesis. Consistent with this notion, 
the level of HRG and PLG is decreased in the plasma of patients with 
lymphocytic leukaemia undergoing L-asparaginase therapy, the side effects of 
which include thrombotic and haemorrhagic diathesis (Vellenga et al., 1984). 
However, the level of HRG is normal in patients with pulmonary 
thromboembolism, and this level does not change during SK therapy (despite 
the infused SK being biologically active). These findings fail to indicate a 
definitive role for HRG in fibrinolysis in vivo (Goodnough et al., 1985).
In contrast to the reported antifibrinolytic effect of HRG, other studies 
(Silverstein et al., 1985b; Borza and Morgan, 1997) showed that HRG, when 
immobilized on a surface (eg. on hydrazide or nickel chelate), can act as a 
profibrinolytic agent and enhance fibrinolysis. Although HRG in solution binds 
PLG with moderate affinity (~ 1 nM), immobilised HRG binds PLG with 50-100 
higher affinity. The high affinity interaction of immobilised HRG with PLG has 
been shown to accelerate PLG activation by tissue PLG activator ~ 30 fold, thus
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possibly leading to the generation of higher amounts of plasmin in the region of 
fibrin clots (Borza and Morgan, 1997). These findings suggest that HRG is likely 
to potentiate PLG activation when immobilized onto cells through the 
interaction of its heparin binding (HRR) region with GAGs on cell surfaces.
Evidence suggests that HRG binds strongly to FBG (Kd = 6.7 nM) (Leung, 1986). 
Although the presence of HRG does not affect the conversion of FBG to fibrin 
and the extent of fibrin polymerization, HRG is known to become incorporated 
into fibrin clots and to promote the formation of thinner and more distributed 
fibrils. These observations suggest that HRG can influence the stability and 
general structure of fibrin clots, especially in focal areas of active hemostasis 
and thrombosis (but not in plasma) where extensive release of platelet HRG 
may elevate the local HRG concentration (Leung, 1986). This interpretation also 
is consistent with the observation that bovine HRG is a substrate for bovine 
plasma factor XHIa (fibrin stabilizing factor) (Halkier et al., 1994), and that 
activated factor XHIa can catalyze the Ca2+-dependent attachment of 1,4- 
[14C]putrescine onto a glutamine residue on bovine HRG (Halkier et al., 1994). 
This suggests that in the presence of factor XHIa HRG can become covalently 
linked to fibrin, thereby modifying the stability and structure of the fibrin clot 
formed (Halkier et al., 1994).
1.1.5.1.2 Coagulation
HRG is reported to bind heparin with high affinity (Kd = 7 nM) and to inhibit 
the neutralization of factor X and thrombin by the ATIII-heparin complex 
(Lijnen et al., 1983b). Evidence suggests that HRG interacts with heparin 
administered in vivo, and that it plays a role in regulating the anticoagulant 
effects of heparin administration in human by inhibiting the interaction of 
heparin with ATIII (Lijnen and Collen, 1983; Lijnen et al., 1984). Consistent 
with this view, the turn-over of HRG was found to be 2.9 ± 0.36 days in healthy 
individuals (Lijnen et al., 1981b), but this was lowered to 2.00 ± 0.14 days in 
patients with deep vein thrombosis during heparin administration (Lijnen and 
Collen, 1983). Furthermore, the effect of HRG on the anticoagulant activity of 
heparin was found to be due to a pH-dependent inhibition of the binding of 
heparin to thrombin and ATIII (Lane et al., 1986).
A study of the modulatory effects of HRG on the anticoagulant activity of 
heparin and dermatan sulfate in plasma and purified systems indicated that 
HRG binds to these sulfated polysaccharides and inhibits their ability to
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prolong the thrombin time (Lijnen et al., 1984; Sakuragawa et al., 1985). HRG 
also inhibits the binding of heparin to monocytes, resulting in a failure of 
heparin to inhibit the procoagulant activity of monocytes at sites of inflammation 
and thrombosis (Leung et al., 1989). A number of studies report that HRG can 
play a procoagulant role by binding to heparin in fluid phase and blocking 
heparin's anticoagulant properties. It is also reported that HRG does not bind 
strongly to the heparin-like structures recognized by ATIII on vascular 
endothelial cells (even in the presence of divalent metal cations), suggesting that 
HRG is unlikely to play a major role in the endothelial cell-mediated 
inactivation of thrombin by ATIII (Shimada et al., 1989).
It has been shown that HRG forms a complex with purified TSP in fluid phase 
(Leung et al., 1984) and also interacts with TSP on the surface of activated 
platelets (Silverstein et al., 1985a), however, no functional relevance for the 
HRG-TSP interaction has been defined. It has been hypothesised that since one 
molecule of TSP can form a complex with three molecules of HRG and three 
molecules of PLG, with the binding of the first ligand augmenting the binding 
of the second ligand, the assembly of the trimolecular complex on the surface of 
various cells (eg. platelets) could regulate coagulation at sites of active fibrin 
deposition (Silverstein et al., 1985a). Consistent with this hypothesis, the 
incorporation of HRG in TSP-PLG complexes was found to augment both fibrin 
deposition and clot formation (Silverstein et al., 1985a). Other studies have 
demonstrated that HRG binds to human platelets in a Ca2+ and Mg2+ 
dependent manner, and remains bound to platelets once they have been 
activated by cross-linked IgG (Lerch et al., 1988). These latter findings also 
provide a mechanism by which HRG can be stored on the surface of platelets.
1.1.5.2 Regulation of apatite formation by HRG
Interestingly, recent studies indicate that HRG may be able to prevent metal 
salt-mediated kidney or blood vessel wall injury, by keeping metal salts in a 
soluble form (eg. inhibition of Ca salt precipitation) in these organs. A 
baculovirus-derived recombinant form of human HRG produced by SF9 insect 
cells, was found to inhibit the precipitation of metal salts (apatite formation) in 
an in vitro system. This finding suggests that HRG could potentially play a role 
in the inhibition of phase separation and Ca2+ deposition at sites of tissue injury 
in blood vessels and kidneys (Schinke et al., 1997).
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1.1.5.3 HRG and muscle function
Recently, a 75 kDa HRG-like protein from rabbit skeletal-muscle was found to 
be a component of adenosine monophosphate (AMP) deaminase, an enzyme 
that interacts with myosin and titin. This finding has raised the possibility that 
HRG also may be associated with muscle function. Rabbit AMP deaminase 
contains two subunits: one with deaminase catalytic activity, and the other 
possessing a high level of homology with rabbit HRG. This suggests the 
existence of a novel muscle-specific form of HRG (Ranieri-Raggi et al., 1997), a 
notion confirmed by the demonstration of the presence of a muscle-specific 
HRG in human skeletal muscle myofibrils by the use of rabbit anti-HRG Abs 
(Ranieri-Raggi et al., 1997). It has been suggested that the role of muscle- 
specific HRG may be to connect the catalytic site of AMP deaminase with 
myosin and titin, and that the HRR of the muscle form of HRG is responsible 
for the rapid clearance of AMP deaminase from the circulation (Ranieri-Raggi et 
al., 1997). Such clearance could occur in liver through an interaction of the 
muscle HRG with cell surface heparan sulfates and subsequent internalization 
of the enzyme by hepatocytes (Ranieri-Raggi et al., 1997).
In a related series of observations, HRG has been shown to inhibit the 
antiproliferative effects of heparin (or heparinoid GAGs) on cultured bovine 
arterial smooth muscle cells and to promote the proliferation of smooth muscle 
cells and atherogenesis (Hajjar et al., 1987). However, other heparin-binding 
proteins in plasma (such as FBG, fibronectin, ATIII and platelet factor 4) were 
found not to affect the action of heparin. It is possible, therefore, that HRG may 
play a role in cell growth and vessel repair of atheromatous vessel walls upon 
release of HRG from macrophages and platelets recruited in response to arterial 
injury (Hajjar et al., 1987).
1.1.6 Regulation of the immune system by HRG
Regulation of the immune system by HRG is indicated by studies which 
suggest that HRG inhibits autorosetting, binds to complement proteins, and 
binds to immune cells including macrophages, and T lymphocytes, altering 
their function. In addition, it has been reported that serum HRG levels are 
significantly decreased in patients with AIDS and in kidney transplant 
recipients on immunosuppressive steroid treatment (Morgan, 1986). These 
findings indicate an involvement of HRG in immune function which is 
discussed below.
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1.1.6.1 Inhibition of rosette formation
Perhaps the first suggestion that HRG could play a role in regulating immune 
function followed from the observation that native human HRG is the major 
plasma protein in human serum which inhibits the formation of autorosettes 
between murine lymphocytes and autologous erythrocytes in vitro (Rylatt et al.,
1981) . HRG isolated from the sera of many vertebrates also was found to inhibit 
the autorosetting of murine lymphocytes and erythrocytes (Rylatt et al., 1981), 
suggesting that HRG from other species has similar activity. The physiological 
relevance of the in vitro phenomenon of autorosetting is not fully understood, 
but it is thought to provide insights into events associated with cell-cell 
interactions in the immune system.
Autorosetting has been studied most extensively in the human and murine 
systems. The T ceil adhesion molecule CD2 has been shown to be involved in 
the human system (Kamoun et al., 1981; Kozarsky et al., 1993). Similarly it has 
been proposed that CD2 is also important in autorosetting in the murine system 
(Sem et al., 1991). However, an important difference between the two systems 
is that with murine cells, in contrast to human cells, products of the major 
histocompatibility complex are involved in the adhesion process (Sia et al.,
1982) .
The mechanism by which HRG inhibits autorosetting is unclear. Evidence 
suggests that in the murine system HRG may mask anionic carbohydrate 
structures on mouse erythrocytes recognised by lymphocytes (Lijnen et al., 
1983a; Parish et al., 1984). In the human system, however, HRG inhibits 
rosetting between human peripheral blood T lymphocytes and sheep 
erythrocytes by masking erythrocyte binding receptors on the lymphocytes, 
suggesting that the molecular mechanism of rosette formation in the human 
and murine systems may be different. It should be noted, however, that the 
human system examined is not autorosetting but the binding of xenogeneic red 
cells to human lymphocytes. In the human system HRG was reported to bind 
to a CD2-unrelated 56 kDa protein on human peripheral blood T lymphocytes 
(Saigo et al., 1989) and partially inhibit rosette formation (Shatsky et al., 1989). 
Interestingly, the 60 kDa HRR of HRG (produced by plasmin cleavage of native 
75 kDa HRG) retains its ability to bind PLG, but has no autorosette inhibitory 
activity, suggesting that the HRR is involved in blocking autorosette formation 
(Lijnen et al., 1983a). Through their ability to secrete HRG it has been suggested
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that under certain conditions macrophages may locally regulate the binding of 
erythrocytes, and possibly other cell types, to lymphocytes in mice (Sia et al., 
1982).
1.1.6.2 Inhibition of T cell proliferation
Studies on the effect of human HRG on the proliferation of resting peripheral 
blood T lymphocytes stimulated with immobilized CD3 monoclonal antibody 
(mAb) indicated that physiological concentrations of HRG inhibit proliferation 
by 80-90% when it is added to the cells at early stages (i.e. initial 2 hrs) of 
activation (Shatsky et al., 1989). The inhibition of proliferation was proposed to 
occur via inhibition of interleukin 2 receptor expression and of interferon 
gamma (IFNy) release. However, HRG had no anti-proliferative activity when 
added to the T cells at later stages of activation, or when the T cells had been 
previously activated (Shatsky et al., 1989). The interaction of HRG with human 
peripheral blood T lymphocytes was not affected by the presence of either Zn2+ 
or EDTA, or by pre-incubating the HRG with heparin (Saigo et al., 1989). These 
observations are consistent with the binding of HRG to human peripheral blood 
T cells occurring predominantly through the binding of HRG to a binding 
site(s) distinct from heparan sulfates.
In contrast, studies with other cell types suggest that HRG can modulate cell 
proliferation by interacting with GAGs on the cell surface. Thus, HRG is 
reported to induce the proliferation of cultured arterial smooth muscle cells by 
inhibiting the anti-proliferative effects of heparin (Hajjar et al. 1987). Other 
studies indicate that human HRG can inhibit the proliferation of BALB/c 3T3 
fibroblasts by interacting with heparan sulfate proteoglycans and inhibiting the 
binding of acidic and basic FGFs to these cells. These findings support a role for 
HRG in modulating the release of FGFs from the extracellular matrix/basement 
membrane, and also in inhibiting the interaction of FGFs with cell surface 
heparan sulfates, a key step in the triggering of cell division by FGFs (Brown 
and Parish, 1994).
1.1.6.3 Modulation of cell adhesion
Studies by Lamb-Wharton and Morgan (1993) demonstrated that HRG alters 
the morphology of human peripheral blood T cells and the human T cell line 
MOLT 3 and increases the concanavalin A (Con A) induced attachment of these
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cells to the culture dish. Other studies, however, indicate that human HRG 
inhibits the adhesion of various human and murine T cell lines to culture dishes 
coated with components of the extracellular matrix, but at the same time 
promotes homotypic adhesion between the cells (Olsen et al., 1996). In these 
latter studies the effect was potentiated by the presence of physiological 
concentrations of Zn2+, but was inhibited by the presence of heparin and certain 
other sulfated polysaccharides, suggesting that the binding of HRG to heparan 
sulfates on the surface of these T cell lines was important (Olsen et al., 1996). 
From these results it would appear that HRG could potentially modulate the 
adhesion of T cells to the surface of endothelial cells and platelets, and thus the 
migration of T cells to sites of inflammation (Lamb-Wharton and Morgan, 1993).
The ability of HRG to interact with TSP with high affinity (Kd = 7 nM) also is 
consistent with HRG playing a role in cell-cell interactions and cell migration. 
The involvement of TSP in cell-cell or cell-matrix interactions, and its presence 
on endothelial cells, fibroblasts and smooth muscle cells, raises the intriguing 
possibility that HRG, by binding to TSP, may interfere with the function of TSP 
(Leung et al., 1984; Jaffe et al., 1982). However, this suggestion has not been 
examined experimentally.
1.1.6.4 Modulation of the reticuloendothelial system
Following the initial observation that HRG interacts with murine macrophages 
(Sia et al. 1982), Chang et al. (1992b) demonstrated that murine HRG binds to 
immobilized oil-elicited inflammatory mouse peritoneal macrophages and 
regulates the binding and phagocytosis of opsonized sheep erythrocytes. The 
incubation of macrophages with native human HRG (125 ng/ml) for 1-2 hours 
at 37°C was found to potentiate, but incubation for more than 8 hrs was found 
to inhibit, their ability to bind and ingest opsonised erythrocytes. The effect of 
HRG was not dependent on the presence of either heparin (1-100 jxg/ml) or 
IFNy, but was dependent on the level of IgG on the erythrocyte surface. It 
remains to be established, however, whether HRG can inhibit the binding of 
antibody (Ab) coated erythrocytes to macrophages in vivo.
The N-terminal 40 kDa domain of HRG was found to bind to macrophages and 
to inhibit the binding and phagocytosis of IgG-opsonized sheep erythrocytes. 
The pretreatment of the human monocytic cell line THP1 with HRG (~ 0.04 - 4 
jig/ml) for 18 hours resulted in increased cellular synthesis, but decreased cell 
surface expression of FcyRII, as assayed using a mAb to CD32 (Chang et al.,
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1994). These studies suggested a role for HRG in regulating macrophage FcyR 
expression and FcyR-mediated phagocytosis, although the mechanisms 
underlying the time-dependent effect of HRG on macrophage endocytosis and 
expression of FcyRII is unclear. The experimental work described in Chapter 5 
of this thesis provides some insight into this phenomenon.
1.1.6.5 Modulation of complement pathways
In humans the plasma levels of HRG are reported to decrease during 
inflammation and after surgery (Saigo et al. 1990a). Thus, unlike protein C or 
mannose binding protein (MBP), which are positive acute phase reactants in 
plasma, HRG was classified as a negative acute phase reactant and was 
suggested to play some role in inflammation (Saigo et al. 1990b). HRG also was 
found to interact with S-protein (vitronectin), factor D and components C8 and 
C9 of complement by in vitro ELISA assays (Chang et al., 1992a). However, the 
functional relevance of these interactions is unclear. On the other hand, 
evidence suggests that the addition of a mixture of HRG and normal human 
serum to a suspension of IgG-opsonized sheep erythrocytes potentiates lysis of 
the erythrocytes by the classical complement pathway in a HRG concentration- 
dependent manner (Chang et al., 1992a). Erythrocyte lysis is inhibited, 
however, when the HRG is preincubated with serum for 10 minutes before 
adding the mixture to the erythrocytes (Chang et al., 1992a). A similar effect is 
seen on the activation of the alternative complement pathway when HRG and 
serum are added to a suspension of rabbit erythrocytes (Chang et al., 1992a). 
These studies suggest that HRG can modulate complement function, although 
the molecular basis of this effect is unknown.
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1.1.7 Concluding Remarks
Based on the information presented in the preceding sections it is clear that 
HRG is a multifunctional protein which deserves further detailed study. 
Overall the data suggest that HRG is a pre-existing plasma protein which 
modulates many biological processes, such as cell adhesion, coagulation, 
complement activation and immune responsiveness. The three domain 
structure of the molecule, with each domain being capable of binding unique 
families of ligands, is consistent with the multifunctional nature of HRG. In 
fact, HRG appears to be ideally placed to act as a linking molecule for disparate 
biological processes such as coagulation and complement activation.
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1.2 PART II Formation and Clearance of Immune Complexes
Part II of this chapter will review two major features of ICs: the mechanism of 
formation of insoluble ICs and the clearance of ICs by the RES. Igs are a major 
component of ICs, and FcRs and complement components play major roles in 
the clearance of ICs. Therefore it is relevant, first of all, to very briefly review 
the general features, structure and functional properties of human Igs, FcRs and 
complement components.
1.2.1 Important molecules involved in IC formation and 
clearance
1.2.1.1 Immunoglobulins
The general properties of Igs are extensively reviewed elsewhere 
(Carayannopoulos and Capra, 1993; Max, 1993; Jefferis and Pound, 1992; Klein 
and Horejsi, 1997) and will be summarised below. Igs are composed of 
disulphide linked heavy and light chains, with each chain type consisting of a 
N-terminal segment of variable sequence, termed the variable region and a C- 
terminal region of constant sequence termed the constant region. The variable 
regions of individual heavy and light chains combine in three dimensional 
space to form a single antigen (Ag) binding site.
There are five classes of human Ig, namely IgM, IgD, IgG, IgA and IgE, which 
correspond to p, 5, y, a, and e heavy chains (Table 1.2). Human IgG is divided 
into four subclasses namely, IgGl, IgG2, IgG3 and IgG4 and IgA is divided into 
two subclasses, IgAl and IgA2. The heavy chains of all isotypes can be 
synthesised in two forms, either membrane-bound or secreted. The only 
difference between these two forms of Ig is the amino acid sequence of the C- 
terminal end of the heavy chains, with the membrane expressed Ig having an 
additional C-terminal membrane insertion sequence. The light chain of an Ig 
molecule can either be kappa (k) or lambda (X). Human Ig only has one type of 
k light chain since the gene encoding the constant region of k light chain only 
contains one segment, whereas there are four different functional human X light 
chains, namely X I ,  X2,  ) 3  and X6. The normal ratio of the different classes and 
subclasses of Ig in plasma may vary from species to species. For example, ~ 95 
% of plasma Ig in mice contain the k light chain but in humans the k : X ratio is 
— 6:4, whereas 95 % of horse light chains are the X form and birds only express 
X light chains. In humans the k : X light chain ratio has been shown to change
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during different pathological conditions. For example, in patients suffering 
from rheumatoid arthritis (RA) the production of Igs with the k light chain has 
been shown to be significantly increased compared to healthy individuals 
(Riesen et ab, 1976).
The Ig classes IgD, IgG, and IgE consist of two identical heavy chains and two 
identical light chains. However, IgM consists of a pentameric arrangement of 
this basic Ig structure, the five subunits being joined by disulphide bonds and a 
polypeptide termed the J-chain. IgA can exist in two forms, a monomer 
consisting of the basic four chain Ig structure and a dimer also linked by a 
polypeptide termed the J-chain (Table 1.2). Each Ig molecule consists of two 
Fab and one Fc region which are joined together by the hinge region of the 
heavy chains. Although there is ~ 95 % identity between the complete amino 
acid sequence of IgG subclasses, the hinge region shows great differences 
among the four IgG subclasses both in terms of amino acid sequence and 
number of residues. The hinge region determines the flexibility of an IgG 
molecule. It should be noted that in contrast to IgG, IgD and IgA molecules, the 
IgM and IgE have no defined hinge region. The flexibility of an Ig molecule 
also may be affected by the position of the disulphide bonds in its heavy and 
light chains. For example, the position of the cysteine residue in the heavy 
chain of IgGl that links the heavy chain to the light chain may make the IgGl 
molecule more flexible than other IgGs and hence influence different functions. 
In addition, the C-terminal cysteine residue of the k light chain may form a 
more flexible Ig when compared to Ig molecules containing X  light chains in 
which the penultimate cysteine residue of the X  light chain forms a disulfide 
bond with the heavy chain. Each IgM molecule has 10 Ag binding sites, but 
presumably because of the lack of flexibility of the Fab arms, a single IgM 
molecule can only bind simultaneously a maximum of five antigenic 
determinants (Klein and Horejsi, 1997).
Igs are classified as glycoproteins since all of the Ig molecules contain some sort 
of carbohydrate. It has been shown that the type of oligosaccharide side chain 
is different and is characteristic for each class of Ig. The heavy chain of human 
IgG (regardless of subclass) contains only one N-linked oligosaccharide 
approximately at position 300, whereas other heavy chains contain either two or 
five oligosaccharides per molecule (Table 1.2). The N-linked oligosaccharides 
have a molecular weight of approximately 2500-3000 dalton and usually consist 
of ~ 15 monosaccharide units.
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Human Igs are encoded for by genes located on three different chromosomes: 
the Ig heavy chain on chromosome 14q32, the k light chain of Ig on 
chromosome 2pl2-pll, and the X  light chain of Ig on chromosome 22qll. The 
heavy chain gene complex consists of 95 variable (V), 32 diversity (D), 9 joining 
(J) and 11 constant (C) segments, whereas, the k light chain gene complex 
consists of 90 V, 5 J, and 1 C segments and the X  light chain gene complex 
consists of 60 V, 7 J, and 7 C segments (Klein and Horejsi, 1997). The two 
striking differences between k and X  light chain gene are that the k light chain 
gene contains only one C segment, whereas, the X  light chain gene contains 
seven segments only four of which are functional. The Ig genes rearrange 
before they are expressed as Ig on the cell surface of B lymphocytes, a process 
which has been extensively reviewed elsewhere (Lewis, 1994). Briefly, Ig 
diversity is generated by a rearrangement process where a single V, D and J or 
V and J segment is selected to produce the heavy chain or light chain variable 
region, respectively. Variation in the joining region between the segments, 
termed functional diversity, generates further sequence variation. Initially the 
rearranged VDJ segment is translocated adjacent to the p chain locus, such that 
IgM is the first cell surface Ig expressed by B cells. However, by a process of 
class switching the rearranged VDJ segments can be subsequently translocated 
adjacent to other constant region loci, the nine different human heavy chain loci 
being arranged in the order p, 8,73, 7I, cxl, i l ,  74, el, and «2 on chromosome 14. 
After the Ig heavy chain, either the k light chain or X  light chain loci are 
rearranged. If the k light chain is productively rearranged first then the cell 
expresses an Ig molecule that contains two identical heavy and two identical k 
light chains. If the X  light chain locus rearrangement succeeds, the cell 
synthesises Igs with two identical heavy chains and two identical X  light chains 
(Max, 1993).
The functional properties of the different human Igs are summarised in Table 
1.3. Igs protect the host against pathogens, either directly or indirectly. Among 
the five Igs, IgA and IgE may undertake functions against pathogens entering 
the host through mucosa or skin, respectively, whereas IgM and IgG mainly act 
against pathogens that have already entered the host and are present in the 
circulation. It has been shown that IgM Abs, after binding to their cognate Ag, 
are very effective at activating the classical complement pathway (see 1.2.1.3), 
whereas IgG Abs although activating the complement pathway in some cases, 
also coat cells or particles for uptake by phagocytic cells, such as macrophages 
and neutrophils, via FcR. Among the four IgG subclasses, IgGl and IgG3 have 
the highest affinity for FcyR on phagocytic cells, whereas IgG4 has a lower
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affinity and IgG2 has the lowest affinity (Table 1.3). The binding affinity of IgG 
subclasses for the complement component Clq, the initiating component of the 
classical complement pathway, follows the hierarchy of IgG3 > IgGl > IgG2 > 
IgG4. As a result of these differring affinities for C lq, hum an IgG3 and IgGl 
can activate complement almost as efficiently as IgM, whereas IgG2 is a less 
efficient activator and IgG4 does not activate complement at all (Table 1.3).
IgA Abs function at body surfaces such as those associated with the digestive, 
respiratory and reproductive tracts (Table 1.3). IgA at the surface can prevent 
pathogens from entering the body by aggregating pathogens together. IgA also 
facilitates phagocytosis of pathogens via Fc alpha receptor (Fca R) on 
phagocytes but this interaction is rather weak compared to the IgG FcyR 
interactions. IgE Abs exist at lowest concentration in plasma and bind to Fc 
epsilon R (FceR) on mast cells and basophils. If an Ag can cross-link the IgE on 
mast cells, this clusters the FceR and triggers the cells to release substances 
which are vasoactive and proinflammatory. IgE does not contain a hinge region 
and is therefore the most rigid Ig. IgD is usually co-expressed with IgM and 
appears on the cell surface of m ature but immunologically naive B cells. 
Flowever, the functional role of IgD is still unclear.
1.2.1.2 Fc receptors
FcR are members of the Ig-superfamily and are a set of heterogeneous cell 
surface molecules that bind to specific sites on Ig molecules (Reviewed by 
H ulett and Hogarth, 1994 and Unkeless et al., 1992). They are classified 
according to the Ig class that they recognise and the strength of the interaction 
(Table 1.4). FcR for IgG, IgA and IgE are well characterised, whereas FcR for 
IgM and IgD have been defined but have not been structurally characterised. 
Two high affinity FcR have been defined in humans, namely FCyRI and Fc£RI. 
Low affinity FcR are Fc^RII, Fc^RIII, Fc£RII and FcaR (Table 1.4). Only the high 
affinity FcR can bind monomeric Ig molecules, whereas the low affinity FcR 
only can bind ICs or aggregated Igs (Unkeless et al., 1992; Hulett and Hogarth, 
1994). Although three major classes of FcR for IgG have been described (Fc^RI, 
FCyRII and Fc^RIII), each class may be heterogenous and consist of different 
subclasses. This heterogeneity may arise from alternative messenger RNA 
(mRNA) splicing or may result from separate genes (Abrass, 1991; Sylvestre 
and Ravetch, 1994; Ravetch and Kinet, 1991).
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Both high and low affinity FcR can only trigger a response in the cell's interior 
when clustered by ICs. Depending on the cell and Ab type the generated signal 
may lead to phagocytosis and/or killing of the Ab coated pathogen or pathogen 
infected cell and the release of inflammatory mediators (Unkeless et ak, 1992). 
Although all FcR are membrane bound, the extracellular domain of FceRII and 
FCyRIII may be cleaved enzymatically and may be released into the surrounding 
medium (Tosi and Berger, 1988; Fleit and Kuhnle, 1988). Additionally, in some 
instances, by splicing the mRNA FcyRII can be expressed without its 
transmembrane region (FcyRIIAa2) and therefore can be released into the 
surrounding medium (Tartour et al., 1993).
The membrane-bound FcR consists of an extracellular region, a transmembrane 
region and a cytoplasmic tail. The extracellular region is comprised of one to 
three Ig-like domains which form the Fc binding region. Depending on the cell 
type they are expressed on, FcR may contain different intracellular domains. 
These differences in the cytoplasmic tail of FcR may lead to the generation of 
different signal transduction pathways and, therefore, may result in 
heterogeneous biological responses upon interaction of ICs with different cell 
types (Unkeless et al., 1992).
1.2.1.3 Com plem ent com ponents
The complement system is composed of approximately 30 proteins which, 
following activation by various stimuli, results in the assembly of a complex 
array of proteins which can lyse cell membranes/walls via the MAC and can 
facilitate uptake of foreign substances by phagocytes (Muller-Eberhard, 1992). 
Some complement components also have a proinflammatory role. The 
complement system can be activated by three different pathways, namely the 
classical, the alternative and the lectin pathways. Activation of any of these 
pathways ultimately leads to the assembly of the MAC (see below). Each 
pathway is comprised of a number of different components which, upon 
activation, results in the generation of complement 3 (C3) convertase and 
subsequent MAC assembly (see Figure 1.2).
The classical pathway can be activated by ICs containing certain IgG subclasses 
and/or IgM (see Table 1.3). Activation of the classical pathway leads to the 
production of a series of Ser proteases (Cls, C4b, C2b). In the presence of ICs, 
serum Cl binds to the Fc region of Ig molecules by the Clq globular head and 
releases associated Cl inhibitor (Golan et al., 1981). The Cl molecule changes
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FIGURE 1.2 Activation of complement
The alternative, lectin, classical and lytic pathways of complement 
activation are depicted. The binding of activating surfaces to a C3b-like 
molecule (C3(H20)) initiates the alternative pathway which leads to the 
formation of C3b. The lectin pathway of complement is initiated by the 
interaction of MBP with carbohydrates on the surface of bacteria which 
leads to the formation of C3b. The classical pathway is initiated when Cl 
recognizes IC and following a series of proteolytic reactions C3b is formed. 
The lytic pathway is initiated by the cleavage of C5 and the formation of 
MAC. Abbreviations are: C: complement, MBP: mannose binding 
protein, MASP: MBP-associated serine proteases, B: factor B, D: factor D, P: 
properdin, Adapted from Muller-Eberhard, 1992.
Activating
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its conformation upon binding to ICs. One of the two Clr molecules becomes 
activated (perhaps by exposing the active site), cleaves the neighbouring Clr 
molecule and activates a proteolytic cascade which eventually results in the 
assembly of the C4bC2b complex, a potent C3 convertase which cleaves C3 to 
C3a and C3b (Porter and Reid, 1979; Nagasawa and Stroud, 1977; Golan et al., 
1981; Isenman and Kells, 1982).
The alternative pathway of complement activates spontaneously at a very slow 
rate but, in the presence of activating surfaces such as bacteria, yeast, viruses, 
IgA containing ICs or insoluble ICs, the activation process is amplified leading 
to the deposition of C3b molecules on the surface of the pathogen or insoluble 
ICs. C3 spontaneously binds to one molecule of H2 O to form C3(H2Ü) which 
changes the structure of C3 (Isenman et al., 1981; Pangburn et al., 1981) and 
allows it to bind factor B. The formation of the C3(H20)B complex exposes a 
site on factor B which is cleaved by plasma factor D (Muller-Eberhard and 
Götze, 1972), leading to the production of Ba and Bb fragments and the 
subsequent release of the Ba fragment into the surrounding medium. The 
C3(H20)Bb complex acts as a mild C3 convertase and cleaves C3 to C3a and 
C3b (Lachmann and Hughes-Jones, 1984). At this stage if the C3b fragments 
generated encounter foreign particles or insoluble ICs, they bind to them by 
covalent ester or amide bonds and the bound C3bBb forms a potent C3 
convertase which randomly deposits C3b on the parasite surface or insoluble IC 
(Figure 1.2). The C3(H20)Bb complex also is stabilized by properdin (factor P) 
(Fearon and Austen, 1975), a plasma protein with a structure similar to that of 
the cell adhesion molecule thrombospondin. Properdin also prevents the 
cleavage of C3 convertase by factor I, thereby further amplifying C3b 
deposition.
The third pathway of complement, the lectin pathway, is activated by bacterial 
surface carbohydrates (Kawakami et al., 1984). MBP, a protein analogous to 
Clq, is the first member of the lectin pathway which interacts with mannose 
and N-acetylglucosamine containing carbohydrates on the surface of bacteria 
(Weis et al., 1992; Holmskov et al., 1994). In plasma, MBP associates with a Ser 
protease called MBP-associated Ser protease (MASP) which is analogous to the 
Clr2 Cls2 tetramer of the classical pathway (Matsushita et al., 1992). Upon 
recognition of mannose and /o r N-acetylglucosamine on bacterial 
polysaccharides by the globular head of MBP, the MBP-bound MASP is 
activated (Ohta et al., 1990; Lu et al., 1990; Matsushita and Fujita, 1992). 
Activated MASP cleaves C4 and C2 and, therefore, triggers the assembly of C3
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convertase by utilizing components of the classical complement pathway 
(Matsushita and Fujita, 1992) (see Figure 1.2).
Upon production of C3 convertase by any of the three complement pathways 
described above, the formed C3b can undertake two functions. Firstly, by 
binding to C3b receptors on phagocytic cells, it may potentiate the clearance of 
opsonised particles (or ICs), and secondly, by binding to the C3 convertase it 
forms the C5 convertase which initiates activation of the lytic MAC pathway of 
complement (Figure 1.2). Briefly, this complex cleaves C5 to C5a and C5b. C5a 
is an anaphylatoxin and C5b is involved in initiating the lytic pathway of 
complement. C5b gains a binding site for C6 and this complex binds C7 which 
produces a trimolecular complex with a hydrophobic domain (Davies et al., 
1989). The trimolecular complex is released from C3b, inserts into the parasite 
membrane via its hydrophobic domain and gains a binding site for C8 and then 
C9 (Monahan and Sodetz, 1981). This multiprotein complex then binds more 
C9 to form C9 polymers and initiates a lytic lesion which forms a pore (Podack, 
1984). As a defence mechanism the affected cell (eg. bacteria) may exocytose 
and release the attached MAC to the surrounding medium. Otherwise, in the 
absence of complement regulatory proteins (see below), the cell will be lysed.
As well as causing cytolysis of foreign organisms by the MAC and opsonisation 
of foreign organisms via complement receptors (CR1, CR2, CR3, and CR4) on 
phagocytes, the complement system also produces proteolytic fragments of 
complement components which induce inflammation. For example, C5a is 
chemotactic for neutrophils and activates the neutrophil oxidative burst. 
Similarly, C5a > C3a »  C4a stimulates mast cell degranulation which results in 
an increase in vascular permeability and smooth muscle contraction 
(anaphylaxis).
Another important feature of the complement system is that it represents a form 
of self non-self discrimination. A series of soluble and cell membrane proteins 
are expressed by vertebrates that inactivate complement and thereby prevent 
inadvertent destruction of self cells by the complement system. Among the 
soluble complement regulatory proteins is Cl inhibitor, a potent Ser protease 
that binds to activated form of Cl (Clq-2Cls-2Clr) and dissociates Clq from Clr 
and Cls (Ziccardi, 1981). Another soluble complement regulatory protein, factor 
I, is a Ser protease that degrades C3b and C4b in the presence of plasma 
cofactors C4 binding protein, factor H, membrane cofactor protein (MCP) or CR 
type 1 (CR1). Two other soluble proteins that regulate the lytic pathway of
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complement are vitronectin (S Protein) and clusterin. It has been shown that 
vitronectin (Bariety et al., 1989) and clusterin (Tschopp et al., 1993) both bind to 
C5b-7 in fluid phase and inhibit its insertion into the lipid bilayer of the cell 
membrane. Recent findings also suggest that the plasma protein, HRG, can bind 
to C8, C9, S protein and factor D and may inhibit lysis of erythrocytes by the 
MAC (Chang et al, 1992b).
Rather than simply inactivating the complement cascade, some soluble 
complement regulatory proteins have additional functions. For example, factor 
I can cleave C3b to iC3b, C3c and C3dg and C4b to iC4b, C4c and C4d. This not 
only results in inhibition of further activation of C3 or C5 by either the classical 
or alternative complement pathways, but also generates biologically active 
components of C3b that bind to specific cell surface receptors. For example, 
iC3b and C3dg bind to CR3 and CR2, respectively, which in turn may mediate 
phagocytosis (Myones et al., 1988) or modify the immune response (Matsumoto 
et al., 1991).
Several cell surface molecules, such as decay accelerating factor (DAF) (Lublin 
and Atkinson, 1989), MCP (Cole et al., 1985; Liszewski et al., 1991) and CR1 
(Holers et al., 1989; Fearon, 1983), have been shown to inhibit the activation of 
complement on self-tissues and prevent self tissue injury. These proteins 
inactivate C3 convertase and inhibit classical, lectin and alternative complement 
activation. It has also been shown that C8 binding protein and CD59 both bind 
to C8 and prevent the assembly of the MAC thus protecting self-cells from lysis 
(Hansch et al., 1981; Davies et al., 1989; Holguin et al., 1989; Yamashina et al., 
1990).
It should be noted that tissues vary in their expression of these inhibitory 
proteins and, thus, the extent of protection against activation of complement is 
somewhat tissue-specific. For example, CR1 is detected on glomerular epithelial 
cells but not on renal endothelial or mesangial cells (Appay et al., 1990). It has 
also been demonstrated that nucleated cells are more resistant to complement 
activation compared to non-nucleated cells, such as erythrocytes and platelets, 
since nucleated cells can continually synthesise the inhibitory proteins (Ramm et 
al., 1984).
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1.2.2 Immune complex formation
The binding of Abs to Ags leads to the formation of ICs. ICs can form following 
the interaction of Abs with intact microorganisms. However, in this section ICs 
that are formed by the interaction of Abs with soluble Ags such as proteins, 
carbohydrates or DNA will be considered. The term "immune complex 
formation" (ICF) refers to the interaction of Abs with their cognate Ags. This 
interaction was proposed to be similar to protein-ligand interactions since 
kinetic analyses of the interaction using immobilized Abs and soluble Ags 
revealed the reaction to be reversible. The reaction therefore could be written 
as:
xAb + yAg ^ * AbxAgy
This type of interaction may occur with mAb where the Ab recognises only one 
epitope on the Ag and the interaction is homogenous for the entire reaction. In 
this type of interaction the ligand can associate and dissociate. Therefore it is an 
Ag-dependent process. However, when polyclonal Abs are mixed with their 
cognate Ag, regardless of the ratio of Ag : Ab or reactant concentration, this 
reversible reaction follows a process of "insolubilisation" which leads to the 
formation of insoluble ICs (Gorgani et al., 1996). The insolubilisation process, 
which is an Ag-independent process, leads the entire process to become an 
"irreversible interaction" (see Scheme 1).
Insoluble ICs form when polyclonal Ab preparations are incubated with their 
cognate Ag, and this system has been widely used as a model to study ICF in 
vitro. Evidence suggests that two types of interactions may be important in 
ICF: the interaction between epitopes on the Ag and the Ag binding sites of the 
Ab molecules (Murphy et al., 1988), and the less well-defined interaction 
between the Fc region of Ab molecules (Möller, 1979; Meller and Steensgard, 
1979; Rodwell et al., 1980; Meller and Bak, 1984; Cosio et al., 1987; Easterbrook- 
Smith et al., 1988; O'Brien et al., 1994). Moreover, it has been proposed that the 
formation of insoluble ICs occurs in three distinct steps, as shown in Scheme 1. 
These include the rapid formation of soluble Ag : Ab complexes within the first 
few seconds of the reaction (Step 1) (Ag-dependent), followed by the 
subsequent insolubilisation of these soluble complexes to form insoluble 
species in a process lasting several minutes (Step 2) (Ag-independent), and the 
coalescence of the larger species to form precipitates on a time scale of minutes 
to hours (Step 3) (Sittampalam and Wilson, 1984a, 1984b).
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xAb + yAg —> AbxAgy Step 1
nAbxAgy -> (AbxAgy)n Step 2
(AbxAgy)n —> precipitate Step 3
Scheme 1: Formation of insoluble ICs
The experimental techniques that have been used to study ICF in vitro include 
sedimentation methods (Möller and Steensgard, 1979), electron microscopy 
(Murphy et aL, 1988) and light scattering techniques (Murphy et al., 1988, 
Sittampalam and Wilson, 1984a, 1984b; Yarmush et al., 1988). Since the 
formation of insoluble ICs leads to the generation of a turbid suspension, and 
the turbidity or light scattering and absorbing properties of the suspension is 
related to the size of the particles in the suspension (Stacey, 1956), this method 
was widely used to study the mechanism of ICF and to elucidate effects of 
human plasma proteins, such as components of complement (eg. Cl, Clq and 
C3b) which affect this process. Previously it was thought that the formation of 
insoluble ICs only leads to the formation of small size insoluble ICs (as shown 
in step 2) which then form precipitates (Easterbrook-Smith, 1993). However, 
recent studies (Gorgani et al., 1996) indicate that after insolubilisation of ICs 
they polymerise rapidly and this leads to the formation of very large insoluble 
ICs observable in a suspension by visual inspection (see below). The 
insolubilisation process, which presumably is vital for the effective functioning 
of humoral immunity, may increase the efficiency of Ab to tightly bind to Ag 
(see below).
As outlined in scheme 1, a major feature in the formation of precipitates (step 3) 
is the insolubilisation of soluble ICs (step 2) following the interaction of Ab with 
their cognate Ag (step 1). Since the size and resultant abnormal clearing of 
insoluble ICs has been proposed to be an important parameter in inducing 
some pathological conditions (Geronski et al., 1985), there have been many 
attempts to estimate the size of insoluble ICs. The use of electron microscopy or 
conventional light scattering (at a single wavelength) techniques only allowed 
the size of insoluble ICs to be estimated at the end of the reaction (Sittampalam 
and Wilson, 1984a, 1984b; Murphy et al., 1988; Yarmush et al., 1988) and no 
technique was available for the continuous accurate measurement of the size of 
complexes during the insolubilisation of ICs. However, in 1993 a technique was 
developed which allowed one to continuously measure the increase in the size 
of insoluble ICs by measuring the light scattering properties of the suspension
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at different wavelengths (Easterbrook-Smith, 1993), although the problem of 
sedimentation of large insoluble ICs led to inaccuracies.
In order to overcome this problem a continuous mechanical stirring of the 
reaction solution has been employed to accurately determine the rate of 
increase in the size of ICs formed between ovalbumin and anti-ovalbumin IgG 
(Gorgani et al, 1996). The results suggest that the formation of insoluble ICs in 
a continuously stirred solution occurs in at least two phases by a mechanism 
dependent on the concentration of the Ab, the Ag : Ab ratio and the ionic 
strength of the reaction medium. In this system, initiation of ICF by mixing the 
Ab and Ag led to the generation of insoluble ICs of radii up to approximately 
100 nm (scheme 1, step 2), and was followed by a rapid increase in the size of 
ICs (Figure 1.3A, B and C) (scheme 1, step 3). By employing continuous 
mechanical stirring of the solution, the rapid polymerisation and formation of 
very large insoluble ICs in the second phase of the reaction could readily be 
quantified (Figure 1.4) (Gorgani et al., 1996).
Similar patterns of ICF were obtained when F(ab')2 fragments of IgG were used 
instead of whole IgG (compare Figure 1.3A and B) but the formation of 
insoluble ICs with a 100 nm radius (scheme 1, step 2) was ~ 70 fold slower. 
These observations suggest that Fc-Fc interactions lead to a 70-fold faster 
insolubilisation of ICs when compared to IgG molecules that lack this region. 
The similarity between the polymerisation phase (scheme 1, step 3) of ICs 
containing whole IgG and those containing F(ab')2 fragments of IgG suggests 
that the rapid polymerization occurs even with IgG molecules that lack the Fc 
region and hence the Fc-Fc interaction. The results suggest that the 
polymerization phase is not dependent on the Fc-Fc interaction but presumably 
involves a Fab-Fab interaction (Figure 1.3A and B). Interestingly, insoluble ICs 
in Ag excess and Ab excess also underwent rapid polymerization after reaching 
the critical size of 100 nm suggesting that the Ag : Ab ratio has its major effect 
on the rate of phase 1 insolubilisation (scheme 1, step 2) with rapid phase 2 
polymerization (scheme 1, step 3) occuring at all Ag : Ab ratios (Figure 3.1C). 
This study also presented evidence that ionic interactions play a role in step 2 
insolubilisation of ICs since there was a sodium halide concentration- 
dependent inhibition of the insolubilisation of ICs containing both whole IgG or 
F(ab')2 when the average radius of ICs was <100 nm (Gorgani et al., 1996).
Since the insolubilisation process results in an increase in turbidity and 
absorbance, the kinetic parameters (eg. on-, off-rates) for the insolubilisation of
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FIGURE 1.3 The effect of Ab concentration on the size of ICs formed 
from ovalbumin and IgG or F(ab')2*
The formation of insoluble ICs was initiated by adding ovalbumin to give 
an Ag : Ab ratio of 0.03 : 1 (w /w ) to solutions of anti-ovalbumin IgG at 1.0 
(a), 0.75 (O), 0.5 (•), 0.375 (□) and 0.25 (■) m g/m l in PBS. The radii of the 
ICs that form ed as a function of time at different w avelengths was 
determined as described (Gorgani et al., 1996) and shown in (A). (B). The 
formation of insoluble ICs using F(ab')2 fragment of IgG instead of IgG. 
The formation of insoluble ICs was initiated by adding ovalbumin to give 
an Ag : Ab ratio of 0.03 : 1 (w /w ) to a solution of F(ab')2 (made from of 
anti-ovalbumin IgG) at 0.56 (■), 1.15 (□), 1.71 (•), 2.25 (o) m g /m l in PBS. 
(C). The effect of Ag : Ab ratio on the size of insoluble ICs that formed. 
The formation of insoluble ICs was initiated by adding ovalbumin to give 
Ag : Ab ratios (w /w ) of 0.015 : 1 (■), 0.03 : 1 (□), 0.045 : 1 (•), and 0.06 *. 1 (O), 
to solutions of anti-ovalbumin IgG (0.5 m g/m l) in PBS. In each instance 
the absorbances associated with light scattering by the ICs at different 
wavelengths were m easured, and the size of the ICs were calculated as 
described (Gorgani et al., 1996).
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FIGURE 1.4 Rapid polymerisation of insoluble ICs.
Photographs show insoluble ICs that were formed at 0 (A), 5 (B), 10 (C), 15 
(D), 30 (E), 60 (F), 120 (G), 300 (H) and 600 (I) seconds after the initiation of 
the reaction by mixing 1 mg/m l of anti-ovalbumin IgG with ovalbumin 
at an equivalence Ag : Ab ratio in a stirred reaction vessel.
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ICs can be determined using absorbance measurements obtained at 350 nm. 
For each concentration of IgG and ovalbumin at an equivalence Ag : Ab ratio, 
the initial absorbance values of the insolubilisation phase (scheme 1, step 2) (as 
depicted in Figure 1.3A) could be fitted to the equation:
A = A0 x e k°bs * + c
Where t is time, A is the absorbance due to light scattering by the insoluble ICs 
at time t, A0 is the absorbance due to light scattering by the insoluble ICs at time 
0, k0bs is the observed rate constant for insolubilisation of ICs and c represents a 
net displacement (constant). For each concentration of ICs, kQbs was calculated 
by fitting the absorbance data to the exponential curve and then the kcbs was 
plotted versus concentrations of IgG assuming that the initial concentration of 
ICs is correlated with the initial concentration of IgG (Ag : Ab ratio is constant). 
This plot revealed that the off-rate of this process is zero and the on-rate is 
42075 M'1s_1. These results therefore indicate that the insolubilisation process is 
an irreversible process with a pseudo-on rate of 42,075 M-1s_1 (Gorgani et al., 
unpublished observations).
1.2.3 Mechanisms of IC clearance
In primates ICs are cleared in different ways depending on the site at which 
they are formed. For example, in the case of formation in the circulation, ICs 
bind to erythrocytes and are transferred to the liver or spleen to be cleared by 
resident macrophages in these organs, whereas in the case of formation in 
lymph nodes, ICs may be cleared by macrophages and dendritic cells, and if ICs 
are formed in other tissue they may be cleared by tissue macrophages.
1.2.3.1 Erythrocyte-IC clearance mechanism
ICs formed in the circulation activate complement and are rapidly opsonized 
following fixation of C3b and C4b. Both C3b and C4b bind erythrocyte CR1, 
thus C3b or C4b opsonised ICs can bind erythrocyte CR1. CR1 only exists on 
the surface of erythrocytes in humans and other primates (Nickells et al., 1995). 
In contrast to leukocytes, the erythrocyte CR1 is clustered and allows C3b 
and/or C4b opsonised-ICs to bind multivalently. Although circulating 
leukocytes such as neutrophils and monocytes possess CR1 on their surface, it 
has been calculated that 85% of CR1 in the circulation is associated with 
erythrocytes. It is likely, therefore, that most circulating ICs (CICs) which are
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not bound to FcR on leukocytes may bind erythrocyte CR1 (Hebert, 1987; 
Hebert, 1991; Hebert et aL, 1991a, 1991b). ICs that are bound to erythrocytes are 
prevented from being deposited in tissues and remain bound until the 
erythrocytes traverse the liver or spleen, at which point the ICs are released 
from the erythrocyte surface and taken up by macrophages. The transfer of ICs 
from erythrocytes to macrophages occurs quickly and involves the binding of 
the Fc region of ICs to FcR on macrophages. The erythrocytes then re-enter the 
circulation and may be able to undertake the same function again. Studies in 
nonhuman primates have shown that decreased binding of ICs to erythrocyte 
CR1 results in a decreased uptake of ICs by the liver or spleen but increased 
deposition of ICs in the kidney (Waxman et al., 1984; Waxman et al., 1986), 
indicating the importance of the erythrocytes CR1 in the clearance of CICs.
1.2.3.2 Clearance of ICs by reticuloendothelial system
The clearance of ICs may occur via the ingestion of ICs by phagocytic cells of 
the RES. Phagocytic cells are divided into two classes: those whose function 
relates to the body's defence such as neutrophils, eosinophils, monocytes and 
macrophages, and those that are non-professional phagocytes such as epithelial 
cells, platelets, fibroblasts, lymphocytes, mast cells and various mucous 
membranes. The ingestion occurs predominantly via IgG-FcR interactions and 
also through CRs if the complement component C3b is attached to the ICs. ICs 
are one of the most potent activators of macrophages, the binding of ICs to FcR 
converting a macrophage from a resting state into a primed (activated) state 
which then leads to the ingestion and digestion of ICs. Hitherto, IgG, IgA and 
the C3b fragment of C3 are the opsonins that facilitate phagocytosis. As 
described earlier in section 1.2.1.2, receptors for the Fc region of Igs are 
heterogenous and present on many cells of the immune system. Several types 
of FcR are expressed by phagocytes: FcyRI (CD64) which is expressed on 
monocytes; FcyRIIa (CD32a) which is expressed on all major types of 
phagocytes; FcyRIIIb (CD16b) which is expressed on neutrophils; and FcaRI 
(CD89) which is expressed on monocytes, macrophages and neutrophils (Table 
1.4). Upon binding of ICs containing the appropriate IgG isotype to these 
receptors they induce phagocytosis. At least three CRs are expressed on the 
phagocyte surface: CR1 (CD35), CR3 (CDllb/CD18) and CR4 (CDllc/CD18). 
These receptors can promote phagocytosis only if the particles are also attached 
to the phagocytic cells via FcR or fibronectin.
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The binding of ICs or opsonised particles to FcR leads to receptor clustering 
which brings together protein kinases bound to the cytoplasmic regions of the 
FcR. Subsequently, the protein kinases are phosphorylated and signal 
transduction pathways initiated that lead to the formation of actin filaments 
and pseudopodia and eventual phagocytosis. Complement receptors 
collaborate with FcR to enhance the intensity of phagocytosis. Upon attachment 
of ICs to FcR and CRs on the cell surface, they are engulfed and retained in 
vesicles which fuse together to form large vesicles called phagosomes. 
Phagosomes containing ICs then move towards the cell centre and fuse with 
lysosomes. The ingested ICs then are digested by a wide variety of enzymes 
(hydrolases) present in the lysosomes and specific granules in the cytoplasm of 
the phagocytic cell. The ICs in the phagosomes may be digested to amino acids, 
sugars, lipids and nucleotides which can then cross the phagosome membrane 
to be re-used by the ingesting cell. The killing of a phagocytosed 
microorganism also can be achieved by mechanisms such as the respiratory 
burst which involves the formation of oxygen derivatives such as the 
superoxide anion ( 0 2‘), hydrogen peroxide (H20 2), hydroxyl radicals ('OH) 
and singlet oxygen (10 2). Upon release of these substances into the phagosome 
they act as oxidants causing lethal changes in the ingested microorganisms.
1.2.3.3 Tissue injury caused by phagocytes
In some instances where ICs are too large (eg. Ab-coated multicellular parasites 
or very large hydrophobic insoluble ICs) or strongly adhere to self tissues, the 
phagocytic cells may bind but may not be able to ingest the ICs. In such 
circumstances they may release their lysosomal contents to the cell exterior in 
an attempt to destroy the particle. The release of such enzymes and other 
soluble substances to the cell exterior may cause local tissue damage. This 
process may happen in the synovium of patients with RA where the phagocytic 
cells fail to ingest the high concentrations of ICs (presumably adhering to the 
tissues) and may release hydrolases into the extracellular space which leads to 
tissue injury (Robinson et al., 1994; Mannik and Person, 1994; Edwards and 
Cambridge, 1998).
1.2.4 Factors which regulate IC formation and clearance
1.2.4.1 The nature of the Ag and the Ab response it induces
The physical nature of an Ag can have a profound affect on the class, subclass, 
charge, and affinity of Ab that are produced against it and, in turn, the class and
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subclass of the Ab determines complement fixing ability, rate of clearance and 
ability of ICs to initiate inflammatory reactions (Gauthier and Abrass, 1992, 
Milstein, 1986). For example, it has been shown that polysaccharide Ags with 
repeating antigenic determinants are most likely to induce IgM production, 
IgGl is mostly produced against soluble protein Ag, whereas IgG2 is mostly 
produced in response to carbohydrate Ag. In contrast, IgA is produced against 
Ag entering through mucosal surfaces such as the respiratory or gastrointestinal 
tracts (Gauthier and Abrass, 1992; Milstein, 1986; Purkerson and Isakson, 1992).
Another important factor is whether the Ag source is chronic or transient in 
nature. For example, exogenous Ag such as drugs may only cause transient IC- 
mediated tissue damage, with eventual clearance of the drug resulting in 
recovery of the affected tissue, whereas an Ab response to an endogenous Ag, 
which always exists at low concentrations, may lead to the gradual formation of 
ICs and chronic progression of ICD. Similarly, in the case of exposure to a 
replicating virus such as hepatitis C virus, if the virus is not efficiently 
eliminated the infection may cause chronic ICD.
1.2.4.2 Rheumatoid factors
RFs are Abs that can recognize other Abs (Panush et al., 1971). They are usually 
of low affinity and, therefore, only bind to Ig in ICs rather than monomeric Ig 
(Johnson and Page Faulk, 1976; Normansell, 1971; Carson et al., 1981). It is 
believed that persistant ICs can activate RF producing B cells, with the resultant 
RF either binding to the persistant ICs and aiding their clearance or enhancing 
their pathological effects (Pisko et al., 1982; Coulie and Van Snick, 1983; 
Nemazee and Sato, 1983). Three types of RFs have been identified, namely Ab 
against the constant domains of the Fc or Fab regions of IgG or against the Ag 
combining site of Ab (anti-idiotypic) (Zanetti and Wilson, 1986). A 
characteristic feature of RA is the production of RFs against the Fc region of IgG 
molecules (Stewart et al., 1997). Ab against the constant domains of the Fab 
regions of IgGs were detected in the plasma of SLE and RA patients (Nasu et al., 
1980). Anti-idiotype Abs have been detected in several models of IC formation 
in the glomerulus. These Abs may add to glomerular immune deposits and 
potentially could contribute to the chronicity of some forms of immunologic 
nephritis (Zanetti and Wilson, 1986). The precise role of anti-idiotype Abs in 
glomerular injury associated with tissue-bound primary ICs is not clear. 
However, it would be expected that the binding of these anti-idiotype Abs to
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primary ICs may change the size, complement fixing ability and other 
biological properties of ICs trapped in tissues (Abrass, 1997).
1.2.4.3 Regulation of IC formation by complement
It has been known for many years that following activation of the classical 
pathway, complement inhibits formation of insoluble ICs (Heidelberger, 1941) 
and activation of the alternative pathway causes solubilisation of already 
formed insoluble ICs (Miller and Nussenzweig, 1975). Moreover, inhibition of 
formation of insoluble ICs has been shown to occur via interaction of Cl with 
soluble ICs (Schifferli et al, 1985) and this action is potentiated by C4b and C3b 
(Schifferli et al, 1982). In addition, a recombinant soluble form of FcyRII has 
been shown to inhibit IC precipitation (Gavin et al., 1995). An additional 
important consequence of the interaction of complement with ICs is to promote 
the clearance of ICs from the circulation by promoting the binding of ICs to 
erythrocyte CR1 and mononuclear phagocytic ceils (see section 1.2.3). These 
findings suggest that complement deficiency, either environmentally induced 
or genetically based, may induce ICDs (Lachmann and Walport, 1987).
1.2.4.3.1 Environmentally induced depletion of complement
In some infectious diseases the presence of a high load of foreign Ag or the 
persistance of Ag (eg. chronic viral hepatitis) may lead to a profound depletion 
of complement since under these conditions the activation and catabolic rate of 
complement would be much higher than its synthesis. In such circumstances, 
the absence of complement or other regulatory plasma proteins may 
compromise the normal pathway of IC clearance.
The plasma level of complement components has been used as a tool for the 
diagnosis of ICD that are associated with hypocomplementaemia. These 
studies indicated that some ICD can cause hypocomplementaemia, whereas 
others do not (Table 1.5). It has been shown that the level of complement 
components C3 and C4 was usually decreased in the plasma of patients 
suffering from hypocomplementaemia-associated ICD (Table 1.6). In cases 
where ICs induced activation of the classical complement pathway the levels of 
both C3 and C4 were similarly decreased. However, in cases where activation 
of the alternative pathway predominated, the C3 component was reduced more 
than C4 (Hebert et a l, 1991c). Despite the fact that the majority of ICD are 
associated with hypocomplementaemia, in some ICD plasma complement
Table 1.5 Immune Complex-Mediated Diseases with or 
without Complement Depletion
Conditions coincident with low plasma levels of complement
SLE
Membranoproliferative glomerulonephritis 
Cryoglobulinemia
Glomerulonephritis of chronic infection
Postinfectious glomerulonephritis
Rheumatoid vasculitis
Idiopathic vasculitis
Drug-induced SLE
Repeated injection of foreign protein
Hypersensitivity to drugs
Chemotherapy for malignancy with immune complex formation 
Thyroid diseases and glomerulonephritis 
Jejunoileal bypass with vasculitis
B-cell lymphoproliferative disorder with immune complex formation
Conditions coincident with high plasma levels of complement
Systemic infections
Chronic inflammatory diseases (eg. RA)
Conditions with normal plasma levels of complement
IgA nephropathy
Idiopathic membranous nephropathy 
Henoch-Schonlein purpura 
Goodpasture's syndrome
Immunotactoid and fibrillary glomerulonephritis 
Clq glomerulopathy
Adapted from Hebert et al., 1991c and 1997
A
dapted from
 W
alport and D
avies, 1996 and H
ebert et al., 1997
C
l
C
l
C
l
C
3
C
4
Fa<
C
5 a  0ro O
' ^  M.^  O 3 "
vq ^ 3- n
>i HH M
di 3
Q.HQ
03 3- 3 0)
o X  oVO o H 3  3
HH * n
I V
3ft
r  r  g  x r* i
03 03 3^  ^  rn ^ rnCD CD O O CD xlr/«, r/N h_H k_H C___ J r r \  C  J
3h-*«
HH
O)h
V/J V/J ”  ' » Nr-*  V/J v*— /
rt rf ^ ^ \£3 *H- HH
no>
3T 3" {£, r+ O 3T O n 3<H*5«^ Vw »-J1 r-* 0
3 3 £ £ 3 a Ssr— lO 3 3 K>r n v vr^  r n Mv*-*' vJI \4-J \4J vJ I
88 55 5 5 88 ron[
o
3
HH
3
a
''J h< *7 I^ S H< s
H*«
CLfD fD 03CD ^ C/3 CD H* 3
c/3 'Ca t*> sr to
^ H 03< ^  OJ < CDM
C/3
0) 5^ 03i-t O'* 1-1 rn
0) "— —' 03
Ol ►£>
°3
Table 1.6 C
om
plem
ent D
eficiency and Im
m
une C
om
plex D
iseases
Chapter 1 Literature Review 40
levels do not change or are rarely associated with hypocomplementaemia 
(Hebert et al., 1991c) (Table 1.5). In addition, it has been shown that some 
conditions may actually raise serum complement levels (Table 1.5).
There is substantial evidence that the processing of ICs is abnormal in diseases 
such as SLE, which are associated with hypocomplementemia. In fact, two 
abnormalities have been detected in IC transport in patients with SLE and 
hypocomplementemia. Firstly, low plasma levels of complement result in the 
formation of larger ICs, which fix less complement and may not bind efficiently 
to erythrocyte CR1. Secondly, erythrocytes of patients with SLE carry reduced 
numbers of CR1 (Miyakawa et al., 1981; Iida et al., 1982). Although there is a 
genetic polymorphism in CR1 expression (Klopstock et al., 1965; Wilson et al., 
1982) the bulk of evidence indicates that the reduction in CR1 is an acquired 
process (Walport and Lachman, 1988). There is evidence showing that CR1 is 
enzymatically cleaved from erythrocytes during the interaction of erythrocytes 
containing ICs with mononuclear phagocytic cells in the liver or spleen 
(Walport et al., 1987; Cosio et al., 1990; Birmingham et al., 1990; Davies et al., 
1990a, 1990b). These abnormalities may result in a reduction in the binding of 
ICs to erythrocytes and may increase IC deposition in blood vessel walls. In 
vitro studies have indicated that the binding of ICs to erythrocyte CR1 prevents 
injury to endothelial cells by reducing the pro-inflammatory reaction of ICs 
with neutrophils (Beynon et al., 1994). These observations provide evidence 
that erythrocyte CR1 may act as a buffer for toxic ICs in the circulation and 
prevent their interaction with other cell types while delivering ICs to the fixed 
mononuclear phagocytic cells in the liver or spleen (Davies et al., 1995).
Major abnormalities in IC processing by the mononuclear phagocytic system 
were observed in humans with acquired complement deficiency (Davies et al., 
1992). The uptake of ICs by spleen showed complete complement dependence 
(Davies et al., 1993), a correlation being observed between defective uptake by 
spleen and the degree of hypocomplementaemia (Davies et al., 1992). In 
contrast, the uptake of ICs by the liver was increased in patients with 
hypocomplementaemia compared to normal subjects but the ICs were rapidly 
released from the liver back into the circulation. It was proposed that in normal 
subjects the complex of C3b-IC may engage both FcR and C3b receptors on liver 
phagocytes (Kupffer cells) and may result in efficient uptake and internalization 
of ICs, whereas in SLE patients the absence of C3b may result in a less efficient 
interaction of ICs with FcR and consequently impaired uptake. Based on this
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model, uptake of ICs by splenic phagocytes appears to be totally C3b receptor 
dependent.
1.2.4.3.2 Effect of genetic deficiencies in complement and complement 
regulatory proteins on IC clearance
Although most complement deficiencies are known to be environmentally 
induced, a number of genetic deficiencies in complement have been shown to 
be associated with a high incidence of ICDs (Table 1.6). For example, 30 of 32 
patients with hereditary Clq deficiency (or Cl deficiency) have a dramatically 
high prevalence of ICDs (Bowness et al., 1994) indicating that the presence of 
Clq (or whole Cl) may be necessary to prevent the development of ICDs 
(Schifferli, 1987; Schifferli et al., 1982,1985,1987). It should be noted, however, 
that although Clq deficient patients are shown to develop SLE, the presence of 
whole Cl rather than just Clq may be necessary for the prevention of ICDs.
The most striking feature of these genetic deficiencies is that deficiencies in 
complement components involved in the classical or lectin pathways (eg. Cl, 
C2, C4) are associated with a very high incidence of ICDs, particularly SLE 
(Table 1.6). In contrast, deficiencies in components associated with the 
alternative pathway or the MAC result in a much lower incidence of ICDs 
(Table 1.6). Interestingly, C3 deficiency is associated with a high incidence of 
other ICDs but not SLE.
1.2.5 IC-mediated diseases
Under normal conditions the interaction of Abs with their cognate Ags should 
result in the clearance of ICs by the RES. However, due to a range of genetic 
defects (eg. see Table 1.6) (Leber and McCluskey, 1974; Theofilopoulos and 
Dixon, 1980; Schifferli, 1996) or to the excessive formation of ICs which may 
saturate FcR and deplete complement components (eg. Cl, C3, see Table 1.5), 
ICs may escape RES clearance (Walport and Davies, 1996; Hebert et al., 1997). 
The escaped-ICs are pathogenic macromolecules with properties that are 
entirely different from Ags or Igs themselves. Escaped-ICs may bind to tissues 
by nonspecific mechanical means, eg. in renal glomeruli, in joints or in blood 
vessels. Persistance of these trapped ICs in tissues can lead to localized 
accumulation of activated complement components and the attraction of 
phagocytic cells (see below) (Theofilopoulos, 1980; Theofilopoulos and Dixon,
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1980). The escaped-ICs also may interact with phagocytic cells in tissues 
leading to activation of the local phagocytic cells and a resultant release of 
cytokines, vasoactive substances, and activators of the coagulation cascade 
(Wener and Mannik, 1986; Haakenstad et al., 1976). Collectively these effects 
are proinflammatory and may cause localized tissue damage and, ultimately, 
pathological effects.
Kidneys, joints and blood vessel walls are the most common sites susceptible to 
deposition of plasma CICs since the capillaries in renal glomeruli (to form 
urine) and synovia (to form synovial fluid) are the vessels in which plasma is 
ultrafiltered at high hydrostatic pressure (Abbas et al., 1991). Since the kidney 
receives 25% of cardiac output, the Ags, Abs and ICs are delivered to the kidney 
at a high rate. The glomerular capillary wall provides a surface upon which 
circulating proteins may be trapped non-specifically or may directly interact 
with constituents of the capillary wall. Almost all glomerular diseases are 
mediated by abnormal regulation of the immune system and most of them are 
mediated by ICs (Abrass, 1997).
Necrosis and cellular infiltrates (predominantly composed of neutrophils) are 
the two morphological hallmarks of ICDs. Sites of necrosis often contain fibrin 
because of leakage of plasma proteins and is termed ’ fibrinoid necrosis”. In this 
section ICDs are discussed where organ dysfuction results primarily from tissue 
damage caused by the deposition of ICs, presumably resulting from abnormal 
regulation of IC processing and clearance.
1.2.5.1 Glomerulonephritis
Glomerulonephritis (GN) is one of the most characteristic pathological 
conditions, caused by the deposition of blood borne ICs in the glomerulus. 
Diseases that are associated with GN are listed in Table 1.7. ICs can accumulate 
in the glomerulus in three ways, namely (a) ICs may initially form in the 
circulation and as a consequence of impaired clearance they may be deposited 
in the glomerulus, (b) ICs may be formed in situ by Ab reacting with Ag, such 
as DNA, trapped in the glomerulus and (c) ICs may result from Ab reacting 
directly against intrinsic glomerular Ag.
The size of ICs is shown to be an important factor in their localization in the 
glomerulus (Wener and Mannik, 1986). In IC-mediated GN (ICGN) latticed 
insoluble ICs accumulate in the mesangium and subendothelial space, whereas
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small soluble ICs penetrate the glomerular basement membrane and deposit in 
the subepithelial space (Mannik et al., 1983; Agodoa et al., 1983). These features 
of ICs indicate that ICs containing the same Ag can cause various type of ICGN.
It also has been demonstrated that the affinity of Ab for Ag may affect the IC 
deposition sites. For example, in animals the formation of membranous 
nephropathy (Table 1.7) was induced by the injection of low affinity Ab which 
deposited ICs in the subepithelial space rather than in the mesangium or 
subendothelial space (Iskandar and Jennette, 1983; Steward, 1979). On the other 
hand, injection of high affinity Ab resulted in the formation of large insoluble 
ICs which were either cleared by phagocytosis or were deposited in the 
mesangium and subendothelial space (Steward, 1979). In non-inflammatory 
glomerular disease it has been shown that CICs can also indirectly initiate 
glomerulosclerosis when the Ig deposits are not detected but the immune 
system is still activated in the glomerulus (Savin, 1993).
Deficiencies in FcR function have also been shown to be related to diseases such 
as ICGN. A number of studies have clearly indicated that the saturation or 
impairment of FcR-mediated phagocytosis leads to IC deposition in various 
organs (Kijlstra et al., 1978; Mauer et al., 1972). Futher studies have 
demonstrated that the enhancement of FcR-mediated phagocytosis minimizes 
the accumulation of immune deposits in the kidneys (Abrass, 1984). In addition 
to facilitating the clearance of ICs, FcR are crucial for the initiation of 
inflammatory responses which are amplified by cytokines and complement 
(Sylvestre and Ravetch, 1994). FcR ligation also has been shown to increase 
expression of IL-10 (Tripp et al., 1995) which in turn increases the expression of 
FcR. Thus by a positive feedback, FcR ligation enhances phagocytosis. 
Glomerular epithelial and mesangial cells of the kidney have been shown to 
express FcR and ingest ICs. However, they may not be able to digest large and 
insoluble ICs (Mancilla-Jimenez et al., 1984; Neuwirth et al., 1988). These 
features of epithelial and mesangial cells may contribute to the accumulation of 
ICs in the glomerulus (Furness, 1993).
1.2.5.2 Tubulointerstitial nephritis
Tubulointerstitial nephritis (TIN) is an example of a pathological condition 
caused by IC deposition and cell-mediated destruction. Although the 
abnormality occurs in the interstitial tubules of the kidney, the mechanisms 
causing TIN are similar to the ones which affect the glomerulus of the kidney. 
Diseases that are associated with TIN are listed in Table 1.7. The disease is
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classified according to the site that Abs bind to Ags and cause inflammation. 
The consumption of drugs such as penicillins, cephalosporins, and phenytoin 
have been implicated in TIN. It has been proposed that the CICs containing Ab 
and drugs may passively deposit in the interstitium and cause the disease or 
they may cause TIN by cell-mediated mechanisms.
A number of bacterial (eg. streptococcal) and viral infections have been 
implicated in TIN since Ab against streptococci have been shown to cross-react 
with the non-collagen-like domain of collagen IV which exists in the tubular 
basal membrane (Lehman et al., 1975). Tubular cells may be infected with 
cytomegalovirus and express new Ag which in turn become a target for Ab or 
cell-mediated immunity. CICs can also deposit in the renal interstitium of 
patients suffering from systemic disease such as serum sickness, IgA 
nephropathy, cryoglobulins, SLE and Sjorgen nephropathy (Table 1.6). When 
accompanied by GN they may lead to renal malfunction.
1.2.5.3 Vasculitis
Vasculitis is a pathological condition characterized by inflammation and 
necrosis of blood vessels, resulting in vessel occlusion and ischemia of tissues 
presumably due to lack of nutrient transport by involved vessels (Fauci et al., 
1978; Cupps and Fauci, 1981, 1982; Fauci, 1983; Andrassy et al., 1983; 
McCluskey and Bhan, 1983; Haynes et al., 1986; Smoller et al., 1990; Smiley and 
Moore, 1989). The deposition of ICs in and around blood vessel walls is 
responsible for the initiation of vasculitis lesions in many of the syndromes 
listed in Table 1.7. Also there is evidence for pathogenic ICF in specific 
vasculitis syndromes. For example, in polyarthritis nodosa (hepatitis B 
associated vasculitis) ICs containing hepatitis B surface Ag are present in the 
circulation and tissues (Gocke et al., 1970) and can induce vasculitis ranging 
from urticarial vasculitis to systemic necrotizing vasculitis (Dienstag, 1981).
Several investigators have outlined mechanisms for the pathogenesis of 
vascular damage when ICs are not cleared by normal mechanisms. For 
example, pathogenic ICs can activate complement components that participate 
in the amplification phase of the inflammatory response via generation of 
chemotactic factors for neutrophils and monocytes such as C5a. Further 
activation of complement can lead to the assembly of the MAC, thereby causing 
cellular damage. Further phagocytic activation causes release of proteolytic 
enzymes (eg. elastase, cathepsin, proteinase 3), reactive oxygen metabolites and
Chapter 1 Literature Review 45
proinflammatory substances such as leukotrienes, and prostaglandins. As a 
consequence of the resultant vessel damage, platelets may adhere to locally 
damaged endothelium, aggregate and obstruct blood vessels, and induce vessel 
necrosis and clot formation (Fauci et al., 1978; Van Es et al., 1984; Tosca and 
Stratigos, 1988). It is noteworthy that local characteristics of the blood vessels 
themselves may influence IC deposition. For example, structural and 
hemodynamic differences among various blood vessels may result in ICs being 
deposited at the branch point of vessels (Giacomelli and Weiner, 1974; Huttner 
et al., 1970).
Although the deposition of pathogenic ICs is responsible for the initiation of the 
vasculitis syndromes, other mechanisms may perpetuate the disease and cause 
further vessel damage. These include the production of Ab of the IgG4 subclass 
against lysosomal enzymes in neutrophils (anti-neutrophil cytoplasmic Ag, 
ANCAs) and monocytes (Van Der Woude et al., 1985; Kallenberg et al., 1991), 
anti-endothelial cell Ab-mediated vessel damage (Cines et al., 1984; Brasile et 
al., 1989), vessel damage due to pathogenic cellular immune responses and 
granuloma formation (Cupps and Fauci, 1981; Fauci, 1983; Fauci et al., 1978), 
and vessel damage or altered vessel function mediated directly by infectious 
agents (Dorff and Lind, 1976; Fernald, 1982; Liu et al., 1989).
1.2.5.4 Arthritis
Arthritis is a pathological condition characterized by inflammation of the joints. 
Many types of arthritis progress from a stage dominated by an inflammatory 
infiltrate in the joint to a later stage in which a neovascular pannus invades the 
joint and begins to destroy the cartilage (eg. in RA). Diseases that are associated 
with arthritis are listed in Table 1.7. In chronic joint inflammation the disease 
manifestation involves largely the activation of cellular immunity. Flowever, it 
also has been suggested that the deposition of pathogenic ICs in both soluble 
and insoluble forms may, at least in part, cause joint inflammation (Edwards 
and Cambridge, 1998). The finding that cell-free synovial fluid of patients with 
RA contains soluble and insoluble ICs that can activate reactive oxidant 
production by macrophages supports this view (Robinson et al., 1994). Recent 
plasmapheresis studies (Balint, 1996) on the removal of CICs from different 
patients with ICDs (including RA), using a protein A/silica column, indicate 
that the removal or clearance of CICs may be of clinical benefit in these 
autoimmune disorders. Moreover, the majority of ICs in the synovium of 
inflammed joints in RA were found to contain IgG but not IgM and the majority 
of the IgG in the soluble and insoluble ICs was of the IgG4 subclass, indicating
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that increased deposition of IgG4 in the joint may contribute to the pathogenesis 
of the disease (Zach et alv 1995).
1.2.6 Treatment of IC-mediated diseases
It has been proposed that IC deposits in tissues are in equilibrium with CICs 
(Abrass, 1997). Therefore reduction of ICs in the circulation may be a viable 
therapeutic approach for ICDs (Balint, 1996). For example, stimulating 
phagocyte function was shown to enhance plasma clearance of CICs and reduce 
glomerular deposits, whereas a reduction in the mononuclear phagocytic 
system (eg. after splenectomy) results in increased amounts of ICs in the 
circulation and their subsequent deposition in glomeruli (Abrass, 1984). 
Similarly, removal of ICs by plasmapheresis through a protein A column has 
been of some clinical benefit (Balint, 1996).
As described above, the majority of self tissue destruction caused by the 
deposition of ICs in tissues is mediated by the activation of complement 
pathways. Under such circumstances, one beneficial way of treating patients 
would be to temporarily attenuate the activation of complement. Four basic 
approaches could be used to diminish the biological activity of complement: (1) 
administration of agents like cobra venom factor that can deplete key 
components of complement such as C3 (Savige et al., 1989). (2) Administering 
agents that inhibit complement activation. Fleparin is the only clinically 
available inhibitor of complement activation, but for efficient inhibition heparin 
has to be administered at a dose much greater than that needed to achieve anti­
coagulation (Waxman et al., 1984). Soluble recombinant forms of CR1, MCP 
and DAF are candidates which can reduce complement-induced injury in 
experimental models of a number of diseases (Causer et al., 1995). However, 
because these recombinant proteins are immunogenic they only can be used for 
acute, not chronic treatment. It has been proposed that the release of CR1 might 
be a natural mechanism for the control of complement activation since CR1 on 
activated neutrophils has been shown to be cleaved and released into the 
surrounding medium (Danielsson et al, 1994). (3) Intravenous injection of high 
doses of Igs has been used to absorb activated complement components before 
they can bind to tissues and initiate further complement activation. Following 
such treatment the Fc portion of the injected IgG absorbs C3b and C4b (Ruiz de 
Souza et al., 1993) and aggregated IgG (~10 % of total injected Ig) binds Cl (Qi 
and Schifferli, 1995). (4) Complement components were removed from the 
circulation by plasmapheresis which was successful in controlling disease
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progression in some cases (Shumak and Rock, 1984). However, other plasma 
components including Ab and coagulation factors are removed following 
plasmapheresis.
Vasculitis is the most common pathological condition associated with ICs and is 
caused by the deposition of ICs in blood vessels. Although some vasculitis 
syndromes can be controlled with a combination of cytotoxic drugs and 
glucocorticosteroids, therapy for vasculitis is usually not optimal and many 
vasculitis syndromes are refractory to therapy. A novel approach has been 
used to inhibit the proinflammatory effects of ICs trapped in the vasculature by 
administering mAbs that deplete leukocyte subsets, block the action of key 
leukocyte adhesion molecules or interfere with proinflammatory cytokine 
action. For example, administration of a combination of anti-CD4 and anti- 
CD52 Abs, which deplete CD4+ T cells and neutrophils respectively, in patients 
with positive ANCAs resulted in resolution of vessel inflammation (Mathieson 
et al., 1990). Similarly, use of CDllb mAbs which block Mac-l-mediated 
adhesion by myeloid cells inhibited inflammation and immune mediated vessel 
injury in many cases (Rosen and Gorden, 1989). It has also been found that 
interleukin 1 receptor antagonists are potent inhibitors of a wide variety of IL1- 
mediated proinflammatory functions and have been in human trials for the 
treatment of RA (Eisenberg et al., 1990, 1991). Other novel biological agents, 
which target tumour necrosis factor alpha (TNFa), including TNFa-blocking 
mAbs (Kavanaugh, 1998), and recombinant soluble TNF alpha receptors 
(Lorenz and Kalden, 1998; Moreland, 1998) are currently being used in clinical 
trials for the treatment of RA.
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As outlined above (Part II), the clearance of ICs from the circulation is largely 
shown to occur via FcR and complement proteins. However, during my PhD 
studies I examined the ability of an additional plasma protein, HRG, to regulate 
the formation and clearance of ICs. As reviewed in Part I of this Chapter, HRG 
has been shown to bind to many ligands associated with the immune and blood 
clotting systems. Furthermore, preliminary studies suggested that HRG binds 
to human IgG and Clq, a result which allowed me to hypothesise that HRG 
may be another endogenous regulator of the formation and clearance of ICs. 
The aim of this thesis was to characterise the interaction of HRG with IgG 
subclasses and clarify the role of HRG in the formation and clearance of ICs, the 
interaction of RF with ICs and the solubilisation of already formed insoluble IC.
CHAPTER 2
MATERIALS AND METHODS
Chapter 2
2.1 Reagents
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H um an myeloma IgGlK, IgGlA, IgG2ic, IgG2^, IgG3K, IgG3^, IgG4K, IgG4A, and 
IgMK were purchased from Sigma, Calbiochem-Novabiochem and Accurate 
Chemicals. Bence Jones (BJ) proteins were a generous gift from Dr Bob Raison, 
University of Technology, Sydney. Hum an IgG (isolated from pooled hum an 
serum), hum an C lq, hum an IgM, bovine serum  albumin (BSA, fraction V), 
ovalbum in (grade V), heparin  (bovine lung) polyoxyethylenesorbitan  
monolaurate (Tween-20), dimethylsulphoxide (DMSO), phosphate-citrate buffer 
w ith sodium  perborate capsules and 2,2'-azino-bis (3-ethylbenzthiazoline-6- 
sulfonic acid) diammonium (ABTS) were purchased from Sigma Chemical Co., 
St. Louis, MO. Biotinylated mAb specific for k or X light chains of rat IgG were 
purchased from Pharmingen, San Diego, CA. Carboxymethyl dextran cuvettes 
for the IAsys biosensor, l-ethyl-3-(3-dimethylaminopropyl carbodiimide) (EDC), 
N-hydroxysuccinimide (NHS) and ethanolamine were purchased from Fisons 
Affinity Sensors, Cambridge, UK. Streptavidin (STP) was purchased from 
P rogen  In d u stries , A ustra lia . The hom obifunctiona l reag en t bis 
(sulfosuccinimidyl) suberate (BS3), sulfosuccinimidyl 6-(biotinamido) hexanoate 
(NHS-LC- Biotin), gentle A g/A b elution buffer (a cuvette regeneration buffer 
gentle to the dextran matrix) and horseradish peroxidase (HRP)-conjugated STP 
(HRP-STP), were purchased from Pierce, Rockford, IL. Avid A1 beads were 
purchased from BioProbe, Tustin, CA. Fluorescine isothiocyanate (FITC) 
conjugated STP (FITC-STP) was purchased from Amersham Life Science 
Limited, Buckinghamshire, UK. mAb MRII against FcyRI was kindly provided 
by Dr Hilary Warren (Canberra Hospital, ACT).
2.2 Purification of proteins
2.2.1 Purification of human Clq and 30 kDa fragment of HRG
H um an C lq  was purified from hum an serum using Biorex-70 ion-exchange 
chrom atography followed by Sephacryl S-300 gel filtration as previously 
described (Tenner et al., 1981). Slight modifications of this procedure (namely 
omitting the (NH4)2S0 4  precipitation step) resulted in the co-purification of two 
other proteins. Reduced SDS-PAGE analysis demonstrated that purification of 
C lq  by this procedure resulted in the co-purification of two proteins of 32 and 
34 kDa. The proteins were electrophoretically transferred onto a Problott 
polyvinyle difluoride (PVDF) membrane, and after staining with Coomassie
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Brilliant Blue, the 32 and 34 kDa bands were excised and subjected to N-terminal 
sequencing using an Applied Biosystems Inc 473A model sequencer.
2.2.2 Purification of native human HRG
Native human HRG of 75 kDa molecular weight was purified from fresh human 
plasma as previously described (Rylatt et al., 1981) by equilibrating a 
phosphocellulose column with loading buffer comprising 10 mM sodium 
phosphate (pH 6.8) containing 1 mM EDTA and 0.5 M NaCl. The plasma was 
mixed with EDTA and NaCl to final concentrations similar to the loading buffer 
and with [4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride] (AEBSF) 
(ICN Pharmaceutical Inc., Costa Mesa, CA) at 100 fig/ml and aprotinin (a 
trypsin inhibitor) at 2 |ig/ml. The plasma was passed through the equilibrated 
column and unbound protein was removed by extensive washing of the column 
with the loading buffer. Bound HRG was then eluted from the column using the 
same buffer containing 2M NaCl. Since the 30 kDa HRG co-purified with Ciq, 
the Clq purification procedure also was used to purify the N-terminal 30 kDa 
fragment of HRG.
2.2.3 Purification of rabbit anti-ovalbumin IgG
Rabbit anti-ovalbumin IgG was purified from immunized rabbit serum by 
Na2SC>4 precipitation and ion-exchange chromatography using a 
diethyleaminoethyl (DEAE)-Sephacel column. The IgG was collected from the 
break through peak as described (Easterbrook-Smith et al., 1988).
2.2.4 Purification of rat anti-ovalbumin IgG
Rat anti-ovalbumin IgG was purified using commercially available Avid-Al 
beads which contain a ligand with high affinity for IgG. The rat serum was 
passed through the column and then the column was washed extensively with 
10 mM sodium phosphate (pH 7.2) plus 150 mM NaCl (phsophate buffered 
saline, PBS) containing 3mM NaN3 (PBS-Az). The bound IgG was eluted using 
0.1 M sodium acetate buffer, pH 3.0, and dialysed against PBS before storing the 
IgG in small aliquots at -20°C until use. The purity of IgG was always > 95%.
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2.3 Conjugation of proteins
2.3.1 FITC conjugation of proteins
The protein (2 mg/ml) to be conjugated was extensively dialysed against 0.05 M 
boric acid, 0.2 M NaCl (pH 9.2). 50 pi of FITC (5 mg/ml) (Molecular Probes Inc, 
Eugene, OR) dissolved in DMSO was added to 1 ml of protein and the mixture 
incubated for 2 hours at room temperature in the dark. Unreacted FITC was 
removed by subjecting the sample to five cycles of concentration and dilution in 
an Amicon ultrafiltration apparatus (Amicon Inc, Beverly, MA). FITC-proteins 
were sterile filtered using a DynaGard 0.2 pm filter (Microgon Inc, Laguna Hills, 
CA), before storing at 4°C until use.
2.3.2 Biotinylation of proteins
The proteins to be biotinylated (eg. IgG, HRG, IgM, BJ proteins, BSA) were 
dissolved in PBS at a concentration of 1 mg/ml and then reacted with NHS-LC- 
biotin (1 mg/ml) (Pierce, Rockford, IL) for 30 min at room temperature. The 
reaction was stopped by the addition of Tris-HCl buffer (pH 8.0) to a final 
concentration of 100 mM. Unreacted biotin was removed by washing the sample 
extensively (five cycles of concentration and dilution) in a Centricon 10 
microconcentrator (Amicon Inc), before storing the biotinylated proteins at 
-20°C in small aliquots until use.
2.4 Preparation of heat aggregated IgG
Human IgG (2 mg/ml) in PBS was heat aggregated by incubation at 63°C for 40 
min and then chilling on ice for 2 h. The aggregated IgG was separated from 
non-aggregated IgG by fast performance liquid chromatography (FPLC) gel 
filtration using a Superose 12 column (Pharmacia, Uppsala, Sweden). The 
aggregated IgG was collected in the exclusion volume peak.
2.5 Preparation of Bence Jones proteins
The k and X  BJ proteins (BJk and BJA.) were a generous gift from Dr Bob Raisen, 
University of Technology, Sydney. The lyophilised proteins were dissolved in 
PBS. SDS-PAGE analysis showed that BJk consisted of two bands of mol. wt. ~ 
22 kDa and ~ 44 kDa, whereas the BJ>. consisted of only a single band of mol. wt. 
~ 44 kDa. These proteins were subjected to gel filtration using a Superose 12
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FPLC column with the monomeric form of BJk being separated from the dimeric 
form, whereas BJX showed only a single peak as the dimer form. The dimeric 
form of both proteins was biotinylated (as in section 2.3.2) and was used in all 
biosensor studies.
2.6 SDS-PAGE
The purity of protein preparations was checked by SDS-PAGE analysis which 
was carried out as described (Laemmli, 1970). Aliquots of proteins were boiled 
in either reducing or non-reducing sample buffer and electrophoresed on a 
12.5% or 10% acrylamide gel. After electrophoresis protein bands were 
identified by Coomassie Brilliant Blue staining of the gel. The purity of the HRG 
and IgG preparations as judged by the intensity of the contaminating bands was 
always > 95%.
2.7 Precipitin curve analysis of ICs containing rabbit IgG 
and ovalbumin
Anti-ovalbumin IgG (1 mg/ml) was mixed with different concentrations of 
ovalbumin at Ag : Ab ratios in the range of 0.005-0.06 (w/w) in PBS containing 
10 mg/ml BSA (PBS-BSA) and 3 mM NaN3 (azide) (PBS-BSA-Az) to a final 
volume of 1 ml and incubated overnight at 37°C. The insoluble ICs in each 
suspension were collected by centrifugation (104 x g , l  min), washed three times 
in PBS, and then dissolved in 0.2 M NaOH. The extent of IC formation was then 
calculated by measuring the absorbance of each solution at 280 nm, assuming E 
0.1% (w/v) = 1.4 for IgG.
2.8 Formation of insoluble ICs
2.8.1 Formation of insoluble ICs containing ovalbumin and rabbit
anti-ovalbumin IgG
The formation of insoluble ovalbumin : anti-ovalbumin IgG ICs was carried out 
by incubating rabbit polyclonal anti-ovalbumin IgG (or rat polyclonal anti­
ovalbumin IgG) in PBS-Az and different amounts of HRG and/or Clq for 5 min 
in a quartz reaction vessel (final volume 1 ml) maintained at 37°C. The 
formation of insoluble ICs was initiated by the addition of ovalbumin at an 
equivalence Ag : Ab ratio. Since the absorbance due to light scattering of a 
suspension of particles is related to the average size of the particles, the
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formation of insoluble ICs was monitored by measuring the absorbance of 
samples at 350 nm, using a Varian Cary-1 spectrophotometer as described 
(Gorgani et al., 1997).
2.8.2 Formation of insoluble ICs containing RF and human IgG.
The formation of insoluble ICs was initiated by the addition of human IgG (from 
pooled human serum) to solutions of anti-human IgG Abs. Insoluble IC 
formation was studied in three different systems namely: (1) rabbit anti-human 
IgG (Fc) Ab (69 ng/ml) were incubated without or with different concentrations 
of HRG in PBS-Az in a quartz reaction vessel (final volume 1 ml) maintained at 
37°C. Insoluble IC formation was initiated by the addition of human IgG which 
was either treated or untreated with HRG at different Ag : Ab ratios. (2) RF (8 
IU/ml) was incubated in PBS-Az without or with different concentrations of 
HRG and insoluble IC formation was initiated by addition of heat-aggregated 
human IgG which was either treated or untreated with HRG at different Ag : Ab 
ratios. (3) biotinylated human IgG (b-IgG, from pooled human serum) (30 
^ig/ml) was incubated without or with different concentrations of HRG for 20 
minutes and then STP was added to form ICs in a quartz reaction cuvette. After 
20 minutes incubation, RF (8 IU/ml) which was treated or untreated with HRG, 
was added to the mixture of STP and b-lgG to initiate the formation of insoluble 
ICs. In all instances the formation of insoluble IC was monitored by measuring 
the absorbance of samples at 350 nm using a Varian Cary-1 spectrophotometer 
as described (Gorgani et al., 1997).
2.9 Solubilization of preformed insoluble ICs by HRG.
Ovalbumin at Ag : Ab ratios between 0.005 and 0.05 was added to a solution of 
rabbit anti-ovalbumin IgG (900 fig/ml) in PBS-BSA-Az containing 20 [iM Zn2+ 
(PBS-BSA-Zn-Az) in an Eppendorf tube. Tubes were rotated for 1 hr at 37°C, 
and then the mixtures were further rotated for 12 hours at 37°C without or with 
addition of 150 f i g /m l of HRG. In some experiments different concentrations of 
HRG were incubated with preformed insoluble ICs containing anti-ovalbumin 
IgG (900 fig/ml) and ovalbumin at equivalence Ag : Ab ratio to assess the effect 
of different concentrations of HRG on the solubilisation of preformed insoluble 
ICs. In all instances, after 12 hours rotation of insoluble ICs with or without 
HRG, the samples were centrifuged at 104 x g for 1 minute to collect insoluble 
ICs. The pellets were washed three times in PBS and then dissolved in 0.2 M 
NaOH. The absorbance of each solution was measured at 280 nm assuming
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that the E 0.1% (w/v) = 1.4 for IgG. The percent precipitation was calculated for 
each sample and was plotted against the ovalbumin/IgG ratio (w/w) or plotted 
against the concentration of HRG.
2.10 Cell culture
The human THP1 and U937 monocyte cell lines, and human Jurkat (CD4+) 
leukaemic T-cell line and human MT4 (CD4+) T-cell line were all cultured in 
RPMI-1640 (Gibco, Gaithersburg, MD) supplemented with 10% heat-inactivated 
fetal calf serum (FCS) (Commonwealth Serum Laboratories, Melbourne, 
Australia) and antibiotics (penicillin 120 mg/1, streptomycin 200 mg/1, 
neomycin 200 mg/1) at 37°C in a 5% CO2 atmosphere. The cell lines were 
routinely subcultured at ~ 0.25 x 106 cells/ml and allowed to grow to the 
maximum concentration of ~ 1 x 106 cells/ml.
2.11 Immunofluorescent flow cytometry
The cultured cells were transfered to plastic 50 ml Falcon tubes (Becton 
Dickinson, Lincoln Park, NJ) and centrifuged at 1500 rpm (450 x g) for 5 
minutes. Supernatants were discarded and the cells were washed three times in 
PBS. The concentration of cells was determined using a haemocytometer and 
the cell suspensions pelleted and resuspended in PBS-BSA or PBS-BSA 
containing 20 pM Zn2+ (PBS-BSA-Zn) buffer to a final concentration of 1 x 107 
cells/ml. The cell suspensions were then pipetted (25 pl/well) into each well of 
a 96-well V-bottomed plastic plate (Nunc, Roskilde, Denmark), human HRG was 
added at different concentrations (25 pi /well), and the mixture incubated for 1 
hr on ice. The cells were washed three times by centrifugation (800 x g, 1 min) 
with the appropriate buffer to remove the unbound HRG, and b-IgG or FITC- 
IgG conjugate was added in the appropriate buffer and incubated with the cells 
for 1 hour on ice. The cells were washed three times by centrifugation and 
bound biotinylated IgG (b-IgG) was detected by incubating the cells with FITC- 
STP (~ 50 pg/ml). After removing unbound FITC-STP by centrifugation, the 
cells were resuspended in PBS-BSA or PBS-BSA-Zn buffer (50 pl/well), and 
fixed by the addition of 4% paraformaldehyde in PBS (50 pi/well).
The fluorescence intensity unit (FIU) of the cells was measured by flow 
cytometry using a FACScan (Becton Dickinson, Mountain View, CA). In some 
experiments cell populations were gated, according to the forward and side 
scatter, to eliminate the fluorescence deriving from dead cells, aggregated cells
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or large insoluble ICs. The results obtained for each sample were analysed by 
the program "Cell Quest". Using this program, the Median FIU value of each 
fluorescence intensity histogram was determined and plotted against the 
concentration of ligand or inhibitor used.
2.12 Ovalbumin immunization of rats
Ovalbumin was dissolved in PBS at 10 mg/m l and mixed with complete 
Freund's adjuvant at a 1 :1 ratio (v/v). Then 200 fil of this mixture was injected 
subcutaneously at four sites into DA rats. After 28 days the injection was 
repeated except that incomplete Freund's adjuvant was used. Twenty one days 
later the rats were injected intraperitoneally with 1 mg of ovalbumin in normal 
saline and 7 days later rats were bled, and their serum were collected.
2.13 ELISA assays
2.13.1 Binding of Clq to immobilized HRG
HRG (125 nM) was coupled for 1 hr to Maxi-sorb ELISA trays in 0.1 M NaHC03 
buffer (pH 9.0). The trays were blocked with PBS-BSA and then incubated with 
Clq in PBS-BSA for 1 hr. Bound Clq was detected using a monoclonal mouse 
anti-Clq Ab (BUS-1) followed by incubation with a HRP-conjugated sheep anti­
mouse Ab and colour development using o-phenylenediamine dihydrochloride 
(2.5 mg/ml) in a 0.05 M sodium citrate, 0.1 M sodium phosphate buffer (pH 5.0) 
containing 0.03% (v/v) hydrogen peroxide as substrate. The binding of Clq was 
dose-dependent in the concentration range tested (15-125 nM). Under these 
conditions non-specific binding was assessed using the mouse mAb anti-DNP-9 
(a mAb to 2,4 dinitrophenyl) as a control. No significant level of non-specific 
binding could be detected using the control mAb, indicating that the signal 
observed using the BUS-1 mAb reflects Clq specific binding.
2.13.2 Binding of rabbit IgG to immobilized HRG
An ELISA assay was also used to study the binding of rabbit anti-ovalbumin 
IgG to immobilized HRG. HRG coupled Maxi-sorb ELISA trays were incubated 
with rabbit IgG (0.03-2 pM) in PBS-BSA overnight at room temperature. Bound 
IgG was detected using a HRP-conjugated polyclonal goat anti-rabbit Ab 
followed by colour development. Parallel experiments in which a HRP- 
conjugated polyclonal goat anti-sheep Ab was used instead of HRP-conjugated
Chapter 2 Materials and Methods 56
goat anti-rabbit Ab, or in which BSA was coated onto the wells instead of HRG, 
indicated that the binding was specific for HRG.
2.13.3 Binding of human IgG , IgG subclasses, IgM and Bence Jones
proteins to immobilized HRG
The binding of biotinylated forms of human IgG (from pooled human serum), 
IgG subclasses (myeloma derived), IgM and BJ proteins to immobilized human 
HRG was examined by ELISA. HRG (20 pg/ml) was immobilized on Maxi-Sorb 
ELISA trays by incubating in 0.1 M NaHC03 buffer (pH 9.6) for 1 hr at 37°C. 
The trays were blocked with PBS-BSA-Az for 1 hr at 37°C and then incubated 
with biotinylated proteins in the concentration range between 1.6 -100 fig/ml in 
PBS-BSA-Az for 3 hours at 37°C. Unbound proteins were washed away three 
times with PBS-BSA containing 0.05 % Tween-20 (PBS-BSA-T). Bound 
biotinylated proteins were detected by incubating the trays with HRP-STP (in 
1/500 dilutions) in PBS-BSA for 1 hr at 37°C. This was followed by incubating 
the trays with the colourimetric HRP substrate ABTS (0.2 mg/ml) for 30 minutes 
at 37 °C in a 0.05 M sodium citrate, 0.1 M sodium phosphate buffer (pH 5.0) 
containing 0.03% (v/v) sodium perborate (a substitute for hydrogen peroxide). 
The absorbance of the solution of each well was measured at 405 and 490 nm 
using an ELISA plate reader (dual end measurement). The results showed that 
the binding of these proteins to immobilized HRG was dependent on the 
concentration of added protein. There was no colour development in control 
experiments when either the trays were coated with BSA instead of HRG or 
when, instead of incubating the tray with biotinylated proteins they were 
incubated with biotinylated BSA (b-BSA). These control experiments, therefore, 
indicated that the binding of these proteins was specific for HRG.
2.14 Determination of binding constants using the
biosensor
An IAsys resonant mirror biosensor (Affinity Sensors, Cambridge, UK) (Cush et 
al., 1993; Buckle et el., 1993) with a carboxymethyl dextran sensing cuvette was 
used to determine the kinetic constants and affinities of the binding of HRG to 
immobilized ligands (eg, IgG, Clq, IgM, BJ proteins). Except where indicated, all 
experiments were performed in PBS-BSA-T and at a temperature of 25°C. The 
BSA (1%, w/v) was included in the buffer to reduce non-specific binding. The 
reaction vessel was stirred continuously by the aid of a propeller. Binding was 
measured at 2 sec intervals, and the readout from the biosensor was in units of
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arc-sec. Each binding reaction was routinely followed for 5 min. All binding 
experiments were performed at least in duplicate. The "Fast Fit" program 
supplied by Fisons was used to evaluate the kinetic constants (George et al., 
1995).
2.14.1 Coupling of STP or Clq to the dextran matrix
STP or Clq was coupled via £-amino groups to the carboxymethyl dextran 
sensing surface of the IAsys biosensor cuvette using EDC and NHS (Cush et al., 
1993; Buckle et el.,1993). This was done by equilibrating the cuvette in PBS 
buffer containing 0.05 % Tween-20 (PBS-T) and then reacting the cuvette with a 
mixture of EDC/NHS for 7 min. Unreacted EDC/NHS was washed away with 
PBS-T followed by three washes with 0.01 M sodium acetate buffer (for 
immobilization of STP the pH was adjusted to 4.5 and for Clq immobilization 
the pH was adjusted to 5.0 using 2 M acetic acid). STP (50 (ig/ml) or Clq (10 
(ig/'ml) in indicated acetate buffer was added to the cuvette and allowed to react 
with the activated carboxyl groups for 5 min. Uncoupled STP or Clq was 
removed by washing with the appropriate acetate buffer, and unreacted 
succinimidyl groups were blocked by incubating with ethanolamine (1 M, pH 
8.5) for 2 min. The cuvette was washed three times with the appropriate acetate 
buffer, and then washed with PBS-T followed by a wash with 10 mM HC1 to 
remove any non-covalently bound protein. Consistent with studies using other 
proteins (eg. George et al., 1995), under these conditions there was no evidence 
that the 10 mM HC1 wash affected the ability of the immobilised Clq to interact 
with soluble HRG since binding constants did not change significantly after 
repeated washing of the cuvette with 10 mM HC1, even when the first HC1 wash 
of the cuvette was omitted to avoid possible denaturation of the immobilised 
Clq. A biosensor response of ~ 500 arc sec for the immobilized STP and 1800 arc 
sec for immobilized Clq were observed. According to the data provided by the 
manufacturer this response represents the coupling of 3 ng of STP and 11 ng of 
Clq per mm^ of sensing surface.
2.14.2 Binding of biotinylated proteins to the biosensor surface
Biotinylated proteins (eg. b-IgG or biotinylated IgM (b-IgM)) were coupled to 
the immobilised STP as follows. Biotinylated protein (50 |ig/ml) in PBS-T (eg. 
IgG or HRG) was added to the STP coupled dextran cuvette equilibrated in PBS- 
T, and allowed to bind to the immobilized STP for 5 min. Nonspecifically bound
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biotinylated protein was removed by washing three times with PBS-T, followed 
by three washes with 10 mM HC1 for 2 min (for three cycles).
2.14.3 Binding of protein ligands to proteins on the biosensor surface
Before immobilization of the biotinylated proteins on the STP-dextran, non­
specific binding between the protein ligands and the STP-dextran was assessed 
by the addition of different amounts of the non-biotinylated protein ligands in 
PBS-BSA-T to the cuvette. Under these conditions no significant level of 
nonspecific binding of any of the protein ligands used in these study could be 
detected.
Preliminary experiments were performed to establish the concentration range of 
protein-ligand suitable for kinetic analysis. PBS-T was added to the protein 
coupled cuvette to establish a baseline (5 min) and protein-ligand was then 
added in PBS-T at different concentrations. Binding of the protein-ligand was 
studied by monitoring the association phase for 5 minutes. Subsequently, the 
cuvette was washed with PBS-T and the dissociation phase was monitored for 5 
min. Bound protein-ligand was removed (cuvette regeneration) by washing with 
either 10 mM HC1 or the gentle A g/Ab elution buffer (Pierce). The baseline was 
then re-established after washing the cuvette with PBS-T. In the HRG inhibition 
experiments, HRG (15 jig/ml) was added to the cuvette, allowed to reach 
equilibrium for 5 minutes and then unbound HRG washed away before 
addition of protein-ligand. As previously (George et al., 1995), we found no 
evidence that the 10 mM HC1 cuvette regeneration wash significantly affected 
the ability of the proteins to subsequently interact with immobilized proteins on 
the cuvette surface.
2.14.4 Evaluation of the kinetic constants
2.14.4.1 Conventional method of analysis of the biosensor data
The IAsys biosensor was provided with a digital DECpc 450D2LP computer. 
Data obtained with the biosensor were transferred directly to the "Fast Fit" 
program (Fison Applied Sensor Technology). This program uses an iterative 
curve fitting to derive the observed rate constant and the maximum response at 
equilibrium due to ligand binding at the particular ligand concentration. The 
association of a soluble ligand with an immobilized macromolecule can be 
described by the pseudo first order equation Rt=Ro+E(l-e"^obs^), when only one
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binding site is available for the ligand (Cush et al., 1993). In this equation: Rt is 
the IAsys response at time t in units of arc secs (this is proportional to the 
concentration of ligand-protein complex at time t, Rt a  [Ligand-Protein]t), Ro is 
the IAsys response at time t=0 in units of arc secs induced by the addition of the 
ligand solution to the buffer in the cuvette (this represents a net displacement of 
the biosensor signal and its value is determined by the Fast Fit program for each 
binding curve analysed, Ro a  [Ligand-Protein]o), E is the maximum IAsys 
response in units of arc secs due to bound ligand at equilibrium (E a  [Ligand- 
Protein] o o ) ,  and K0bs is the observed rate constant (termed kon in Fast Fit) given 
by K0bs = k0n[Ligand] + kQff (George et al., 1995). For two binding sites the 
"Fast Fit" program uses the equation Rt=Ro+Ei(l-e"^obsit)-hE2(l-e"^obs2t) to 
derive the kinetic constants (Cush et al, 1993). In this equation El and E2 are the 
maximum response at equilibrium due to binding of the ligand to the high and 
low affinity binding site, respectively; and k0bsl and k0bs2 represent the 
observed rate constants for the high and low affinity binding site, respectively. 
This equation assumes that, at equilibrium, the ligand-protein complex is stable; 
thus, the equilibrium line must be parallel to the starting baseline ([Ligand- 
Protein] oo) and at least 80-90% of the data must be taken into account when 
fitting data to a curve for either single or double exponential binding.
2.14.4.2 Kinetic constants for HRG-Clq, HRG-lgM and HRG-lgG 
interactions
A linear relationship between kQbs and ligand concentration was obtained when 
the binding data for the interaction of HRG with immobilized Clq was fitted to 
a double exponential curve, whereas the binding data for the HRG-lgM 
interaction was fitted only to a single exponential. Using this method the kon 
(on-rate) and k0ff (off-rate) values for the interaction are given by the slope and 
y-intercept of the plot, respectively.
The binding of HRG to X  containing IgG subclasses (IgGA,) could only be fitted 
to a single exponential and not to a double exponential. A linear relationship 
was obtained by plotting kQbs versus ligand concentration for the interaction of 
HRG with these IgG subclasses (IgGA,). In contrast, no linear relationship was 
obtained by plotting k0bs versus ligand concentration for the interaction of HRG 
with immobilized human IgG ( from pooled human serum) or human IgG 
subclasses containing k light chain (IgGic), indicating that the data does not fit an 
exponential curve. Therefore, in these instances, similar to other kinetic analyses 
(George et al., 1995), the first region of the progress curve that best fits the single
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exponential term (assuming that thermodynamic equilibrium is reached) was 
used to evaluate the parameters for the highest affinity interaction. This was 
done by plotting Ln((E-(Rf Ro))/E) versus time and selecting the linear region of 
this plot.
In some instances the Fast Fit program was used to extrapolate the dissociation 
data to the baseline for determination of the k0ff. Values of Kds obtained by 
using the relationship Kd=koff/kon were in good approximation with those 
obtained by Scatchard analysis of the extent of association (not shown).
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Purification of the complement component Clq from human serum using an 
established method resulted in the co-purification of two 30 kDa proteins with a 
N-terminal sequence identical to human HRG. Therefore, to explore the 
possibility that HRG can interact with Clq, the ability of 75 kDa (native) and the 
30 kDa proteins (presumably proteolytic N-terminal fragments of HRG) to bind 
to Clq was examined, using both ELISA and optical biosensor techniques. Both 
forms of HRG were found to bind to the human complement component Clq 
and also to purified human and rabbit IgG by ELISA. Kinetic analyses of the 
HRG-Clq and HRG-IgG interactions using the IAsys biosensor indicate two 
distinct binding sites with affinities Kdl 0.78 x 10"® M and Kd2 3.73 x 10"® M for 
Clq, and one binding site with affinity Kd 8.5 x 10"® M for IgG. Moreover, the 
fact that both native and 30 kDa HRG bind to Clq and to IgG, suggests that the 
IgG and Clq binding regions on HRG are located in the 30 kDa N-terminal 
region of the HRG molecule. The Fab region of IgG is likely to be involved in 
the HRG-IgG interaction since HRG also bound to F(ab')2 fragments with an 
affinity similar to that seen with the complete IgG molecule. Interestingly, the 
binding between HRG and IgG was significantly potentiated (Kd reduced from 
85.0 to 18.9 nM) by the presence of physiological concentrations of Zn^+ (20 
^M). Conversely, the presence of Zn2+ weakened the binding of HRG to Clq 
(Kd increased from 7.80 to 29.3 nM). Modulation of these interactions by other 
divalent metal cations was less effective with relative potencies being 
Zn2+>Ni2+>Cu2+. An examination of the effect of native and 30 kDa HRG on the 
formation of insoluble ICs between ovalbumin and polyclonal rabbit anti­
ovalbumin IgG, revealed that physiological concentrations of HRG can 
markedly inhibit insoluble IC formation in vitro. The results show that human 
HRG binds to Clq and to IgG in a Zn2+-modulated fashion, and that HRG can 
regulate the formation of insoluble IC in vitro, thus indicating a new functional 
role for HRG in vivo.
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It is well established that certain autoimmune diseases, such as SLE and RA, are 
associated with the production of auto antibody (aAb) (Mountz et al., 1994). 
Moreover, in vitro studies have shown that aAb can be cross-linked with their 
cognate Ag to form insoluble ICs (Sittampalam & Wilson, 1984a), which can 
precipitate in target tissues (e.g. joint synovial membrane) and lead to a lack of 
nutrient transport and consequent tissue injury. Evidence suggests that the 
effective clearance of CICs is necessary to limit IC-mediated tissue injury 
(Charlesworth et al., 1982). Protective measures may include mechanisms which 
inhibit insoluble IC formation, as well as those which promote solubilisation of 
formed insoluble ICs.
Evidence suggests that the complement components C3b and Clq, can 
modulate the formation of insoluble IC, in vitro. Upon activation of the 
complement cascade the generation of complement C3b and its covalent 
binding to the Fc (Cy2 or hinge domains) and/or Fab portion of IgG molecule, 
may both inhibit the formation of insoluble IC and promote their solubilisation 
(Anton et al., 1994; Schifferli, 1987; Takata et al., 1984). In contrast, Clq (a 
constituent of the Cl component of complement) is reported to enhance the 
formation of insoluble IC by binding to IgG molecules via the Cy2 domain 
(Burton et al.,1980) and may lead to the cross-linking of IgG molecules 
(Geronski et al., 1985; Easterbrook-Smith et al., 1988). The interaction of Clq 
with the Fc region of IgG molecules in ICs may also activate the complement 
cascade by the classical pathway (Schifferli, 1987). In addition, Clq is reported 
to bind to specific receptors on normal endothelial cells through its collagen-like 
fragment and to act as an FcR for circulating IgG ICs (Zhang et al., 1986). In 
contrast, studies on the anti-opsonic effect of serum suggest that Clq inhibits 
the interaction between IgG and the FcR on neutrophils (Hakansson et al., 1982). 
Recently, it has been shown that a recombinant form of FcyRII also inhibits the 
formation of insoluble ICs (Gavin et al., 1995).
In order to compare the effects of rabbit and human Clq on the formation of 
insoluble IC between ovalbumin and rabbit anti-ovalbumin IgG in vitro, rabbit 
and human Clq was purified using an established method. During these studies 
two proteins with a N-terminal sequence identical to HRG co-purified with Clq 
(Gorgani et al., unpublished observation), suggesting that Clq may form a 
complex with this protein. Preliminary data also suggested that HRG may 
associate with IgG molecules. HRG is a 75 kDa protein present in human
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plasma at a concentration of 150 fig/ml, and was first described by Heimburger 
et al. (1972). The protein has since been isolated from the plasma of other species 
such as mouse, rabbit, cattle and chicken. In vitro studies have implicated HRG 
in divalent metal ion binding component of serum (Guthans and Morgan, 1982), 
regulation of the coagulation cascade (Leung et al., 1984; Leung, 1986), 
regulation of growth factor action (Brown and Parish, 1994) and regulation of 
immune function (Rylatt et al., 1981; Saigo et al., 1990a, 1990b; Chang et al., 
1992a, 1992b; Olsen et al., 1996). Its precise physiological role, however, 
remains to be determined.
In this study an ELISA and the IAsys resonant mirror biosensor were used to 
study the binding of human HRG to human Clq and IgG, and to determine the 
kinetic constants for these interactions. In addition, light scattering techniques 
(Easterbrook-Smith et al., 1988) were used to examine the effects of human HRG 
and Clq on the formation of insoluble IC between ovalbumin and polyclonal 
rabbit anti-ovalbumin IgG. The results show that physiological concentrations 
of HRG bind strongly to Clq and to IgG, and inhibit the formation of insoluble 
IC in vitro, suggesting a previously undescribed functional role for HRG.
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3.2.1 Human Clq co-purifies with and binds to HRG
My preliminary studies showed that purification of the complement component 
C lq  from hum an serum using an established procedure (Tenner et al., 1981) 
employing Biorex-70 ion exchange chromatography followed by Sephacryl S- 
300 gel filtration resulted in the co-purification of a contaminating protein of 30- 
35 kDa molecular w eight which m igrated as a 32-34 kDa doublet under 
reducing conditions (see Figure 3.1). N-terminal amino acid sequencing of the 
two protein bands seen under reducing conditions, after their electrophoretic 
transfer to PVDF membranes, indicated that the residues identified in the N- 
terminal sequence of both bands (VSPTDXSAV) were identical to that reported 
for the N-terminal sequence of HRG (VSPTDCSAV) (Koide et al., 1986). Since 
the purification of forms of HRG in this molecular weight range (Heimburger et 
al., 1972), presumably derived from the cleavage of native 75 kDa HRG by 
plasmin and kallikrein in serum, has been reported (Smith et el., 1985; Lijnen 
and Collen, 1983) these findings suggested that the 30-35 kDa protein co­
purified with C lq  may be derived from the cleavage of native HRG (75 kDa) 
(see Figure 3.1) and that HRG may interact with Clq.
The possibility that C lq  can interact with HRG was initially explored using an 
ELISA assay. Significant binding of soluble hum an C lq  to 30-35 kDa and to 75 
kDa (native) HRG, each immobilized onto the wells of a 96-well plate, was 
detected by the ELISA assay (data not shown). In order to validate these 
preliminary experiments the strength of the interaction between HRG and C lq  
was studied using the IAsys biosensor. C lq  was immobilized onto the biosensor 
cuvette using the EDC/NHS procedure and the binding of soluble HRG to the 
immobilized C lq  was studied by adding different concentrations of HRG in 
PBS-BSA-T. The biosensor traces in Figure 3.2A show that the binding of soluble 
HRG to immobilized C lq  over a 5 min period exhibits saturation kinetics with 
near-maximal binding occuring with 320 nM HRG (see Figure 3.2A). Under 
these conditions no non-specific binding of HRG to the dextran matrix could be 
detected (not shown). Analysis of the data obtained from these studies using the 
Fast Fit program  indicated that the data did not fit to a single exponential 
function but that it could be fitted to a double exponential function, indicating 
that HRG reacts at two different sites on immobilised C lq  with about five-fold 
difference in affinity. The kQff and k0n for the higher affinity binding site was 
found to be 1.04 ± 0.57 x 10'3 s '1 and 1.39 ± 0.095 x 105 M"1 s’1, respectively. The
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FIGURE 3.1 SDS-PAGE analysis of native HRG and 30 kDa proteins co­
purified with Clq.
Native HRG and the 30 kDa proteins co-purified with Clq were analysed 
by SDS-PAGE (12.5 % gel) under reduced and non-reduced conditions, and 
then stained with Coomassie Brilliant Blue. Lane M, reduced molecular 
weight marker proteins; lane A, non-reduced 30 kDa HRG ; lane B, 
reduced 30 kDa HRG; lane C, non-reduced native HRG; lane D, reduced 
native HRG.
MW  (kDa)
97.4
66.3
55.4
36.5
31.0
21.5
14.4
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FIGURE 3.2 Determination of the binding constants for the binding of 
soluble HRG to immobilized Clq.
The IAsys resonant m irror biosensor was used to study the binding of 
HRG to C lq  immobilized onto the biosensor surface. After establishing a 
baseline in PBS-BSA-T the indicated concentration of HRG was added to 
the cuvette and the association phase was monitored for 5 min. Overlay 
plots of the responses observed following the addition of different 
concentrations of HRG in the range of 20 to 320 nM are shown in (A). The 
cuvette was then washed with PBS-BSA-T and the dissociation phase was 
m onitored for 5 min (not shown). For each concentration of HRG the 
values of kQbs(l) and k0bs(2) (rate constants) were determ ined by the 
linearization procedure using the Fast Fit program. As shown in (B), the 
plot of k0bs values related to high (•) and low (■ ) affinity binding sites 
against HRG concentration gives two straight lines with slopes of kGn and 
intercepts with the y-axis of k0ff- Error bars show the ±SEM of triplicate 
experiments perform ed for each concentration of HRG; the absence of 
error bars indicates an error < ± 0.001.
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Kd for this interaction (as shown in Figure 3.2B and Table 3.1) as determined 
either by Scatchard analysis of equilibrium binding data (not shown), or by 
using the relationship Kd=k0ff/k0n/ was found to be 0.78 ± 0.46 x 10'® M. The 
k0n for the lower affinity binding site was determined from the slope of the plot 
shown in Figure 3.2B and found to be 0.32 ± 0.027 x 10  ^M 'l s"l. The kQff value 
was obtained from the intercept of the plot shown in Figure 3.2B (koff=3.60 ± 
2.30 x 10'4 s"l). According to the manufacturer koff values in the range (10'3 > 
koff > 10"  ^s"l) need to be determined from the dissociation phase. Therefore, 
for the low affinity binding site the k0ff value was determined by extrapolating 
the dissociation data to the baseline and then fitting to a curve using the Fast Fit 
program (not shown). The koff was similar for all concentrations of HRG tested; 
the average k0ff = 1.17 ± 0.16 x 10"® s"l. The dissociation constant as determined 
using Kd=koff/kon was 3.73 ± 0.81 x 10"® M.
The binding of soluble C lq to immobilized F1RG was studied also by 
immobilizing biotinylated HRG (b-HRG) via STP coupled to the dextran surface 
of the biosensor cuvette and adding Clq in solution at different concentrations 
in the range of 2.5-250 nM. The binding of soluble Clq to immobilized HRG 
over a 5 min period was dependent on the Clq concentration. There was no 
detectable non-specific binding of Clq to the immobilized STP (not shown). The 
binding was saturable at the higher Clq concentrations with near-maximal 
binding occurring with about 250 nM Clq. The kon and koff for the reaction as 
determined using the Fast Fit program were found to be 7.08 ± 0.19 x 10  ^M"1 s" 
1 and 6.4 ± 2.0 x 10~3 s'l, respectively, and the dissociation constant was 0.92 ± 
0.30 x 10"® M (see Table 3.1).
3.2.2 Human HRG binds to IgG
The ability of HRG to bind to Clq with high affinity, and the reported ability of 
Clq to enhance the formation of insoluble IC in vitro, prompted me to explore 
the possibility that HRG also binds to IgG. Preliminary experiments in which 
the binding of polyclonal rabbit anti-ovalbumin IgG to immobilized human 
HRG was examined using an ELISA assay indicated that HRG also interacts 
with rabbit IgG and that the binding is concentration dependent. A similar dose 
dependent increase in the binding was observed when the F(ab')2 fragment of 
rabbit IgG was used instead of IgG, and when 30 kDa human HRG was used 
instead of native HRG (data not shown).
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The HRG-IgG interaction was further studied with the biosensor using 
immobilized IgG. For these experiments biotinylated human IgG was 
immobilized by binding to STP coupled to the dextran surface, and the binding 
of different concentrations of HRG to the immobilized b-IgG was monitored 
over a 5 min period. The data in Figure 3.3A indicates that native human HRG 
binds to human IgG, and that the binding is concentration dependent in the 
range of 10-400 nM HRG. The binding was saturable with near-maximal 
binding occurring with 400 nM HRG. The k0bs value for the binding of each 
concentration of HRG was calculated using the linearization procedure and the 
Fast Fit program. The plot of k0bs against the corresponding HRG 
concentration is shown in Figure 3.3B and gives a straight line with a slope of 
kon (1.0 ± 0.054 x 10  ^M"1 s'l) and an intercept with the y-axis of k0ff (8.6 ± 1.0 x 
10"3 s '1). The dissociation constant was 8.5 ± 1.5 x 10"  ^M (see Table 3.1).
Experiments also were carried out to study the binding of human IgG to 
immobilized human HRG. For these studies the HRG was coupled to the 
dextran surface using EDC/NHS procedure or via the biotin-STP linkage (as 
above) or was chemically linked to a cuvette with an amino-silane surface using 
the amino reactive homobifunctional cross-linker BS3. Although the binding of 
Clq to HRG immobilized via the biotin-STP linkage was fast, strong and 
concentration dependent under these
conditions no significant binding of soluble human or rabbit IgG to the 
immobilized HRG could be detected. Thus, it appears that the direct covalent 
cross-linking of the F1RG to the biosensor cuvette, as well as linking the HRG 
via biotin-STP, each can destroy the IgG binding site on the HRG.
The biosensor also was used to investigate the binding of human HRG to 
immobilized F(ab')2 fragments of rabbit IgG. For these experiments biotinylated 
F(ab')2 fragments were immobilized by binding to STP coupled to the dextran 
cuvette, and HRG was added at a concentration range of 10-625 nM in PBS- 
BSA-T. As previously, the binding and dissociation of HRG was carried out for 
5 min. A dose-dependent increase in the binding of HRG to F(ab')2 fragments 
was observed. After calculating the kobs for each concentration of HRG using 
the linearization and Fast Fit program the kon and koff of the reaction were 
found to be 0.55 ± 0.029 x 105 M 'l s '1 and 4.70 ± 0.87 x 10'3 s '1, respectively, 
and the dissociation constant was 8.30 ± 1.70 x 10'3 M (see Table 3.1). This 
dissociation constant is similar to that observed with the whole IgG molecule.
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FIGURE 3.3 Determination of binding constants for the interaction of 
soluble HRG with immobilized IgG.
The IAsys resonant m irror biosensor was used to study the binding of 
HRG to biotinylated hum an IgG immobilized onto the biosensor surface 
by coupling to immobilized STP. The biosensor cuvette was equilibrated 
in PBS-BSA-T and HRG was added at the indicated concentrations and the 
association phase was monitored for 5 min. The cuvette was then washed 
w ith PBS-BSA-T and the dissociation phase was m onitored for 5 min. 
The overlay plots for the different concentrations of HRG are shown in 
(A). The value of kQbs (rate constant) related to each concentration of 
HRG w as determined by linearisation using the Fast Fit program  and the 
results are shown in (B). The plot of k0bs against HRG concentration 
gives a straight line with a slope of k0n and an intercept with the y-axis of 
k 0ff. Error bars show the ±SEM of triplicate experiments perform ed for 
each concentration of HRG.
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3.2.3 Effect of Zn2+ on the binding of HRG to human IgG and to
c iq
HRG is reported to bind divalent metal cations like Zn2+, which can alter the 
ability of HRG to interact with heparin and to bind to T cells and elicit T cell 
responses (Kazama and Koide, 1992; Olsen et al., 1996). To determine whether 
Zn2+ also can affect the ability of HRG to interact with IgG or with Clq, binding 
studies using the biosensor also were carried out in the presence of 20 jiM added 
Zn2+, with and without 1 mM EDTA. These studies showed that mixing the 
HRG (100 nM) with different concentrations of Zn2+ (2.5-20 i^M) increases the 
binding of HRG to the immobilized human IgG. The increase was positively 
correlated with the amount of added Zn2+ and the potentiation was 
Zn2+>Ni2+>Cu2+ (not shown). As shown in Figure 3.4A the presence of Zn2+ 
potentiated the binding of HRG to immobilized IgG by 2-3 fold. In contrast, the 
presence of 1 mM EDTA markedly reduced the binding (probably by binding to 
trace metal ions in the PBS buffer) compared to that seen in the absence of 
added Zn2+ (see Figure 3.4A, and compare Figure 3.3B and 3.4B). The on-rate of 
the interaction between HRG and immobilized IgG increased from 1.0 ± 0.054 x 
103 M"1 s"1 in the absence of added Zn2+ (control) to 1.40 ± 0.031 x 103 M"1 s"1 
in the presence of added Zn2+. Similarly, the presence of Zn^+ decreased the 
off-rate from 8.60±1.0xl0'3 to 2.7±0.67xl0'3 s '1. Collectively, these changes in 
the on- and off-rates produced by Zn2+ resulted in approximately a five-fold 
increase in the affinity of HRG for IgG. Moreover, experiments carried out in 
the presence of Zn2+ and EDTA indicated that the on-rate of the interaction was 
decreased from 1.4 ± 0.031 x 103 M '1 s '1 to 0.70 ± 0.033 x 103 M '1 s '1 by the 
addition of 1 mM EDTA. These experiments also showed that in the presence of 
EDTA the off-rate of the reaction was increased from 2.70 ± 0.67 x 10-3 to 13.0 ± 
0.69 x 10"3 s '1, and the dissociation constant was increased from 1.89 ± 0.46 x 10" 
8 M to 18.0 ± 1.83 x IO"3 M following the addition of the EDTA. The two-fold 
reduction in the affinity of HRG for IgG produced by EDTA suggests that some 
metal ions may already be bound to the HRG, perhaps as a result of trace 
amounts of metal ions being present in the PBS used in these experiments.
Similar experiments carried out using immobilized Clq instead of IgG showed 
that, in contrast to the results observed with IgG, the affinity of HRG for 
immobilized Clq was decreased in the presence of 20 ^M Zn2+. At the two 
different HRG concentrations tested (50 and 600 nM) the inhibition of binding 
was dependent on the Zn2+ concentration (2.5-50 |iM). Similar to the IgG-HRG 
interaction, the potencies of inhibition was Zn2+>Ni2+>Cu2+. As shown in
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FIGURE 3.4 The effect of Zn2+ on the binding of native HRG to 
immobilized IgG.
Pooled IgG (from hum an serum) was immobilized onto the biosensor 
surface and the binding of HRG to the immobilized IgG was measured in 
the absence and presence of 20 \iM  Zn2+. For each experiment a baseline 
was established in PBS-BSA-T-Zn for 5 m in before adding HRG at the 
indicated concentration (in the same buffer). HRG binding was followed 
for 5 min and the cuvette was w ashed w ith the same buffer before 
m onitoring the dissociation phase (data not show n). For some 
experiments a baseline in buffer also containing 1 mM EDTA (PBS-BSA- 
T-Zn-EDTA) was obtained for 5 m in before adding HRG in the same 
buffer. The interaction also was followed for 5 min before washing the 
cuvette with PBS-BSA-T-Zn-EDTA and monitoring the dissociation phase 
(data not shown). The maximum binding (in units of arc sec) versus 
ligand concentration is shown in (A). For each concentration of HRG the 
rate constant (kQbs) was determ ined by linearisation using the Fast Fit 
program. The m easured k0bs values obtained from experiments carried 
out in PBS-BSA-T-Zn (•) and in the presence of 20 |iM Zn2+ and 1 mM 
EDTA in the reaction buffer (■ ), were plotted against HRG concentration 
and are shown in (B). Error bars show the ±SEM of triplicate experiments 
performed for each concentration of HRG.
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FIGURE 3.5 The effect of Zn2+ on the binding of native HRG to 
immobilized Clq.
C lq  was immobilized onto the biosensor surface and the binding of HRG 
to the immobilized C lq  was measured in the absence and presence of 20 
jiM Zn2+ as described in the legend of Figure 3.4. The association phase of 
the interaction (in units of arc sec) versus time (for 600 nM  HRG) is 
shown in (A). For each concentration of HRG the rate constants related to 
high (k0bs(l)) and low (k0bs(2)) affinity binding sites were determined by 
linearisation using the Fast Fit program . The m easured kobs(l) a n d  
k0bs(2) values obtained from experiments carried out in PBS-BSA-T-Zn 
(•) and in the presence of 20 Zn2+ and 1 mM EDTA in the reaction 
buffer (■ ), were plotted against HRG concentration and are shown for the 
high affinity site in (B) and for low affinity site in (C). Error bars show the 
±SEM of triplicate experiments performed for each concentration of HRG.
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FIGURE 3.6 Effect of 30 kDa and native HRG and Clq on the formation 
of insoluble ICs.
The formation of insoluble ICs was initiated by the addition of ovalbum in' 
at an equivalence Ag : Ab ratio to a solution of IgG (175 ng /m l) p re­
incubated with native HRG or Clq. To evaluate the inhibitory effect of 30 
kDa HRG, the 30 kDa HRG was pre-incubated with a solution of IgG (200 
|ig/m l) and then ovalbumin was added at an equivalence Ag : Ab ratio. 
ICF was m onitored as a function of time by measuring the absorbance at 
350 nm  associated w ith light scattering produced by the insoluble ICs that 
form ed in the m ixtures. The results in (A) show the increase in 
absorbance as a function of time due to formation of insoluble ICs for a 
control experiment (A, no additions), and for experiments carried out in 
the presence of 25 ng /m l C lq  (□), and 150 M-g/ml native HRG (O). The 
results in (B) show the time to reach 50% maximum absorbance as a 
function of the concentration of native HRG (•), 30 kDa HRG (O) or C lq  
(■). Each set of results is representative of 5 experiments perform ed in 
triplicate.
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FIGURE 3.7 Effect of native human HRG on the formation of insoluble 
ICs in the presence of human plasma.
The results in (A) show the absorbance change due to the formation of 
insoluble ICs which was initiated by the addition of ovalbum in to a 
solution of IgG (175 jig/m l, at equivalence Ag : Ab ratio) pre-incubated in 
PBS (A), PBS containing a 1 in 10 dilution of whole human plasma (O), or 
containing a 1 in 10 dilution of hum an plasma in which the levels of 
HRG w ere reduced to <10% of norm al levels by phosphocellulose 
chrom atgraphy (□). ICF was m onitored as described in the legend to 
Figure 3.6. In addition, similar experiments were carried out in which the 
IgG was pre-incubated with plasma containing the reduced levels of HRG 
(at 1 in 10 d ilu tion  in PBS) and also containing the indicated 
concentration of added purified native HRG. Each point in (B) shows the 
time to reach 50% maximum absorbance, and is a representative result of 
three separate measurements perform ed at the indicated concentration of 
HRG.
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incubated with whole human plasma, and potentiated when pre-incubated with 
plasma in which the level of HRG was reduced to <10% of that in normal 
human plasma by passing through a phosphocellulose column as described 
(Rylatt et al., 1981). Furthermore, the potentiating effect of pre-incubating with 
the plasma containing reduced levels of HRG on insoluble IC formation was 
abrogated when exogenous human HRG was included in the pre-incubations of 
this plasma with IgG (see Figure 3.7B). These findings are consistent with 
previous studies showing that Clq enhances the formation of insoluble IC 
(Easterbrook-Smith et al., 1988), and suggest that the presence of HRG can 
inhibit the formation of insoluble IC under physiological conditions.
Chapter 3
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The present study shows that HRG binds Clq and IgG with relatively high 
affinity compared to other HRG ligands (eg. PLG and heparin) and, as a 
consequence, effectively inhibits the formation of insoluble IC between 
ovalbumin and anti-ovalbumin IgG in vitro. The co-purification of HRG with 
Clq was first reported by Haupt and Heimburger (1972), but they provided no 
evidence that the two proteins can interact. Furthermore, previous studies have 
shown that HRG purified from human serum consists of two identical 30 kDa 
subunits, held together by ionic interactions (Heimburger et al., 1972). In the 
present study two bands of similar molecular mass (~ 30 kDa) were observed to 
co-purify with Clq and N-terminal sequencing indicated that the two molecules 
have a N-terminal sequence identical to HRG. The possibility that Clq could 
bind to HRG was first suggested by our observation that the two 32-34 kDa 
contaminating proteins were not separated from Clq (400 kDa) by gel filtration 
on a Sephacryl S-300 column. These findings, therefore, provided evidence that 
Clq can interact with HRG.
The binding of HRG to immobilized human Clq was detected by optical 
biosensor techniques. The fact that biosensor data for the binding of HRG to 
immobilized Clq could be fitted to the double exponential relationship suggests 
that the binding of HRG to Clq occurs with two dissociation constants namely 
0.78 ± 0.46 x 10'8 M and 3.73 ± 0.81 x 10‘8 M. It would appear, therefore, that at 
least two distinct binding sites are involved in the HRG-Clq interaction. This 
notion is supported also by the dissociation phase in which, after the 
dissociation of the protein ligand from immobilized Clq (presumably from a 
lower affinity binding site), re-association also could be detected (probably due 
to the re-binding of HRG to the higher affinity binding site) (not shown). The 
binding of human Clq to immobilized human HRG could be detected by ELISA 
and optical biosensor techniques. Kinetic studies of the binding of Clq to 
immobilized HRG using the biosensor showed the binding to have a 
dissociation constant of 0.92 ± 0.30 x 10"8 M (see Table 3.1). The fact that the 
results indicate a single homogeneous response (ie. no heterogeneous 
interactions) provides evidence that either hexameric Clq (Reid, 1974) is 
required to form the HRG binding site, and/or that the tail region of the 
hexameric structure (as opposed to the head region) is involved in the 
interaction with HRG. While a precise determination of the stoichiometry of the 
binding between HRG and Clq awaits the use of other techniques such as
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ultracentrifugation, the present results show that HRG and Clq interact with 
high affinity.
The present studies using ELISA and optical biosensor techniques also show 
that HRG binds to immobilized IgG, and the results are consistent with the 
previous observation that a trace amount of IgG is present in HRG preparations 
when the HRG is purified using carboxymethyl cellulose (Haupt and 
Heimburger, 1972). Biosensor analyses indicate that binding of soluble HRG to 
immobilized IgG is dependent on the concentration of soluble HRG and that the 
complex has a dissociation constant of 8.50 ± 1.50 x 10'8 M (Figures 3.3A and B). 
Interestingly, a similar dissociation constant was observed when the F(ab')2 
fragment of rabbit IgG was used instead of whole IgG. Thus, the binding of 
HRG to immobilized F(ab')2 was concentration dependent, and the dissociation 
constant was 8.30 ± 1.70 x 10"8 M (see Table 3.1). These findings suggest that 
HRG binds to IgG with a modest affinity resembling that of low affinity FcR 
(Van de Winkel and Anderson, 1991), and that the HRG-IgG interaction occurs 
predominantly via the Fab region of IgG. The IgG and Clq binding sites of 
HRG are likely to be located on the 30 kDa N-terminal domain of the HRG 
molecule since this domain interacted with both Clq and IgG in ELISA assays.
Although HRG interacts with immobilized IgG, no binding of human or rabbit 
IgG to immobilized HRG could be detected when the HRG was immobilised 
directly onto the biosensor surface using the homobifunctional cross-linking 
reagent BS3. Similarly, despite the fact that both native and b-HRG bound to 
immobilised IgG with the same affinity, no binding of IgG to HRG could be 
detected when the HRG was immobilised by the biotin-STP linkage, even if the 
first 10 mM HC1 wash of the cuvette was omitted to avoid the possibility of 
denaturation of the HRG (data not shown). Additional studies showed that 
soluble HRG which had been exposed to 10 mM HC1 for 5 min (before being 
neutralised with PBS) still retained its ability to bind to immobilised IgG in 
biosensor studies, and that IgG still bound to HRG when immobilised in an 
ELISA assay (not shown). The most likely explanation consistent with these 
observations is that the free E-amino groups on the HRG involved in the 
biotinylation and cross-linking reaction are located close to the IgG binding 
region(s), and that this region(s) is stearically hindered upon the immobilisation 
of the HRG.
Consistent with our recent finding that physiological concentrations of Zn2+ 
potentiate the binding of HRG to T cells (Olsen et al., 1996), the present study
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shows that Zn2+ also potentiates the binding of HRG to IgG. The affinity of the 
binding of HRG to immobilized IgG was increased about 5-fold in the presence 
of a physiological concentration of Zn2+ (20 pM). Interestingly, the presence of 
added Zn2+ induced a two-fold increase in the on-rate of HRG binding, but 
reduced the off-rate of the reaction to ~ 20% of that observed in the absence of 
added Zn2+. These results suggest that the presence of Zn2+ leads to a faster 
and stronger interaction between HRG and human IgG. In contrast, the high 
affinity binding of HRG to immobilized Clq was markedly inhibited by Zn2+ 
with the dissociation constant increasing from 0.78 ± 0.46 x 10“8 M in the absence 
of added Zn2+, to 2.93 ± 0.80 x 10"8 M in the presence of 20 pM added Zn2+. The 
results suggest that Zn2+ can potentiate the ability of HRG to interact with some 
ligands (eg. IgG) while at the same time inhibit the ability of HRG to interact 
with other ligands (eg. Clq).
The mechanism by which Zn2+ potentiates the interaction between HRG and 
IgG is unclear. It has been shown that divalent metal cations like Zn2+ interact 
with the HPR domain of HRG (Morgan, 1985). Further studies have shown that 
protonation of the HPR domain of HRG transmits a conformational change to 
the rest of the molecule and may regulate its physiological function (Borza et al., 
1996). In this study the potencies of enhancement by other divalent metal ions 
such as Ni2+, Cu2+ or Zn2+ did not follow the lyotropic series but was more 
specific for Zn2+ and Ni2+ than for Cu2+, suggesting that the binding of divalent 
cations to the HRG molecule does not depend only on charge-charge 
interactions. It is conceivable that a conformational change induced by the 
binding of Zn2+ may also explain the potentiation of the interaction between 
HRG and immobilized IgG.
Similarly, the inhibitory effect of Zn2+ on the binding of HRG to Clq may be 
due to a Zn2+-induced conformational change in the HRG molecule which 
results in a reduced affinity for Clq. These features of the HRG molecule may 
also reflect its ability to regulate diverse physiological functions. Thus, the 
potentiation of the HRG-IgG interaction by Zn2+ may result in more effective 
inhibition of insoluble IC formation, whereas the ability of Zn2+ to inhibit the 
HRG-Clq interaction may indicate an ability of HRG to regulate the classical 
complement pathway (see below).
A major finding from the present work is that physiological concentrations of 
either 30 kDa or native HRG can inhibit the formation of insoluble IC between 
ovalbumin and polyclonal rabbit anti-ovalbumin IgG in vitro. This finding
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suggests that HRG may also play a role in regulating insoluble IC formation in 
vivo, and is consistent with the observation that HRG is an acute phase reactant 
(Saigo et al., 1990b). Our results indicate that 30 kDa HRG is as effective as 
native HRG in inhibiting insoluble IC formation (Figure 3.6B), suggesting that 
the N-terminal region of HRG is involved in the interaction of HRG with IgG. 
Despite the fact that HRG binds to Clq with high affinity, in preliminary studies 
I was unable to detect any effect of HRG on insoluble IC formation in the 
presence of Clq. A possible explanation for this latter observation is that other 
plasma proteins also are involved in regulating insoluble IC formation. 
Alternatively, it is possible that the failure to detect any effect is due to the fact 
that a stirred reaction vessel was not employed in the present studies and Clq 
enhances insoluble IC formation in the second phase of the progress curve when 
the insoluble ICs are larger than 100 nm in radii (Gorgani et al., 1996).
Interestingly, C3b is the only plasma protein previously reported to modulate 
the formation of insoluble IC by covalently binding to the Fc and /  or Fab region 
of IgG (Anton et al., 1994), and evidence suggests that this interaction may be an 
important factor in both inhibiting insoluble IC formation, and promoting 
solubilisation of already formed insoluble IC (Schifferli, 1987; Takata et al., 
1984). C3b is produced, however, only after activation of the complement 
pathway which may result in the concommitant release of other complement 
proteins not involved in regulating insoluble IC formation. Interestingly, it is 
also reported that HRG-depleted serum has less complement functional activity 
than whole serum (Chang et al., 1992a). This is consistent with the present 
studies suggesting that, whereas whole human plasma inhibits the formation of 
insoluble ICs in a dose-dependent manner, human plasma containing reduced 
levels of HRG (<10% of that in normal plasma) enhanced the formation of 
insoluble ICs (see Figure 3.7A). Moreover, the enhancement of insoluble IC 
formation by plasma containing these reduced levels of HRG was inhibited by 
the addition of physiological concentrations of purified native HRG (Figure 
3.7B). These observations suggest that HRG is a key plasma inhibitor of 
insoluble IC formation and is able to inhibit this process in the presence of 
plasma proteins, thereby supporting the notion that this function of HRG is 
physiologically relevant.
Recently I have shown that the process of formation of insoluble IC can be 
divided into two phases (Gorgani et al., 1996). Initially the radii of the 
complexes increase slowly with time (during the process of insolubilisation) 
until the average radius reaches a critical size (approximately 100 nm for
Chapter 3 Discussion 74
ovalbumin and rabbit anti-ovalbumin IgG-containing ICs). This is followed by 
a phase of rapid increase in the radii (polymerization phase), leading to the 
formation of very large complexes. Interestingly, the enhancement of insoluble 
IC formation by Clq occurs in the second phase of the progression curve when 
IgG containing ICs are insoluble (Gorgani et al., 1996). The present study shows 
that HRG inhibits only the first phase of the progression curve when the mean 
radius of ICs is less than critical size and soluble IgG-containing ICs are present 
(not shown). The enhancing effect of Clq on insoluble IC formation may not be 
physiologically relevent, therefore, if ICs are kept under critical size in radius by 
the non-covalent interaction of HRG with soluble IgG ICs in early stages of 
disease or by the covalent binding of C3b to IgG ICs in chronic disease states.
It has been proposed that the production of aAb may be responsible for the 
induction of ICD, eg. RF, against the IgG molecule in patients suffering from 
RA. It has also been shown that goat anti-human IgG and human IgG molecules 
can aggregate and insolubilise in vitro (Sittampalam and Wilson, 1984a). In 
addition, Charlesworth et al., (1982) have shown that the effective clearance of 
CICs is necessary to limit IC-mediated tissue injury in a mouse model of 
infectious mononucleosis. These observations may imply that the clearance of 
circulating insoluble IC (in early stages) is also necessary to limit insoluble IC 
mediated tissue injury in patients suffering from other ICD, such as RA or SLE. 
At the molecular level an inhibition of the insolubilisation of soluble ICs (which 
can lead to the formation of very large hydrophobic particles [Gorgani et al., 
1996]), may play an important role in the initiation and pathogenesis of the ICD. 
The mechanism by which insoluble IC precipitate in target tissues (eg. kidney or 
synovium of patients suffering from SLE or RA, respectivly) is still unclear, 
although, inhibition of the insolubilisation process may be a factor which can 
limit this process and thus the pathogenesis of ICD.
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In Chapter 3 it was shown that human HRG interacts with high affinity with 
pooled human IgG. In this Chapter myeloma proteins consisting of the 
different human IgG subclasses were examined for their ability to interact with 
human HRG. Using the optical biosensor it was found initially that IgG 
subclasses differed substantially in their affinity of interaction with HRG. 
However, the most striking finding was the observation that whether the IgG 
subclasses contained k or X  light chains had a dramatic effect on the kinetics of 
the HRG interaction. Thus, it was found that the on-rate for the binding of 
HRG to k light chain containing IgGl and IgG2 (IgGlK and IgG2x) was ~ 4- 
and ~ 10- fold faster than the on-rate for the binding of HRG to >v light chain 
containing IgGl and IgG2 (IgGl^ and IgG2^), respectively. In contrast, the on- 
rate for the binding of HRG to IgG3>, and IgG4>. was found to be 9- and 20-fold 
faster than the on-rate for the binding of HRG to IgG3K and IgG4K, respectively. 
Furthermore, the binding of HRG to IgGs containing k light chains was 
generally enhanced in the presence of Zn2+, an effect particularly apparent with 
IgGlK, but Zn2+ had no effect or slightly inhibited the binding of HRG to 
immobilized IgG subclasses expressing X  light chains. Interestingly, HRG also 
bound to BJ proteins. The binding of HRG to k light chain BJ (BJk) was two fold 
faster than the binding of HRG to X  light chain BJ (BJ?i) and the presence of 
physiological concentrations of Zn2+ enhanced the binding of HRG to BJk but 
inhibited the binding of HRG to B J X ,  giving rise to a 14-fold higher affinity of 
HRG for BJk than BJA, in the presence of Zn2+. HRG also bound to IgM with a 
low affinity and the presence of Zn2+ actually decreased the affinity of HRG for 
IgM by 4-fold. Collectively, these data suggest that the ability of HRG to bind 
to IgG subclasses is influenced by both the heavy chain and light chain isotypes 
and the presence of Zn2+.
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Autoimmune diseases such as RA and SLE are often associated with an 
excessive production of aAb and the formation of insoluble ICs in the blood 
circulation. The failure of insoluble ICs to be cleared from the circulation may 
result in their deposition in specific target tissues, and this may be an important 
factor in the pathogenesis of ICD (reviewed by Walport and Davies, 1996). The 
pathology associated with ICD may be caused, at least in part, by the ability of 
the deposited insoluble ICs to activate the complement pathway and to induce 
inflammation in the target tissue. In addition, the deposition of insoluble ICs 
can limit nutrient transport, and consequently, cause tissue injury. For 
example, patients with RA or SLE have been shown to have high levels of the 
aAb RF in their sera and affected tissues (Heimer et al., 1982; Nasu et al., 1980). 
Evidence suggests that RF may form complexes with IgG containing insoluble 
ICs (self-association) and precipitate in the tissue causing tissue injury and 
disease (Winchester, 1975).
Interestingly, evidence suggests that aAb of several different isotypes can be 
found in the sera of patients with RA, and that the form of aAb most frequently 
found in the affected synovia of these patients is the IgG form of RF (Brown et 
al., 1982). For example, B cell hybridomas generated from mononuclear cells 
isolated from the synovial tissue of RA patients are reported to secrete Igs 
which are predominantly IgGl containing k light chains, and IgG2 containing k 
light chains (Randen et al., 1993). Moreover, compared to patients that lack 
aAbs, the overall ratio of k : X is often increased in the sera of patients with aAb 
(Riesen et al., 1976). This raises the possibility that specific IgG subclasses may 
play a role in the pathogenesis of RA or SLE. However, the functional role of 
the different Ig classes/subclasses and more particularly, that of the constituent 
light chains (k and X) in the development of ICD is not well understood.
Although the formation of insoluble ICs can occur as a result of the interaction 
of an Ab with its cognate Ag, the molecular mechanism(s) which regulates the 
formation, polymerization and precipitation of ICs in the blood circulation and 
in tissues, is not well understood. Evidence indicates that the formation of 
insoluble ICs may be regulated by the activation of the classical complement 
pathway. Thus, the complement component C3b is known to inhibit the 
formation of insoluble ICs and to promote the solubilisation of already formed 
insoluble ICs (reviewed by Schifferli, 1987). I have shown that the formation of 
insoluble ICs occurs in at least two distinct phases: an initial phase of insoluble
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IC formation followed by a second phase of rapid polymerization (Gorgani et 
al., 1996). In addition, the results in Chapter 3 demonstrate that physiological 
concentrations of HRG bind strongly to IgG, and can inhibit the formation of 
insoluble ICs between ovalbumin and polyclonal rabbit anti-ovalbumin IgG in 
vitro (Gorgani et al., 1997). These findings raise the question of whether HRG 
can interact with the different IgG subclasses (which can possess either k or X 
light chains) with the same affinity.
The work in this chapter employs the IAsys biosensor to determine the affinities 
of the interaction between HRG and different IgG subclasses, and hence 
establish whether different IgG subclasses differ in their ability to interact with 
HRG. The effect of the light chain type (k or X) on the binding of HRG to IgG 
was also examined. It was found that different IgG subclasses varied in the 
ability to interact with HRG. However, the most striking finding was that the 
on-rate for the binding of HRG to IgGlK and IgG2x was found to be ~ 4- and 10- 
fold higher than the on-rate for the binding of HRG to IgGl>. and IgG2Ä., 
respectively. In contrast, the on-rate for the binding of HRG to IgG3A, and IgG4>- 
was found to be 9- and 20-fold higher than the on-rate for the binding of HRG to 
IgG3K and IgG4ic, respectively. Furthermore, the binding of HRG to IgGs with 
the k light chains was enhanced in the presence of Zn2+, but Zn2+ slightly 
inhibited the binding of HRG to immobilized IgG with the X light chain. These 
findings provide, for the first time, convincing evidence that the light chain type 
of IgG has a profound effect on the binding of HRG to IgG subclasses and hence 
indicates functional differences between the k and X light chains of Igs.
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4.2.1 Binding of HRG to IgG subclasses possessing k light chains
The studies in Chapter 3 showed that HRG binds to immobilized human IgG 
(from pooled human serum) with high affinity (Kd =85 + 15 nM) (see Chapter 
3). To determine whether HRG binds with a similar affinity to each different 
IgG subclass, preliminary experiments were carried out to examine the binding 
of biotinylated IgGlK, IgG2K, IgG3K and IgG4K to immobilized HRG in an 
ELISA assay. In these studies the binding of each IgG subclass to the 
immobilized HRG could be detected by incubation with HRP-STP conjugate 
followed by color development as described in Materials and Methods (Chapter 
2). The experiments indicated that each of the four different subclasses of IgG 
binds to immobilized HRG in a concentration-dependent manner. Moreover, 
the dissociation constants (Kd) for the binding of IgG(ic) to immobilized HRG, 
as determined by Scatchard analysis after plotting (1/maximum bound) versus 
(1/IgG concentration), was found to follow the relationship IgG2K > IgGlK » >  
IgG3K > IgG4K (data not shown).
To further characterise the interaction of HRG with IgG subclasses, the binding 
of native human HRG to each of the four IgG subclasses possessing the k light 
chain also was examined using the IAsys biosensor. For these studies 20-60 ng 
of biotinylated human IgG (of the indicated subclass possessing k light chain) 
was immobilized via STP coupling onto the surface of a dextran cuvette, and 
the binding of soluble HRG to the immobilized IgG subclass was carried out 
following equilibration of the cuvette in PBS-BSA-T. Thus, HRG was added in 
PBS-BSA-T and the association phase for the binding of native human HRG to 
the immobilized IgGlK was monitored for 5 minutes. Subsequently, the cuvette 
was washed three times with PBS-BSA-T buffer (to bring the liquid phase HRG 
concentration to zero) and the dissociation phase was monitored for 5 minutes. 
The biosensor profiles for the binding of different concentrations of HRG to 
immobilized human IgGlK are shown in Figure 4.1 A. The data show that the 
binding of HRG to IgGlK is dependent on the HRG concentration in the range 
of 10-400 nM, and that within this concentration range the binding of HRG is 
saturable with near-maximal binding (-500 arc sec) occurring at a HRG 
concentration of 400 nM. The binding of HRG was significantly inhibited (> 
80%) when the HRG was pre-incubated, before addition to the cuvette, with 
soluble IgGlK (IgGlK/HRG molar ratio > 4, data not shown) suggesting that the 
HRG interacted specifically with IgGlK. The observed rate constant for each
Chapter 4 Legends to Figures
FIGURE 4.1 Determination of the binding constant for the interaction 
of HRG with immobilized IgGlK.
The binding of hum an HRG to IgGlK was examined using the IAsys 
biosensor. H um an IgGlK was biotinylated and then immobilized onto 
the carboxymethyl dextran sensing surface of the biosensor cuvette by 
coupling to immobilized STP. The cuvette was equilibrated in PBS-BSA- 
T for 5 minutes to obtain a base line and then (at time zero) HRG at the 
indicated concentration was added to the cuvette in the same buffer. For 
each concentration of HRG the association or binding of HRG to the 
im m obilized IgGlK was m onitored for 5 minutes. The overlay plots 
representing the binding of HRG to the immobilized IgGlK are shown in 
(A). Subsequently, the contents of the cuvette were removed, and the 
cuvette was washed three times w ith PBS-BSA-T before monitoring the 
dissociation phase for 5 m in (not shown). The value of k Qbs for the 
binding curve for each HRG concentration was determined using the 
linearization method (FAST FIT program) and each value plotted against 
the concentration of HRG (B). The p lo t of kQbs against HRG 
concentration gives a straight line (•); the slope represents kon and the y- 
intercept represents kDff for this interaction. Error bars represent the ± 
SEM obtained from three separate experiments for each concentration of 
HRG.
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binding curve, at the indicated concentrations of HRG, was obtained by fitting 
the curve to the single exponential expression using the "FAST FIT" program as 
previously described (Gorgani et al., 1997, see Chapter 3). A plot of the 
observed rate constant (k0bS/ s-1 ) against the concentration of HRG (nM) 
approximated a straight line (see Figure 4.IB), with the line of best fit revealing 
that HRG binds to immobilized IgGlK with an on-rate of 1.73± 0.04 x 10  ^M~ls"l 
(slope of the plot) and an off-rate of 0.53 ± 0.02 x 10"3 s 'l  (intercept with the y- 
axis) (see Table 4.1). The dissociation constant for this interaction was 
determined either using the relationship Kd=koff/kon, or by Scatchard analysis 
of the maximum amount of bound HRG at equilibrium; both methods gave a 
Kd of 3.04 ± 0.13 nM (see Table 4.1).
Similar biosensor experiments carried out to study the interaction of soluble 
HRG with immobilized IgG2K, IgG3ic and IgG4K, (each immobilized on to 
separate biosensor cuvettes) also indicated that the binding of HRG to each of 
these subclasses was saturable and dependent on the HRG concentration. As 
previously, the biosensor profiles for the binding of HRG (at each 
concentration) to each IgG subclass was fitted to a single exponential to derive 
the kobs- As shown in Figure 4.2B and Table 4.1 the on-rate, off-rate and Kd for 
the interaction of HRG with IgG2x were found to be 2.76 ± 0.27 x 10  ^M"ls"l, 
1.36 ± 0.22 x 10~3 s"1 and 5.04 ± 1.29 nM, respectively. Interestingly, the on-rate 
for the interaction of HRG with IgG3ic was 0.13 ± 0.004 x l(fi M 'V 1 (see Figure 
4.2C) and that for HRG with IgG4x was 0.11 ± 0.005 x 105 M 'V 1 (see Figure 
4.2D); these values are ~ 15-30 fold slower than those observed for IgGlK or 
IgG2K. Further analysis showed that the off-rate and Kd for the interaction of 
HRG with immobilized IgG3K were 1.92 ± 0.11 x 10'3 s"l and 147.57 ± 13.01 nM, 
respectively. The corresponding values for IgG4K were different, being off-rate 
= 2.86 ± 0.16 x 10"3 s"l and Kd = 268.01 ± 26.98 nM. The on-rates for the binding 
of HRG to the four different IgG subclasses therefore follows the series IgG2K > 
IgGlK » >  IgG3K > IgG4K (see Figure 4.2 and Table 4.1). These studies show 
that the kinetics of the binding of HRG to IgG depends on the IgG subclass, 
with HRG having a faster binding rate and higher affinity for IgGlK and IgG2K, 
than for IgG3K and IgG4K.
4.2.2 Binding of HRG to IgG subclasses possessing X  light chains
The finding that HRG differs in its ability to interact with different subclasses of 
IgG containing the k light chain, suggested that differences also may exist in the 
ability of HRG to interact with subclasses of IgG containing the X  light chain.
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Chapter 4 Legends to Figures
FIGURE 4.2 Determination of the binding constants for the interaction 
of HRG with immobilized IgGl, IgG2, IgG3 and IgG4.
The binding of hum an HRG to each of 8 different IgG subclasses (IgGlK, 
IgGlA, IgG2K, IgG2A., IgG3K, IgG3^, IgG4K and IgG4A.) was examined using 
the IAsys biosensor. Each hum an IgG subclass was biotinylated and then 
immobilized onto a carboxymethyl dextran biosensor cuvette by coupling 
to immobilized STP. Subsequently, different concentrations of HRG was 
added to the cuvette and the association and dissociation of HRG was 
m onitored exactly as described in the legend for Figure 4.1. The kQbs 
values for the binding of HRG to each IgG subclass was determined by 
fitting the biosensor data to a single exponential. The results in (A) 
shows plots of the k Qbs against HRG concentration for the binding of HRG 
to IgGlK (•)  and to IgGlX (■). Similarly, the results in (B) show plots of 
k 0bs against HRG concentration for the binding of HRG to lgG2 subclasses 
(IgG2K#, IgG2>.H). Also the results in (C) shows plots of the kGbs against 
HRG concentration for the interaction of HRG with IgG3x (• )  and w ith 
IgG3A, (■), whereas, the plots of k obs against HRG concentration for the 
interaction of HRG with IgG4 subclasses are shown in (D) (IgG4x • ,  IgG4>. 
■). Error bars represent ± SEM obtained from three separate experiments 
for each concentration of HRG.
0.08 0.08
0.06 -
0.0 4 -
0 .0 2 -
0.00
HRG concentration (nM)
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Therefore, to study the binding of HRG to different ^-containing IgG subclasses, 
each subclass IgGlX, IgG2>*, IgG3X and IgG4A, was immobilized onto a separate 
biosensor cuvette, and the binding of soluble HRG to each subclass was 
analysed using the biosensor. The binding of HRG to each different IgG 
subclass was carried out separately at a range of different concentrations of 
HRG (10 - 600 nM) in PBS-T-BSA. The binding of HRG to each IgGA, subclass 
was found to be saturable and dependent on HRG concentration (data not 
shown). The biosensor read out for each concentration of HRG was fitted to a 
single exponential to obtain the average k0bs for the interaction, and the average 
k0bs was then plotted against the HRG concentration.
To facilitate comparison of the results from IgG subclasses containing either k 
or X  light chains, the data for each ^-containing subclass was plotted on the 
same graph as the corresponding K-containing subclass; the results for IgGl and 
IgG2 are shown in Figure 4.2 (A,B), and those for IgG3 and IgG4 are shown in 
Figure 4.2 (C,D). From the line of best fit it was calculated (Table 4.1) that the 
on-rate for the interaction of HRG with IgGlX and IgG2A, was 0.44 ± 0.024 x 103 
M 'ls"l and 0.27 ± 0.011 x 103 M ' , respectively; these values are 5-10-fold 
slower than for the binding of HRG to IgGlK and IgG2K (Figure 4.2A and B). 
The off-rates and Kd were found to be 8.07 ± 1.36 x 10'3 s 'l  and 188.73 ± 43.26 
nM for HRG-IgGU, and 3.07 ± 0.20 x 10'3 s’1 and 111.93 ± 2.68 nM for HRG- 
IgG2>. interactions, respectively. Interestingly, the dissociation constants were 
20-60 fold higher than those observed for IgG I k and IgG2K (see Figure 4.2 and 
Table 4.1).
As shown in Figure 4.2 and Table 4.1, similar studies indicated that the binding 
of HRG to immobilized IgG3>. and IgG4>* is faster than the binding of HRG to 
IgGl^ and IgG2>.. The on-rate, off-rate and Kd for the HRG-IgG3X interaction 
were 1.16 ± 0.090 x 105 M 'V 1, 12.20 ± 2.10 xl0‘3 s '1 and 109.31 ± 28.95 nM, 
respectively (Figure 4.2C). The corresponding values for the HRG-IgG4^ 
interaction were 2.16 ± 0.030 x 103 M'^-s'l, 20.8 ± 0.77 x 10"3 s 'l and 96.10 ± 4.78 
nM, respectively (Figure 4.2D).
The data indicate that although the on-rate of these interactions are similar to 
those observed for the interaction of HRG with IgGlK and IgG2K, the off-rates 
are much higher, resulting in a higher Kd (approximately 20-fold higher) than 
for the interaction of HRG with IgGlK and IgG2K (see Table 4.1). The on-rates 
for the binding of HRG to IgG subclasses containing the X  light chain followed
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the relationship I g G A X  > IgG3^ » >  IgGlA, > IgG2>» (see Figure 4.2 and Table 
4.1).
4.2.3 Effect of Zn2+ on the binding of HRG to IgG subclasses
As described in Chapter 3, the presence of Zn2+ potentiates the binding of HRG 
to human IgG (from pooled human serum), but inhibits the binding of HRG to 
the complement component Clq (Gorgani et al., 1997 and Chapter 3). To 
determine the effect of Zn2+ on the binding of HRG to IgG subclasses, biosensor 
experiments were performed using separate cuvettes containing each 
immobilized IgG subclass (as described above). The binding of HRG to each 
different IgG subclass was carried out in PBS-BSA-T containing 20 |iM added 
Zn2+ (PBS-BSA-T-Zn). As shown in Figure 4.3 and Table 4.2, in the presence of 
Zn2+ the on-rate of the HRG-IgGlK interaction was increased from 1.73 ± 0.04 x 
105 to 6.21 ± 0.13 x 105 M"ls"l, whereas the off-rate was decreased from 0.53 ± 
0.02 x 10"3 to 0.37 ± 0.17 x 10"3 s'l. The dissociation constant was decreased ~ 5 
fold changing from 3.04 ± 0.13 to 0.6 ± 0.01 nM (see Table 4.2).
Experiments also were performed to examine the effect of Zn2+ on the binding 
of HRG to immobilized IgGlL In contrast to the HRG-IgGlK interaction, the 
presence of Zn2+ slightly decreased the on-rate of the HRG-IgGl>. interaction 
from 0.44 ± 0.024 x 105 to 0.34 ± 0.025 x 105 M" V 1, (without affecting the off- 
rate of this interaction). Thus the Ka was increased from 188.73 ± 43.26 to 266.33 
± 34.60 nM (see Figure 4.3A and Table 4.3). Similarly, the effect of Zn2+ on the 
binding of HRG to other IgG subclasses was studied as described above. The 
results show that although the presence of Zn2+ generally increases the affinity 
of the binding of HRG to all IgG subclasses possessing k light chains, it tends to 
decrease the affinity of the binding of HRG to IgG subclasses possessing X  light 
chains (see Table 4.2 and 4.3). However, except for IgGlK, the effects of Zn2+ on 
the HRG-IgG interaction were small and, in most cases, not statistically 
significant.
4.2.4 Binding of HRG to Bence Jones proteins
The above studies indicated that the type of constituent light chain may be a 
major factor determining the kinetics and behavior of the interaction between 
HRG and IgG subclasses containing different light chains. To further 
characterise the interaction of HRG with IgG, studies also were carried out 
using k and X  light chains of BJ proteins. For these studies, lyophilized BJ
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FIGURE 4.3 Effect of Zn^+ on the binding of HRG to IgGlK, IgGl^. and 
k and X Bence Jones proteins (BJk and BJ>0.
The binding of human HRG to immobilized IgGlK, IgGl^, BJk and BJX 
was examined in the presence and absence of Zn2+. All experiments were 
performed as described in the legend to Figure 4.1 with exception that for 
some experiments HRG was added in PBS-BSA-T buffer containing 20 
pM Zn2+ instead of PBS-BSA-T. For each concentration of HRG, the kQbs 
value for the binding of HRG was determined by fitting to a curve (as 
detailed in the text) and each kcbs value was plotted against HRG 
concentration for the HRG-IgGlK interaction in PBS-BSA-T buffer (#, 
control), and for the same interaction in PBS-BSA-T buffer containing 20 
pM Zn2+ (O) as shown in (A). Similarly, (A) shows the kGbs values plotted 
against the HRG concentration for the HRG-IgGlÄ» interaction in PBS- 
BSA-T (■, control) and in PBS-BSA-T containing 20 pM Zn2+ (□). The 
data for the effect of Zn2+ on the HRG-BJk and HRG-BJA, interactions are 
presented in (B) which shows plot kobs against HRG concentration for the 
HRG-BJk interaction in PBS-BSA-T (•, control), and for the same 
interaction in PBS-BSA-T buffer containing 20 pM Zn2+ (O). Also shown 
is the plot of k0bs against HRG concentration for the HRG-BJ>. interaction 
in PBS-BSA-T (■, control), and for the same interaction in PBS-BSA-T 
containing 20 pM Zn2+ (□). Error bars represent ± SEM obtained from 
three separate experiments for each concentration of HRG.
IgGlK + Zn2+
IgGlK (control)
IgGlA, (control)
BJk (control)
BJÄ, (control)
HRG concentration (nM)
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proteins were dissolved in PBS and purified by gel filtration on FPLC using a 
Superose 12 column. Two protein peaks were obtained with the BJk 
preparation and a single higher molecular weight peak, with BJ .^ 
Subsequently, SDS-PAGE analysis of the protein peaks showed that BJk 
consisted of a lower molecular weight monomeric and a higher molecular 
weight dimeric form, whereas only a single peak of the dimeric form of BJA. 
could be detected (see Figure 4.4). The dimeric forms of both BJk and BJÄ, were 
biotinylated as described in the Materials and Methods (Chapter 2), and then 
used in ELISA assays to assess their ability to bind immobilized HRG. 
Preliminary experiments indicated that both biotinylated k and X  BJ proteins 
bound to immobilized HRG in an ELISA assay, that the binding was 
concentration dependent, and that HRG bound more strongly to the k than to 
the X  light chains (data not shown).
The interaction of HRG with BJ proteins also was studied using the biosensor. 
For these studies each BJ protein was immobilized onto a separate biosensor 
cuvette to permit an analysis of the binding of HRG in solution. The biosensor 
data indicated that the binding of HRG to both BJk and BJA, proteins was 
saturable and dependent on the HRG concentration. Three sets of experiments 
were performed for the interaction of HRG with either k or X  BJ proteins. 
Before each repeat experiment, bound HRG was removed from the cuvette by 
acid wash or using Pierce gentle A g/Ab elution buffer. Similar to the analysis 
of other biosensor data described above, for each concentration of HRG, the 
observed rate constant (k0bs) was obtained by fitting the binding curve to a 
single exponential using the "FAST FIT program". As shown in Figure 4.3B 
(control experiments, in PBS-T-BSA buffer) the change of the k0bs for the 
interaction of HRG with both BJk and the BJA, was dependent on the HRG 
concentration. The results (Table 4.1) indicate that the on-rate, off-rate and the 
Kd for the binding of FIRG to immobilized BJk are 0.77 ± 0.042 x 10  ^M"^s‘ ,^ 2.56 
± 0.29 x 10'3 s"l and 35.21 ± 4.89 nM, respectively; and that the corresponding 
values for the binding of HRG to immobilized BJÄ* are 0.38 ± 0.022 x 10  ^M'l-s'l, 
2.87 ± 0.042 x 10"3 s 'l and 76.35 ± 5.60 nM, respectively. The results indicate, 
therefore, that the affinity for the binding of HRG to BJk is significantly higher 
than for the binding of HRG to BJL
To determine whether Zn2+ affects the ability of HRG to interact with the light 
chains (k and X ), biosensor experiments to study the binding of HRG to 
immobilized BJk and BJA also were carried out as described above, with the 
exception that the HRG was added to the cuvette in PBS-BSA-T-Zn. As shown
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FIGURE 4.4 SDS-PAGE analysis of the kappa and lambda Bence Jones 
proteins.
The k and X  BJ proteins (BJk and  BJX) obtained from Dr Bob Raison, 
University of Technology, Sydney, were each dissolved in PBS and then 
subjected to gel filtration by FPLC (using a Superose 12 column). The 
FPLC indicated that the BJk preparation contained two protein peaks (a 
lower molecular weight and a higher molecular weight peak), whereas, 
B ] X  preparations contained only a higher molecular weight protein peak. 
Aliquots of the protein peaks resolved by FPLC were analysed by SDS- 
PAGE (10% gel) under non-reducing conditions, and the proteins then 
stained w ith Coomassie Brilliant Blue. The analysis indicate that BJk 
consists of monomeric and dimeric forms, whereas, the BJ>. was only in 
dimeric form. Lane M (molecular weight markers) was analysed under 
reducing conditions; whereas lane A (dimeric BJX,), lane B (monomeric 
BJ>.) and lane C (dimeric BJk) were all analysed under non-reducing 
conditions.
M A B C
M W  (kDa)
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in Figure 4.3B and Table 4.2, in the presence of Zn2+ the on-rate of the HRG-BJk 
interaction was increased from 0.77 ± 0.042 x 103 to 1.30 ± 0.038 x 103 M"ls"l 
and the off-rate was decreased from 2.56 ± 0.29 x 10"3 to 1.35 ± 0.69 x 10“3 s"l. 
The Kd was significantly reduced from 35.21 ± 4.89 to 10.38 ± 1.21 nM.
Similarly, an investigation of the effect of Zn2+ on the HRG-BJA, interaction 
(Figure 4.3B and Table 4.3) indicated that the presence of Zn2+ decreases the on- 
rate of the interaction from 0.38 ± 0.022 x 103 to 0.32 ± 0.048 x 103 M"ls~l, and 
increases the off-rate of the interaction from 2.87 ± 0.042 x 10”3 to 4.48 ± 0.11 x 
10-3 s 'l. The Kd was thus significantly increased from 76.35 ± 5.60 to 139.75 ± 
4.60 nM. These results show that Zn2+ potentiates the binding of HRG to BJk, 
but inhibits the binding of HRG to BJ>* (Figure 4.3B and Tables 4.2 and 4.3).
4.2.5 Binding of HRG to IgM
The ability of HRG to interact with IgG subclasses (particularly IgGlK) with 
high affinity in a Zn2+-dependent manner prompted an examination of whether 
HRG also binds to other Igs such as IgM. For these studies, experiments were 
conducted to determine whether human b-IgM binds to immobilized HRG in 
an ELISA assay. A concentration dependent increase in the binding of b-IgM to 
the immobilized HRG was detected. In subsequent studies the IAsys biosensor 
was used to determine the kinetic constants for the interaction of HRG with 
immobilized IgM. The b-IgM (20 ng/cuvette) was immobilized onto the 
sensing surface of a biosensor cuvette by coupling it to immobilized STP, and 
the association and dissociation of HRG in PBS-BSA-T buffer was monitored 
using the biosensor. As shown in Figure 4.5A, the binding of HRG to 
immobilized IgM was saturable and was dependent on the concentration of 
added HRG in the range of 0.5 - 5 |iM. For each concentration of HRG the 
observed rate constant (k0bs), was determined from the biosensor data and the 
results are presented in Figure 4.5B. It was calculated (Table 4.3) that the on- 
rate and off-rate for the binding of HRG to IgM was 0.036 ± 0.005 x 103 M"^s"  ^
and 7.11 ± 0.102 x 10"3 s '1, respectively, and that the Kd for this interaction was 
1989.50 ± 50.50 nM.
Experiments also were carried out to assess the binding of HRG (1 pM) to 
immobilized IgM in the presence of different concentrations of Zn2+ (5-20 |iM). 
The results showed a decrease in the binding of HRG to IgM with increasing 
concentrations of Zn2+ (data not shown). Studies of the binding of HRG at 
different concentrations (0.5-5 fiM) to immobilized IgM in the presence of 20 pM
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FIGURE 4.5 Determination of the binding constant for the interaction 
of HRG with immobilized IgM.
The IAsys biosensor was used to study the binding of HRG to biotinylated 
IgM immobilized onto the biosensor cuvette by coupling to immobilized 
STP. After equilibrating the system in PBS-BSA-T to obtain a base line, 
HRG was added at the indicated concentration (in the same buffer) and 
the binding of HRG was monitored for 5 minutes. The cuvette was then 
washed three times w ith PBS-BSA-T and dissociation of the bound HRG 
was m onitored for 5 minutes. Overlay plots representing the binding of 
HRG at concentrations of 0.5 - 5 pM to the immobilized IgM are shown in 
(A). O verlay plots for sim ilar experim ents carried out in buffer 
containing 20 )iM Zn2+ (PBS-BSA-T-Zn) instead of PBS-BSA-T also were 
obtained (not shown). The value of k0bs for foe binding curve at each 
concentration of HRG in the presence or absence of added Zn2 r w as 
determ ined using the linearization m ethod (FAST FIT program). The 
results in (B) show plots of k0bs against HRG concentration for the HRG- 
IgM interaction in PBS-BSA-T buffer ( I ,  control) and for the same 
interaction in PBS-BSA-T containing 20 pM Zn2+ (□). The slope of the 
line of best fit for each set of data represents the kon and the y-intercept 
represents the k0ff for the interaction. Error bars represent ± SEM 
obtained from three separate experiments for each concentration of HRG.
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Zn2+ were carried out to determine the effect of Zn2+ on the on- and off-rates of 
the HRG-IgM interaction (see Figure 4.5B and Table 4.3). These experiments 
indicated that in the presence of Zn2+ the on-rate of the interaction is decreased 
from 0.036 ± 0.005 x 10  ^ to 0.016 ± 0.003 x 10  ^M"ls"l (~ 2.3 fold decrease), 
whereas the off-rate is increased from 7.11 ± 0.102 x 10"3 to 11.84 ± 1.60 x 10"3 s"
1 (~ 1.7 fold increase). The presence of Zn2+ therefore results in a 3.9 fold 
increase in the Ka for the HRG-IgM interaction, increasing it from 1989.50 ± 
50.50 to 7754.0 ± 1707.0 nM (see Figure 4.5B and Table 4.3).
4.2.6 Effect of HRG on the formation of insoluble ICs between
ovalbumin and k containing anti-ovalbumin IgG (IgGic)
The ability of HRG to interact with IgGlK and IgG2ic with high affinity raised 
the question of whether HRG can inhibit the formation of insoluble ICs 
containing IgGic. To explore this possibility experiments were aimed at 
examining the effect of HRG on the formation of insoluble ICs between 
ovalbumin and rat anti-ovalbumin IgGic in vitro. These experiments required 
the production and use of polyclonal anti-ovalbumin IgG which was obtained 
by immunizing rats with ovalbumin. The anti-ovalbumin IgG was purified 
from the sera of rats immunized with ovalbumin using Avid-Al beads (see 
Materials and Methods). The proportion of k and X light chain in this IgG 
preparation was assessed using two commercially available mAbs specific for 
rat k or X light chains in ELISA assays. These assays showed that the rat anti­
ovalbumin IgG used contained only the k light chain, since no X light chain 
could be detected using anti-A, mAb (data not shown). Only the preparations of 
IgGic for which the purity was > 95% (as assessed by SDS-PAGE analysis, see 
Figure 4.6) were used in studies of insoluble IC formation.
The formation and increase in the size of insoluble ICs can be monitored by 
measuring the absorbance of the suspension at 350 nm as a function of time, 
since the increase in absorbance can be correlated with the size of the particles 
in suspension (Gorgani et al., 1996). The effect of HRG on the formation of 
insoluble ICs was examined by the addition of ovalbumin to a solution of IgGic 
(that was either untreated or pre-treated with indicated concentrations of HRG) 
in PBS at 37°C. As shown in Figure 4.7A, the formation of insoluble ICs in a 
control experiment in which ovalbumin was added to a cuvette containing anti- 
ovalbumin IgGic (200 |ig/m l) in PBS buffer indicated that the maximum 
absorbance was increased from 0.00 initially to 0.07 after 30 minutes. In some 
experiments the anti-ovalbumin IgGic (200 |ig/m l) was pre-incubated with
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FIGURE 4.6 SDS-PAGE analysis of purified k containing rat IgG (IgGic).
IgGic was purified from ovalbumin immunized rat serum as described in 
Materials and Methods (Chapter 2) and then analysed by SDS-PAGE (10 % 
gel) under reducing and non-reducing conditions. After electrophoresis, 
the gel w as stained w ith  Coomassie Brilliant Blue. Lane M i, high 
m olecular w eight markers; lane B, IgGic (non-reduced); lane C, IgGic 
(reduced); lane M2, low molecular weight markers (reduced).
MW (kDa) 
200
A B
MW (kDa)
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FIGURE 4.7 The effect of HRG on the formation of insoluble ICs 
containing IgG with the K light chain (IgGK).
O valbum in was mixed w ith a solution of anti-ovalbum in IgGK in PBS 
(with or w ithout native HRG) at 37°C and the formation of insoluble ICs 
was m onitored by measuring the absorbance of the suspension at 350 nm 
using the light scattering technique. The formation of insoluble ICs was 
initiated either by addition of ovalbumin (6 pg /m l) to a solution of IgGK 
(200 jig /m l) in PBS (O, control), or by the addition of ovalbum in to a 
solution of IgGK which was pre-incubated for 5 minutes with 75 Jig/ml U), 
150 (ig/m l (■) or 300 p g /m l (•) of native hum an HRG. The results for the 
absorbance of the suspension as a function of time is shown in (A). For 
each inhibition assay the time to reach 50% maximum absorbance was 
plotted versus HRG concentration (•) and is shown in (B). The data 
shown is representative of four experiments performed in duplicate.
Control 
75 |ig/ml 
150 |LLg/ml 
300 Jig/ml
Time (min)
HRG concentration (jag/ml)
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HRG before the addition of ovalbumin to initiate the formation of insoluble ICs. 
Interestingly, the presence of HRG at a concentration between 75 and 300 
pg/m l decreased the initial rate of formation of rat IgGx containing insoluble 
ICs (see Figure 4.7A). A plot of the time to reach 50% maximum absorbance 
against the HRG concentration is shown in Figure 4.7B, where it can be seen 
that at the higher HRG concentrations there is a longer lag time to reach 50% 
maximum absorbance, consistent with an ability of HRG to inhibit insoluble IC 
formation.
Chapter 4
4.3 Discussion
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The present study shows that HRG binds to different IgG subclasses and that 
the affinity of the interaction depends on the subclass. Thus, HRG interacts 
with IgG I k and IgG2K with much faster on-rate (and higher affinities) than with 
IgG3K and IgG4K. In contrast, although the affinities of the binding of HRG to 
IgG subclasses possessing X  light chains were similar, HRG interacts much faster 
with IgG4>. and IgG3>. than with IgG2A, and IgGIL
Interestingly, the results show that the affinity for the binding of HRG to IgGlK 
is ~ 60-fold greater than the affinity for the binding of HRG to IgGlA, (see Figure 
4.2A and Table 4.1). Similarly the affinity of the binding of HRG to IgG2K is ~ 
20-fold greater than that for binding to IgG2A. (Figure 4.2B and Table 4.1). In 
contrast, the binding of HRG to IgG3 and IgG4 (when each contained the X  light 
chain instead of k) showed a different pattern. HRG bound to IgG3A, with ~ 1.3- 
fold higher affinity than it bound to IgG3K. Similarly, HRG bound to IgG4A, 
with ~ 2.8-fold greater affinity than it bound to IgG4K (see Figure 4.2 C,D and 
Table 4.1). These findings, therefore, suggest that human HRG interacts with all 
human IgG subclasses and the kinetics of binding are dependent not only on 
the particular subclass (or constituent heavy chain) of the IgG molecules, but 
also on the type of its constituent light chains. Thus, this study provides the 
first direct evidence for a functional role for the k and X  light chains of Igs.
Structure studies have shown that most of the amino acid sequence differences 
between the different IgG subclasses are located in the hinge region, which may 
give rise to differences in the length and flexibility of this region of the IgG 
molecule. This also may reflect possible differences in the function of the 
different IgG subclasses (see Figure 4.8). Although the amino acid sequence of 
the constant region of the k light chain is different to that of the constant region 
of the X  light chain, evidence suggests that the the constant region of the k and X  
light chains are homologous and structurally related. The structural homology 
between the variable regions of the k and X  light chains, however, is less 
pronounced (Abbas et al., 1991).
The finding that HRG binds with different affinities to different IgG subclasses 
depending upon whether K o r l  light chains are present raised the intriguing 
possibility that HRG binds directly to the Ko r l  light chains of IgG. An analysis 
of the binding of HRG to BJ proteins with k or X  light chains using the IAsys 
biosensor revealed that HRG binds to both BJk and BJA,, but that the on-rate for
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FIGURE 4.8 Three dimensional structure of IgG subclasses.
The illustrations, reproduced from (Abbas et ah, 1991), represent 
computer-generated space filling models of the different IgG subclasses. 
The models indicate that the structure of each subclass of IgG is distinct, 
and that the major differences in structure occurs in the IgG hinge region. 
This conclusion was also confirmed by comparing the amino acid 
sequence of each IgG subclass (Abbas et al., 1991).
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the HRG-BJk interaction is 2-fold faster than for the HRG-BJ^ interaction. This 
difference resulted in the affinity of the binding of HRG to immobilized BJk 
being ~2 fold higher than for the binding of HRG to immobilized BJA, (see Figure 
4.3B and Table 4.1). The higher affinity of the binding of HRG to BJk suggests 
that the k light chain in the IgGlK and IgG2K molecules is a factor in the high 
affinity interaction between HRG and these IgG subclasses. This conclusion 
may have implications for the function of HRG and IgG subclasses (see below).
Consistent with our recent finding that Zn2+ potentiates the binding of HRG to 
IgG (from pooled serum) (Gorgani et al., 1997), the present study shows that 
Zn2+ also potentiates binding of HRG to specific IgG subclasses. Physiological 
concentrations of Zn2+ had little if any effect on the binding of HRG to IgGlX, 
but substantially potentiated the binding of HRG to IgGlK. Figure 4.3A shows 
that the presence of Zn2+ led to an approximately 5-fold increase in the affinity 
of the binding of HRG to IgGlK and led to a slight decrease in the affinity of the 
binding of HRG to IgGl>* (~ 1.4 fold). Therefore, in the presence of Zn2+, HRG 
binds to IgGlK with ~ 440-fold higher affinity than to I g G l X ,  suggesting that 
Zn2+ strongly potentiates interaction of HRG with IgGl containing the k light 
chain, but only slightly effects the interaction of HRG with IgGl containing the X  
light chain.
Additional studies on the binding of HRG to IgG subclasses showed that 20 pM 
Zn2+ slightly increased the overall affinity of the binding of HRG to other IgG 
subclasses possessing k light chains, and generally slightly reduced the affinity 
of binding of HRG to IgG subclasses possessing X light chain, although in most 
cases these effects were not statistically significant. These results are consistent 
with each molecule of HRG interacting with both a heavy chain (presumably 
hinge region or CHI domain) and a light chain (constant region) of the IgG 
molecule. Compared to the interaction of HRG with other IgG subclasses, the 
HRG-IgGlK interaction was substantially affected by Zn2+ (5-fold increase), 
indicating that Zn2+ also potentiates the binding of HRG to the heavy chain of 
IgG (subclass difference). Similar results were obtained when different 
myeloma sources of the same IgG subclass and light chain isotype were used, 
indicating that the constant regions of heavy and light chains, rather than the 
variable regions, determine HRG binding.
Another interesting finding from the present work relates to the effect of Zn2+ on 
the binding of HRG to BJ proteins. As shown in Figure 4.3B and Table 4.2, the 
presence of Zn2+ led to a ~ 3.4-fold increase in the affinity of the binding of HRG
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to BJk and a ~ 1.8-fold decrease in the affinity of the binding of HRG to BJX. 
Therefore, in the presence of Zn2+ the affinity of binding of HRG to BJk is ~ 14- 
fold higher than the affinity of binding to BJL These findings are consistent 
with an effect of Zn2+ on the HRG-k light chain interaction, and further support 
the notion that HRG binds more strongly to the k light chain.
BJ proteins are of pathological importance in renal and systemic diseases 
associated with elevated levels of light chains in the blood circulation. The 
deposition of BJ proteins as tubular casts can cause diseases such as light chain 
deposition disease (LCDD). These light chain deposits, which may involve 
deposition of k light chain in ~ 80 % of LCDD patients (Preud'homme et al., 
1994), may result in the loss of renal function and account for morbidity and 
mortality in these patients (Solomon et al., 1991). Evidence suggests that the 
insolubilisation and aggregation of the unfolded protein may occur via 
intermolecular hydrophobic interactions (Bellotti et al., 1996). However, no 
protective mechanisms against insolubilisation and the deposition of these light 
chains in the kidney or blood vessel wall has yet been described. Clearly, in 
view of the present findings, it will be important, therefore, to establish whether 
HRG plays a role in inhibiting the insolubilisation and aggregation of BJ 
proteins, and hence whether HRG may play a role in protecting against their 
pathological effects.
Although it has been proposed that the IgG form of RF is the more pathogenic in 
relation to RA and SLE, the IgM form of RF is the most predominant form 
detected in the sera of these patients. It was important, therefore, to determine 
whether HRG also interacts with IgM. Kinetic studies of the binding of soluble 
HRG to immobilized IgM showed that HRG binds to IgM with a very low 
affinity. The affinity of the binding of HRG to IgM was ~ 650 fold lower than for 
the binding of HRG to IgGlK (see Figure 4.5 and Table 4.2 and 4.3). In addition, 
the presence of 20 pM Zn2+ reduced the affinity of the HRG-IgM interaction by ~ 
3.9 fold. Since the physiological concentration of HRG in plasma is ~ 2 gM, 
these observation suggest that the interaction of HRG with IgM may not be 
physiologically relevent. Importantly, the interaction of HRG with IgM and 
other immobilized ligands tested in the present work was inhibitable by pre­
incubation of the HRG with a 4-fold molar excess of the ligand in solution (not 
shown), indicating that the binding of HRG was specific for each immobilized 
ligand.
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It has been shown that of the total IgG in normal human plasma approximately 
65 % and 25 % is in the IgGl and IgG2 form, respectively (Abbas et al., 1991). 
HRG may be expected, therefore, to be more efficient at inhibiting the formation 
of insoluble ICs containing IgGlK or IgG2x than the formation of insoluble ICs 
containing other IgG subclasses. These observations suggest that the observed 
stronger interaction of HRG with IgG subclasses possessing k light chains may 
be important in regulating the formation and clearance of ICs under normal 
conditions. Thus, the ability of HRG to interact with IgGlK with a higher 
affinity than with IgGlA,, also may inhibit the insolubilisation of IgGlK 
containing ICs more efficiently than those containing IgGl^. On the other 
hand, the faster binding of HRG to IgG4>. may indicate a role for HRG in other 
pathological conditions where the IgG4A, concentration is high compared to 
IgG4K. The differential binding of HRG to IgG subclasses may also allow ICs 
containing different IgG subclasses to insolubilise at different rates. The 
insolubilisation rate of ICs may prevail the persistence of Ags in insoluble ICs. 
This finding may also imply that HRG can direct ICs to different Ag presenting 
cells (see Chapter 5). Thus, HRG may lead to the clearance of insoluble ICs by 
the RES, whereas, soluble ICs may be used as an Ag depot.
Functional studies using light scattering techniques revealed that HRG 
efficiently inhibits the formation of insoluble ICs between ovalbumin and the 
purified polyclonal rat anti-ovalbumin IgG containing > 98 % IgGK (see Figure 
4.7A). The inhibition was similar to that seen for the formation of insoluble ICs 
containing rabbit IgG (see Chapter 3) and was dependent on the HRG 
concentration. As shown in Figure 4.7B, the time to reach 50% maximum 
absorbance was positively correlated with the HRG concentration, indicating 
that human HRG can inhibit the formation of insoluble ICs containing IgGK. 
This finding is consistent with our previous observation on the effect of HRG on 
the formation of insoluble ICs containing ovalbumin and rabbit anti-ovalbumin 
IgG (Gorgani et al., 1997). The finding that human HRG inhibits the formation 
of insoluble ICs containing IgG from different species (eg. rabbits and rats) also 
further strengthens the notion that this function of HRG is physiologically 
relevant. These findings provided the basis for the studies in Chapter 6, the 
results of which also support the notion that HRG regulates the formation of 
insoluble ICs in humans, in vivo.
CHAPTER 5
HISTIDINE-RICH GLYCOPROTEIN 
REGULATES THE BINDING OF 
MONOMERIC IgG AND IMMUNE 
COMPLEXES TO MONOCYTES
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HRG is a relatively abundant plasma protein which I have shown previously 
inhibits the formation of insoluble ICs. In this study the ability of HRG to 
regulate the binding of monomeric IgG and ICs to monocytes was examined. 
Initial studies demonstrated that HRG interacts with FcyRI on the monocytic cell 
line THP1 and blocks the binding of monomeric IgG to these cells. However, 
despite totally blocking the binding of monomeric IgG to FcyRI, preincubation of 
THP1 cells with HRG had no effect on the binding of ICs to these cells. In 
contrast, depending on the HRG : IgG molar ratio, preincubation of monomeric 
IgG with HRG resulted in either enhanced or reduced IgG binding to FcyRI. 
Similarly, under certain highly defined conditions, incorporation of HRG in IgG 
containing ICs potentiated the binding of ICs to THP1 cells. The key conditions 
involved incorporating approximately equimolar concentrations of HRG and 
IgG in the ICs, the ICs being formed at a near equivalence Ag : Ab ratio and 
usually physiological concentration (20 pM) of Zn2+ being present. Based on 
these observations, a model is proposed where the IgG binding domain of HRG 
can interact with FcyRI on monocytes and block monomeric IgG binding. In 
contrast, if HRG interacts with monomeric IgG or IgG containing ICs the FcyRI 
binding site on HRG is masked and HRG enhances IC binding to monocytes, 
probably via its heparan sulfate binding domain.
Chapter 5
5.1 Introduction
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The recognition of a cognate Ag by polyclonal Ab molecules in the blood 
circulation may result in the formation of soluble and insoluble ICs. The 
mechanisms by which such ICs are cleared from the circulation and from tissues 
are not well understood, but the binding of ICs to FcRs (Anderson, 1989; Abrass, 
1984) and, following complement fixation, to CRs (Schifferli et al., 1988; Walport 
and Davies, 1996) on mononuclear phagocytic cells is known to be important. 
Three different types of FcRs specific for IgG, namely FcyRI, FcyRII and Fc^RIII 
(each similar in biological function but capable of binding distinct IgG 
subclasses) are known to exist in humans (Van de Winkel and Anderson, 1991; 
Van de Winkel and Capel, 1993). Evidence suggests that the binding of IgG to 
FcRs on mononuclear cells can trigger a number of responses; including the 
phagocytosis, uptake and clearance of ICs. Thus, under normal physiological 
conditions ICs may be recognized by the RES including the peripheral blood 
mononuclear phagocytic cells (Anderson and Abraham, 1980; Anderson, 1982; 
Anderson, 1989) and the resident mononuclear phagocytic cells in liver and/or 
spleen, and cleared from the circulation (Schifferli et al., 1988; Emlen et al., 1992; 
Davies et al., 1992). Similarly, in many tissues ICs may be cleared by tissue 
macrophages and monocytes which are recruited from the circulation as part of 
the inflammatory response (Walport and Davies, 1996).
A role for components of complement in the uptake and clearance of ICs by 
phagocytic cells was first suggested by the demonstration that receptors for 
complement C3 exist on monocytes (Huber et al., 1968), and that large ICs in 
blood can activate complement, and both generate and incorporate C3 
fragments such as C3b and C3d (Schifferli, 1987). Subsequent studies showed 
that blood borne C3b-opsonized ICs are usually recognized by C3b binding 
receptors (CR1) on erythrocytes (Veerhuis et al., 1986; Schifferli et al., 1988 and 
Davies et al., 1992). Erythrocytes, upon entering the liver and/or spleen 
(Comacoff et al., 1983, 1984) may release bound ICs (Yokoyama and Waxman, 
1994) which are then free to interact with resident tissue mononuclear cells such 
as macrophages and monocytes via receptors for Fc, C3b and C3d (Ehlenberger 
and Nussenzweig, 1977; Emlen et al., 1992; Taylor et al., 1997).
Studies described in Chapter 3 showed that HRG binds to IgG-containing 
soluble ICs, and inhibits the formation of insoluble ICs in vitro by promoting the 
maintenance of ICs in a soluble form (Gorgani et al., 1997). HRG also is reported 
to bind to macrophages and to regulate FcR expression and phagocytosis
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(Chang et al., 1992b, 1994). Since HRG incorporates in ICs and binds to 
macrophages, it was important to examine whether HRG plays any role in the 
uptake of ICs by mononuclear cells. The present work uses flow cytometry to 
study the effect of HRG on the binding of IgG and ICs to the human 
mononuclear phagocytic cell line THP1. The results show that HRG inhibits the 
binding of monomeric human or rabbit IgG to FcyRI on THP1 cells, but 
promotes the binding of ICs containing either human or rabbit IgG to these cells 
in a Zn2 +-dependent manner. The results indicate that HRG regulates the 
binding of both monomeric IgG and ICs to mononuclear cells, and provides 
strong evidence for the existence of a complement-independent mechanism for 
enhancing the clearance of ICs from the circulation.
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5.2 Results
5.2.1 Binding of human IgG and HRG to THP1 cells
It is well established that monomeric IgG binds to monocytes and macrophages 
through Fc^RI on the surface of these cells (Anderson and Abraham, 1980; 
Anderson, 1982; Woof et al., 1986; Ravetch and Kinet, 1991; Sylvestre and 
Ravetch, 1994; Abrass, 1991). Initial experiments were aimed at determining the 
level of binding of human IgG to the monocytic cell lines THP1 and U937 by 
flow cytometry. For these studies the cells were incubated with different 
concentrations of human b-IgG in PBS-BSA, washed and then stained with 
FITC-STP. The data in Figure 5.1 A show histograms representing the FITC- 
fluorescence of THP1 cells incubated either with 20 nM b-BSA (control), or with 
1.25, 5, and 20 nM b-IgG. A plot of the Median FIU of the cells against different 
b-IgG concentrations indicates that the level of b-IgG binding to the cells 
increases with increasing concentrations in the range of 40 pM - 40 nM (Figure 
5.IB). These results indicate that binding of the IgG to THP1 cells is saturable 
with near-maximal binding occurring at an IgG concentration of ~ 20 nM. A 
similar value for near-maximal binding also was obtained when U937 cells were 
used instead of THP1 cells (not shown).
Previous studies have shown that HRG binds to peritoneal macrophages and 
regulates phagocytosis of Ab opsonized erythrocytes (Chang et al., 1992b, 1994). 
To determine whether binding of HRG to THP1 and U937 cells also can be 
detected by flow cytometry, experiments were performed in which the cells 
were incubated in PBS-BSA in the presence of human b-PIRG, and the binding 
of the b-HRG to the cells assessed by fluorescence activated cell sorter (FACS) 
analysis after staining with FITC-STP. The fluorescence profiles for the binding 
of 5 pM b-BSA (control) and different concentrations of HRG (0.28, 1.12 and 4.5 
pM) to THP1 cells are shown in Figure 5.1C. Similar experiments were carried 
out at a number of different HRG concentrations in the range 9nM to 9 pM, at 
each concentration the Median FIU of the cells being plotted against the 
concentration of HRG (see Figure 5.ID). These data show that HRG binds to 
THP1 cells, and that the binding is concentration-dependent and saturable, with 
near-maximal binding occurring at ~ 4.5 pM HRG. A similar value for near- 
maximal binding also was obtained using U937 cells instead of THP1 cells (not 
shown).
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Additional experiments indicated that preincubation of b-HRG (2 pM) with 
heparin (50 pg/ml) inhibited the binding of b-HRG to THP1 cells by ~ 60 %, 
whereas, preincubation with 2 pM IgG inhibited binding by ~ 35 %. 
Furthermore, these inhibitory effects were additive: preincubation of HRG (2 
pM) with both heparin (50 pg/ml) and IgG (4 pM) inhibiting the binding of 
HRG to THP1 cells by 80 - 90 %. In addition, preincubation of THP1 cells with a 
saturating amount of a mouse mAb (MRII) specific for human FcyRI partially 
inhibited (35%) the subsequent binding of HRG to the cells, at a wide range of 
concentrations (9 nM - 9 pM), supporting the notion that HRG interacts with 
FcyRI (not shown). As previously shown for other cell types, the presence of 
physiological concentrations (20 pM) of Zn2+ potentiated the binding of HRG to 
THP1 cells by ~ 45% (data not shown), an effect which has been shown to be 
due to an enhancement of heparin-inhibitable binding (Olsen et al., 1996; Borza 
and Morgan 1998). These results are consistent with HRG interacting with at 
least two different binding sites on THP1 cells: sites inhibitable by heparin 
(presumably cell surface heparan sulfates), and sites inhibitable by IgG (the cell 
surface FcyRI).
5.2.2 Effect of pre-treating THP1 cells with HRG on IgG binding
The observation that HRG binds to FcyRI on THP1 cells raised the question of 
whether cell-bound HRG affects the ability of the cells to bind monomeric IgG. 
To explore this, THP1 cells were either preincubated in PBS-BSA or 
preincubated in PBS-BSA containing 2, 4 and 8 pM HRG, before washing and 
incubating the cells with different concentrations (40 pM - 40 nM) of b-IgG. 
After washing away unbound b-IgG the cells were then stained with FITC-STP 
and subjected to FACS analysis. The data in Figure 5.2A show the Median FIU 
of cells following incubation with different IgG concentrations and indicate that 
preincubation of THP1 cells with 2, 4 and 8 pM HRG strongly inhibited 
subsequent binding of IgG. In fact, at the higher concentrations of HRG (4 and 8 
pM) an almost total inhibition of IgG binding was observed. Similar 
experiments also were carried out in which the effect of preincubating THP1 
cells with different concentrations of HRG (9nM - 9 pM), on the subsequent 
binding of a constant concentration of IgG (20 nM) was examined (Figure 5.2B). 
The results indicate that the pre-treatment of THP1 cells with HRG inhibits the 
subsequent binding of IgG, and that this inhibition is dependent on the HRG 
concentration with HRG concentrations > 2 pM inhibiting monomeric IgG 
binding by 90% or more (Figure 5.2B).
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FIGURE 5.2 Effect of HRG on the binding of IgG to THP1 cells
THP1 cells were either left untreated (control) or preincubated for 1 hr on 
ice with different concentrations of HRG in PBS-BSA or in PBS-BSA-Zn. 
All cells were then washed to remove any unbound HRG, and incubated 
with the indicated concentration of biotinylated IgG (b-IgG). In some 
experiments, the b-IgG also was pre-incubated with the HRG (either in 
PBS-BSA or in PBS-BSA-Zn) before incubation with the THP1 cells. After 
the incubation(s) the cells were then washed, stained with FITC-STP, and 
subjected to FACS analysis. Each data point in (A) shows the median 
fluorescence due to the binding of a different concentration of b-IgG to 
control THP1 cells (•), and to THP1 cells pre-treated with 2 pM (O), 4 jiM 
(A) and 8 p,M (□) HRG. The binding of b-IgG (20 nM) to THP1 cells pre- 
treated with different concentrations of FIRG (9 nM -9 pM) in either PBS- 
BSA P )  or in PBS-BSA-Zn (□) is shown in (B). In some experiments, the 
b-IgG (20 nM) was pre-incubated with different concentration of HRG (9 
nM -9 JiM) and this mixture was then incubated with THP1 cells in either 
PBS-BSA (A) or in PBS-BSA-Zn (A) and the effect on b-IgG binding 
determined (B). Each point is a representative result obtained from 3 
separate experiments carried out at each concentration of IgG (A) and 
HRG (B).
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Recently we showed that the presence of Zn2+ modulates the binding of HRG to 
several different T cell lines (Olsen et al., 1996) and to IgG (Gorgani et al., 1997). 
To determine whether Zn2+ also can modulate the effect of HRG on the binding 
of IgG to THP1 cells, the experiments described above also were performed 
with 20 pM Zn2+ being included in the binding buffer (PBS-BSA-Zn). The 
results of these studies indicate that the presence of 20 jiM Zn2+ had no 
significant effect on the binding of IgG to THP1 cells (not shown), and had little 
or no modulatory action on the inhibitory effect of HRG on IgG binding (Figure 
5.2B, open squares).
5.2.3 Effect of preincubating IgG with HRG on IgG binding to THP1
cells
The ability of HRG to bind IgG (see Chapter 3), suggested that the pre­
incubation of IgG with HRG also might influence the binding of IgG to FcyRI on 
THP1 cells. To explore this possibility b-IgG was first pre-incubated with 
different concentrations of HRG in PBS-BSA, and the mixture was then 
incubated with THP1 cells. Binding of the IgG to the cells again was assessed 
by FACS analysis after staining the cells with FITC-STP. As shown by the plot 
of relative binding against HRG concentration (Figure 5.2B), the pre-incubation 
of b-IgG (20 nM) with relatively low concentrations ( ~ 20 - 280 nM) of HRG 
enhanced binding of the IgG to THP1 cells, whereas pre-incubation of the IgG 
with higher concentrations (1.12 - 9 pM) of HRG partially inhibited binding of 
the IgG to these cells (Figure 5.2B filled triangles). Parallel experiments also 
were carried out in which 20 nM b-IgG was pre-incubated with different 
concentrations of HRG in PBS-BSA-Zn before incubating the mixture with THP1 
cells. Overall Zn2+ had little or no effect on the ability of HRG to modulate the 
binding of IgG to THP1 cells, although there was a suggestion that at low 
concentrations of HRG (approximately 20 nM -1 pM) Zn2+ further potentiated 
the effect of HRG on IgG binding (see Figure 5.2B, open triangles). Control 
experiments indicated that Zn2+ alone had no effect on the binding of IgG to 
THP1 cells (not shown).
5.2.4 The binding of monomeric rabbit IgG and rabbit IgG
containing ICs to THP1 cells
To facilitate studies on the binding of ICs to THP1 cells, the binding of FITC 
labeled monomeric rabbit anti-ovalbumin IgG (FITC-IgG) to THP1 cells was first 
examined by FACS analysis. As reflected by the increase in FITC-fluorescence
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of the cells, the binding of the FITC-IgG to THP1 cells was dependent on the 
FITC-IgG concentration and was saturable, with near-maximal binding 
occurring at ~ 10 nM FITC-IgG (see Figure 5.3A). This result is similar to that 
observed for the binding of biotinylated human IgG to THP1 cells (see Figure 
5.IB). Also, an analysis of the precipitin curve (see Materials and Methods) for 
ICs containing ovalbumin and FITC-anti-ovalbumin IgG indicated that 
maximum precipitation (~ 38% of the total added FITC-IgG) occurs when the 
ratio of ovalbumin : FITC-IgG is between 0.02 and 0.04 (Figure 5.3C, open 
squares). This ratio is similar to that obtained from an analysis of ovalbumin 
and non-FITC labelled anti-ovalbumin IgG containing ICs (not shown). These 
results suggest that the labelling of the anti-ovalbumin IgG with FITC does not 
significantly affect the ability of the monomeric IgG to bind to THP1 cells or to 
form ICs with ovalbumin.
To study the binding of ICs to THP1 cells, different concentrations of ovalbumin 
were pre-incubated with FITC-IgG (0.5 pM) for 30 minutes in PBS-BSA buffer to 
allow the formation of ICs and then each mixture was incubated separately with 
THP1 cells. Ovalbumin/FITC-IgG ratios were used to yield ICs in Ab excess, 
Ag excess and at equivalence. After incubation with ICs, the cells for each IC 
preparation were washed to remove unbound fluorescent ICs and subjected to 
FACS analysis. The data in Figure 5.3B shows that relative to cells incubated 
with 0.5 pM of free FITC-IgG (control, blue line), THP1 cells incubated with ICs 
formed in Ag excess (Ag: Ab ratio = 0.06) showed a homogenous increase in 
FITC-fluorescence (Figure 5.3B, green line) as a consequence of the binding of 
FITC-containing ICs to the cells. When THP1 cells were exposed to ICs formed 
at an equivalence Ag : Ab ratio, the binding of fluorescent ICs became more 
heterogeneous and broadly distributed, with some cells showing a very high 
level of fluorescence while others showed a level of IC binding similar to that 
seen with ICs formed in Ag excess (Figure 5.3B, red line). This broad 
distribution in fluorescent IC binding to the cells most likely reflects great 
heterogeneity in the size of ICs formed at equivalence. Figure 5.3C clearly 
shows that ICs formed at equivalence or in slight Ab excess bind best to THP1 
cells whereas IC binding is less evident when the complexes are formed in Ag 
excess (Figures 5.3B and C). Interestingly, the inclusion of 20 pM Zn2+ in the 
reaction buffer (PBS-BSA-Zn) resulted in a decrease in the binding of ICs 
formed at near equivalence Ag : Ab ratios to THP1 cells (Figure 5.3C, triangles).
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FIGURE 5.3 The binding of ICs containing FITC-labelled rabbit IgG to 
THP1 cells
THP1 cells were incubated with different concentrations (0 - 36 nM) of 
FITC labelled rabbit anti-ovalbumin IgG (FITC-IgG) in PBS-BSA for 1 hr 
on ice. The cells were washed to remove unbound FITC-IgG and the 
FITC-fluorescence profile of the cells was determined by FACS analysis. 
The Median FIU obtained for the cells incubated at each different 
concentration of FITC-IgG was plotted against the concentration of FITC- 
IgG (A) as shown in (A). To examine the binding of ICs to THP1 cells, ICs 
were formed by incubating FITC-IgG (0.5 pM) with ovalbumin at different 
Ag : Ab ratios in the range of 0.005-0.06 in PBS-BSA buffer for 30 minutes 
on ice and the IC mixture was then incubated with THP1 cells. The cells 
were washed to remove unbound ICs, and the fluorescence profile of the 
cells was determined by FACS analysis. The histograms in (B) represent 
the FITC-fluorescence profiles due to the binding to THP1 cells of ICs 
formed either at Ag excess (0.06 Ag : Ab ratio) (green line) or at 
equivalence (0.03 Ag : Ab ratio) (red line) . The blue line represents the 
fluorescence profile of cells incubated with 0.5 |iM of free FITC-IgG (no 
ovalbumin added control). The binding to THP1 cells of fluorescent ICs 
formed at different Ag : Ab ratios is shown in (C), IC binding being 
assessed either in PBS-BSA (•) or in PBS-BSA containing 20 |iM Zn2+ (A). 
The precipitin curve analysis (□) for the formation of insoluble ICs 
containing FITC-IgG and ovalbumin also is shown in (C), with the 
percent precipitation of FITC-IgG at each Ag : Ab ratio being depicted. The 
data are representative results obtained from 3 separate experiments 
carried out at each concentration of FITC-IgG in (A) and at each Ag : Ab 
ratio (B and C).
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5.2.5 Effect of pretreating THP1 cells with HRG on IC binding
The binding of ICs containing ovalbumin and anti-ovalbumin FITC-IgG to 
THP1 cells pre-incubated with HRG also was investigated. For these 
experiments THP1 cells were either left untreated (control), or were pre- 
incubated with 2 jiM HRG in PBS-BSA buffer, and then washed to remove 
unbound HRG. Subsequently, the cells were incubated with preformed 
fluorescent ICs, the cells washed to remove unbound ICs and analysed for 
bound IC by fluorescence flow cytometry. From the fluorescence profiles of the 
cells, it can be seen that pre-treatment of the THP1 cells with HRG inhibited the 
binding of free FITC-IgG (Figure 5.4A), but had little if any affect on the binding 
of ICs formed at equivalence (Ag : Ab ratios of 0.03) or in Ag excess (Ag : Ab 
ratios of 0.06) (see Figures 5.4B and C).
To determine whether the presence of Zn2+ alters the effect of HRG in this 
system, parallel experiments also were carried out in which 20 pM Zn2+ was 
included in the incubations. It was found that HRG, when preincubated with 
cells, also had no effect on the binding of ICs to THP1 cells when Zn2+ was 
present.
5.2.6 Effect of pretreating ICs with HRG on the binding of ICs to
THP1 cells
The results presented in section 5.2.3 indicate that the binding of human IgG to 
THP1 cells is enhanced when monomeric human IgG is preincubated with HRG 
(HRG : IgG molar ratio ~ 1 - 10 :1) before incubating the HRG-IgG mixture with 
the cells. To determine whether HRG also enhances the binding of ICs to THP1 
cells, HRG was incorporated in ICs by preincubating anti-ovalbumin FITC-IgG 
with HRG prior to the addition of ovalbumin, and then incubating the resultant 
ICs with THP1 cells. The pre-incubation of FITC-IgG (0.5 pM) with HRG (0.25 
pM) had no effect on the binding of free FITC-IgG to the THP1 cells (Figure 
5.5A), but slightly potentiated the binding of ICs formed at Ag : Ab equivalence 
to THP1 cells (Figure 5.5B) an effect not seen with ICs formed in Ag excess 
(Figure 5.5C). Interestingly, the binding of ICs formed at Ag : Ab equivalence to 
THP1 cells was slightly potentiated by increasing concentrations of HRG up to 
an HRG : IgG molar ratio of ~ 0.5, but further increases in the concentration of 
HRG resulted in a less efficient enhancement of the binding of ICs (not shown).
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FIGURE 5.4 Effect of preincubating THP1 cells with HRG on IC 
binding
THP1 cells were preincubated with 2 pM HRG in either PBS-BSA or PBS- 
BSA-Zn on ice for 1 hr. After the preincubation the cells were washed to 
remove any unbound HRG, and then incubated with IC-mixture formed 
by preincubating anti-ovalbumin FITC-IgG (0.5 pM) for 30 minutes with 
no ovalbumin (A, D) or with ovalbumin at Ag : Ab ratios of 0.03 
(equivalence; B, E) and 0.06 (Ag excess; C, F). The fluorescence profiles for 
the binding of IgG and ICs to untreated THP1 cells (thin line) or THP1 
cells pre-treated with 2 pM HRG (thick line) in PBS-BSA are shown in A- 
C and in PBS-BSA-Zn are shown in D-F. Each histogram is a 
representative result obtained from three separate experiments.
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FIGURE 5.5 Effect of preincubating ICs with HRG on IC binding to 
THP1 cells
ICs were formed by preincubating anti-ovalbumin FITC-IgG (0.5 pM) with 
or without 0.25 pM HRG and with no ovalbumin (A, D) or with 
ovalbumin at Ag : Ab ratios of 0.03 (equivalence; B, E) and 0.06 (Ag excess; 
C, F). The FITC-fluorescence profiles of the THP1 cells which were 
incubated with IgG and ICs untreated with HRG (thin line), or pretreated 
with 0.25 pM HRG (thick line) in PBS-BSA are shown in (A-C) and in 
PBS-BSA-Zn are shown in (D-F). Each histogram is a representative 
result obtained from three separate experiments.
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Subsequent experiments also revealed that in the presence of 20 (J.M Zn2+, HRG 
(0.25 fiM) still had no effect on the binding of free FITC-IgG (0.5 pM) to THP1 
cells. However, Zn2+ did result in HRG substantially enhancing the binding of 
ICs formed at Ag : Ab equivalence to THP1 cells (compare Figures 5.3B and 
5.3E). In the presence of HRG a higher proportion of TF3P1 cells bound ICs and 
more cells bound high levels of ICs (Figure 5.3E). Furthermore, HRG also 
slightly enhanced the binding of ICs formed in Ag excess, an effect not seen in 
the absence of Zn2+ (compare Figures 5.5C and 5.5F). This potentiating effect of 
HRG, in the presence of Zn2+, on the binding of ICs to THP1 cells was seen 
when the HRG : IgG molar ratio approached 0.5 -1 (Figure 5.6A). However, at 
higher HRG : IgG molar ratios little potentiation occured and, in fact, HRG at a 
4-fold molar excess to IgG began to inhibit IC binding (Figure 5.6A). A similar 
effect of the HRG : IgG molar ratio on IC binding to THP1 cells was observed 
when ICs were formed over a wide range of Ag : Ab ratios (Figure 5.6B).
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FIGURE 5.6 Effect of the HRG : IgG molar ratio on the binding of ICs to 
THP1 cells
ICs were formed between ovalbumin and anti-ovalbumin FITC-IgG (0.5 
pM) at different Ag : Ab ratios and in the presence of different F1RG : 
FITC-IgG molar ratios. Binding of fluorescent ICs to THP1 cells was then 
determined by flow cytometry and the data in (A) presented as relative 
binding (RB) for each HRG : FITC-IgG molar ratio where RB = 
(fluorescence of THP1 cells incubated with HRG treated ICs - background 
THP1 cell fluorescence) /  (fluorescence of THP1 cells incubated with HRG 
untreated ICs - background THP1 cell fluorescence) x 100. In (A) the effect 
of the HRG : IgG molar ratio on the binding of ICs to THP1 cells formed at 
Ag : Ab ratios of 0.01 (O) , 0.02 (□) and 0.03 (A) is depicted. (B) shows 
overlay plots of the binding to THP1 cells of ICs containing 0.5 pM anti­
ovalbumin FITC-IgG formed at different Ag : Ab ratios when ICs were 
either untreated (• )  or were pretreated with 0.25 (A), 0.5 (□), 1 (A) and 2 
(■) pM HRG in PBS-BSA-Zn. Experiments in (B) were performed at six 
different concentrations of HRG in the range of 62.5 nM - 2 pM however, 
for clarity, only the data for four concentrations of HRG are plotted 
against the different Ag : Ab ratios. The data are representative results 
obtained from three separate experiments.
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This study shows that the presence of human HRG markedly affects the binding 
of free human IgG and IgG-containing ICs to the human monocytic cell lines 
THP1 and U937. Consistent with the known ability of monomeric IgG to bind 
to FcyRI on mononuclear cells (Anderson, 1982; Anderson and Abraham, 1980; 
Woof et al, 1984; Woof et al., 1986; Ravetch and Kinet, 1991), and the reported 
interaction of HRG with mouse peritoneal macrophages (Chang et al., 1992b, 
1994), our flow cytometric analyses indicate that biotinylated human IgG and 
biotinylated human HRG each binds to THP1 cells in a concentration- 
dependent manner with near-maximal binding of the IgG to THP1 cells 
occurring at a concentration of 20 nM IgG, a result similar to that reported in 
previous studies (Anderson and Abraham, 1980; Allen and Seed, 1989; 
Anderson, 1982; Fries et al., 1982; Kurlander and Batker, 1982; Cohen et al., 1983; 
Perussia et al., 1983). Near-maximal binding of b-HRG to THP1 cells occurred 
at ~ 4.5 pM HRG (Figure 5.1D). Of particular interest, however, was the finding 
that HRG binds to FcyRI on THP1 cells. Three lines of evidence support this 
conclusion. Firstly, the binding of HRG to THP1 cells is inhibited by 
monomeric human or rabbit IgG which are known to interact only with FcyRI. 
Secondly, the mAb MRII against FcyRI (anti-CD64) partially inhibited (35%) the 
binding of HRG to THP1 cells. Thirdly, IgG does not interfere with the binding 
of HRG to the T cell lines Jurkat and MT4 which lack FcyRI (not shown).
A major finding of the present study is that the pretreatment of THP1 cells with 
HRG significantly inhibits the binding of monomeric human IgG to THP1 cells, 
with the binding being inhibited about 90% by 2 pM HRG. It should be noted 
that this observation is physiologically relevant as the plasma concentration of 
human HRG is approximately 2 pM. Interestingly, the preincubation of THP1 
cells with HRG also inhibited the binding of both monomeric human IgGl and 
IgG3 to these cells (not shown), but the presence of Zn2+ did not alter the effect 
of HRG on the interaction of IgG with THP1 cells (Figure 5.2B). Since 
monomeric IgG binds to FcyRI on THP1 cells, these findings suggest that the 
pre-treatment of the THP1 cells with HRG can mask the IgG binding site on the 
FcyRI. Interestingly, the presence of ICs in the reaction vessel did not change 
the ability of HRG to inhibit the subsequent binding of monomeric IgG to THP1 
cells. However, the fact that pretreatment of the cells with HRG did not affect 
the binding of ICs to these cells (Figure 5.4) may be explained by the ability of 
the ICs to bind to low affinity FcRs (FcyRII, etc.) on THP1 cells which may not be 
blocked by HRG. Another possibility is the established ability of ICs to bind to
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cells multivalently and hence with higher avidity, a process which may displace 
HRG from FcyRI on the cell surface.
Despite the fact that preincubation of THP1 cells with HRG inhibited 
subsequent binding of monomeric IgG, the binding of IgG to THP1 cells was 
potentiated when IgG was preincubated with HRG (Figure 5.2B, triangles). 
Similarly, the preincubation of HRG with monomeric human IgGl and IgG3 
also resulted in an enhanced binding of these IgG subclasses to THP1 cells (not 
shown). The potentiating effect of HRG under these conditions is likely to be 
due to the binding of the IgG-HRG complexes to heparan sulfates on the cell 
surface via heparan sulfate binding sites on HRG (Brown and Parish, 1994; 
Olsen et al, 1996). The ability of Zn2+ to potentiate the augmenting effect of 
HRG on the binding of IgG to THP1 cells (Figure 5.2B, open triangles), 
presumably occurs through the ability of Zn2+ to increase both the binding of 
HRG to heparan sulfates on the cell surface (Olsen et al., 1996), and the binding 
of HRG to IgG molecules (Gorgani et al., 1997). The data presented also show 
that the molar ratio of HRG : IgG is an important factor in determining whether 
HRG potentiates (HRG : IgG molar ratio ~ 1 - 10 : 1) or inhibits (HRG : IgG 
molar ratio > 50 : 1) the binding of monomeric IgG to FcyRI. Thus, when the 
concentration of HRG exceeds that of IgG (~ 50-fold in this system), free HRG 
blocks the binding of IgG to FcyRI receptors even after pre-incubation of the 
HRG with IgG (Figure 5.2B, filled triangles). It would be expected that under 
physiological conditions plasma HRG (2 (iM) would not enhance the binding of 
monomeric plasma IgG (~ 60 pM) to monocytes since the molar ratio of HRG : 
IgG is ~ 1 : 30. This notion is also supported by the data shown in Figures 5.5A 
and D in which preincubation of HRG with FITC-IgG did not affect the binding 
of FITC-IgG to THP1 cells when the HRG : IgG molar ratio was — 1:2.
Another major finding from the present work is that HRG potentiates the 
binding of IgG-containing ICs to THP1 cells. ICs containing FITC-IgG and 
ovalbumin were used to study the effect of HRG on the interaction of ICs with 
THP1 cells. Turbidity assays and precipitin curve analysis of insoluble IC 
formed using FITC-IgG and ovalbumin indicated that insoluble IC formation in 
this system was indistinguishable from that which occurred when using 
unlabelled IgG and ovalbumin (not shown). Also, the binding of ICs to THP1 
cells showed a similar pattern to the precipitin curve analysis of FITC-IgG- 
ovalbumin IC (see Figure 5.3C, compare circles with squares). These findings 
indicate that the binding of ICs to FcyR is dependent on the Ag : Ab ratio of the 
IC-mixture, and that maximum binding of ICs occurs at or near the equivalence
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Ag : Ab ratio. This result is consistent with the observation that ICs formed at 
an equivalence Ag : Ab ratio are more effective in stimulating mouse peritoneal 
macrophages (Tripathi et al, 1993). Interestingly, at the equivalence Ag : Ab 
ratio the presence of Zn2+ slightly decreased the binding of ICs to THP1 cells 
(see Figure 5.3C, triangles), despite Zn2+ having no effect on the binding of free 
IgG to THP1 cells. Consistent with previous findings (Bauer et al., 1997), our 
studies show that Zn2+ increases IC insolubilisation and promotes the formation 
of larger insoluble ICs (not shown), but Zn2+ may also interfere with the ability 
of insoluble ICs to bind to FcyRs.
ICs containing FITC-IgG, ovalbumin and HRG were found to bind to THP1 cells 
at much higher levels than ICs containing only FITC-IgG and ovalbumin 
(Figure 5.5B) particularly when 20 pM Zn2+ was present. Although, the 
presence of 20 pM Zn2+ slightly inhibited the binding of ICs to THP1 cells 
(Figure 5.3C, triangles), in the presence of Zn2+ the binding of ICs to THP1 cells 
was markedly increased by HRG (Figure 5.5E). The results show, therefore, that 
HRG promotes the binding of ICs to THP1 cells in a Zn2+-dependent fashion. 
There are two possible explanations for this phenomenon. First, my previous 
studies showed that Zn2+ substantially enhances the binding of HRG to IgG 
(Gorgani et al., 1997). Second, Zn2+ enhances the binding of HRG to heparan 
sulfate structures on cell surfaces (Olsen et al., 1996). HRG appears to 
maximally potentiate the binding of ICs to monocytes when the ICs are formed 
with a HRG : IgG molar ratio of ~ 1. However, at higher HRG : IgG molar ratios 
little or no enhancement of the binding of ICs occurs and, in fact, when the HRG 
: IgG molar ratio was > 4 inhibition of IC binding was observed, presumably 
due to excess HRG masking FcRs on monocytes.
The findings presented herein, in conjunction with my previous findings that 
HRG binds to IgG and IgG-containing ICs and inhibits the formation of 
insoluble ICs in vitro (Gorgani et al., 1997), allows me to propose a model for the 
regulation of the binding and uptake of monomeric IgG and ICs by monocytes. 
As illustrated in Figure 5.7A HRG can inhibit the binding of monomeric IgG 
molecules to FcyRI on monocytes by interacting with FcyRI and masking their Fc 
binding site. The interaction of HRG, via its heparan sulfate binding domain, 
with heparan sulfate moieties on the monocyte surface would be expected to 
further stabilize the binding of HRG to FcyRI. In contrast, if HRG is 
incorporated into ICs it enhances IC binding to FcyRI, probably via its heparan 
sulfate-binding domain (Figures 5.7 B and C). This model implies that the 
region of HRG which binds IgG also binds to FcyRI, a distinct possibility since
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the extracellular portion of FcyRI contains three truncated Ig-like domains (Allen 
and Seed, 1989). The ability of monomeric IgG to inhibit the capacity of HRG to 
mask FcyRI on monocytes supports this view. Interestingly, the interaction of 
HRG with IgG in ICs does not interfere with the binding of IgG to FcyR. This is 
probably due to the fact that HRG binds to the F(ab')2 region of IgG (Chapter 3) 
and not the Fc region, as is the case with FcyR.
To date the uptake of ICs by the RES has been proposed to involve two 
mechanisms; namely, the binding of ICs to FcRs, and the binding of ICs 
complexed with complement C3b to CRs. The production of C3b or C3d 
requires activation of the complement cascade which results in the release of 
other factors (eg. anaphylatoxins, MAC) not yet shown to be involved in the 
clearance of ICs (Schifferli et al., 1988; Davies et al., 1992). The present study 
provides evidence for the existence of a third mechanism for enhancing the 
uptake of ICs by monocytes namely by incorporation of HRG in ICs. These 
results indicate that HRG can promote the binding of ICs to FcRs probably via 
binding to the GAG, heparan sulfate, and possibly to other HRG receptors on 
the cell surface. The binding or incorporation of HRG into ICs also may 
increase the avidity of these ICs for the cell surface due to the formation of 
multivalent interactions between ICs and heparan sulfate receptors for HRG 
(Figure 5.7C).
The finding that HRG inhibits the binding of monomeric IgG to monocytes has 
major implications for the role of HRG in regulating immune function. 
Importantly, the absence of HRG in plasma may lead to the complete saturation 
of FcyRI on mononuclear cells by monomeric IgG and hence to a serious 
disruption of the clearance of ICs by RES. Moreover, the fact that HRG does not 
usually affect the binding of ICs to these cells may ensure that FcRs are still 
available to bind ICs that may be present in the circulation. Whether HRG can 
interact with FcRs other than FcyRI and regulate their function needed to be 
investigated.
It has been shown that the deposition of CICs in various organs (eg. kidney, 
joint and the blood vessel wall) may lead to the development of pathological 
conditions such as GN, arthritis and vasculitis (Abrass, 1997; Haynes, 1992). It 
also has been shown that tissue IC deposits are in equilibrium with CICs 
(Abrass, 1997; Abrass, 1984) and that a reduction of ICs in the circulation is 
necessary for therapy in the majority of ICDs (Balint, 1996). Attenuation of the 
activation of complement also was proposed to be a clinical strategy to treat
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these pathological conditions (Savige et al., 1989; Waxman et al., 1984; Causer et 
al., 1995; Shumak and Rock, 1984). Since HRG is a plasma protein, it is possible 
that in the treatment of ICDs HRG may be used as a therapeutic agent for the 
prevention of the pathogenic effects of ICs in terms of keeping ICs in a soluble 
form and potentiating their uptake by the RES.
CHAPTER 6
HISTIDINE-RICH GLYCOPROTEIN BLOCKS 
THE BINDING OF RHEUMATOID FACTOR 
TO HUMAN IgG AND SOLUBILISES 
ALREADY FORMED INSOLUBLE IMMUNE
COMPLEXES
Chapter 6
Abstract
Abstract 104
In Chapters 3 and 4 it was demonstrated that HRG inhibits the formation of 
insoluble ICs. Results in this chapter demonstrate that HRG, when 
incorporated in ICs, blocks the binding of RF to ICs and inhibits the subsequent 
insolubilisation of ICs by RF. Biosensor studies also support this view and show 
that preincubation of HRG with immobilized IgG blocks the subsequent binding 
of RF to IgG. Based on these data it is proposed that HRG plays important roles 
in regulating IC size in humans and that HRG may control the production of RF 
and the pathogenic effects arising from excessive production of RF in vivo. This 
Chapter also provides evidence that HRG can solubilise already formed 
insoluble ICs, a phenomenon which may be important in preventing the 
pathogenic effects of insoluble ICs deposited in tissues.
Chapter 6
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RFs are aAbs produced against antigenic determinants on the Fc portion of IgG 
molecules and have been detected as IgM, IgA and IgG forms in plasma and 
tissues (Panush et al., 1971). Two general types of RFs have been described; 
namely, pathologic RFs associated with RA (Stewart et al., 1997), and natural 
RFs which exist in healthy individuals (Nasu et al., 1980). Both types of RF are 
known to bind to the Fc portion of IgG, but RFs within each type possess several 
characteristic differences such as use of different variable region sequences and 
different Ig isotypes (Stewart et al., 1997). It has also been proposed that 
pathologic RF can be tolerized at the B cell level by competition with natural RF 
(Stewart et al., 1997). Although pathologic RF may be present at low levels in 
normal human plasma, the concentration of this RF is often elevated in the 
plasma of patients suffering from infections such as infectious mononucleosis 
and hepatitis C virus infection (Johnson and Page Faulk, 1976; Capra et al., 1969; 
Carson et al., 1981). On the other hand, sustained levels of pathologic RF are 
observed in ICD such as RA, SLE and vasculitis (Johnson and Page Faulk, 1976; 
Carson et al., 1981; Schifferli, 1996; Walport and Davies, 1996).
It is reported that the plasma level of pathologic RF is correlated with the 
severity of RA (Nasu et al., 1980; Johnson and Page Faulk, 1976), and that 
patients with high RF titers have a higher frequency of rheumatoid nodules 
(Naranjo et al., 1997). The high level of pathologic RF production in these 
patients may be associated with the presence of high concentrations of 
pathogenic ICs. Although IgM-RF is increased in the plasma of patients with 
RA, IgG-RF is the predominant RF present in pathogenic ICs (both soluble and 
insoluble) found in the synovial fluid, with IgG4 containing k light chains being 
the major IgG-RF found in the synovium of RA patients (Zach et al., 1995; 
Corper et al., 1997), despite IgG4 representing only 4% of normal serum IgG. 
This predominance of IgG4 in synovial IC in RA patients may be due to IgG4 
interacting with the Fc region of most IgG subclasses via its constant rather than 
its variable region (Zach et al., 1995). Evidence also indicates that the 
widespread vascular complications associated with RA are mediated, at least in 
part, by CICs containing IgG and RF (Weisman and Zvaifler, 1975).
Although evidence suggests that natural RF may be involved in the clearance of 
ICs (Mellow and Clarkson, 1982; Heyman, 1990), the precise function of RFs and 
the mechanism(s) regulating their production in vivo is unclear. Kinetic studies 
have shown that IgM-RF or IgG-RF each interact with aggregated IgG or ICs
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with much greater affinity (~ 100 fold) than with monomeric IgG, indicating that 
RF binds specifically to ICs containing IgG (Johnson and Page Faulk, 1976; 
Normansell, 1971). Other studies have shown that human peripheral blood 
mononuclear leukocytes secrete RF when cultured in the presence of ICs, but not 
when cultured in the presence of monomeric IgG, suggesting that only ICs can 
appropriately display antigenic determinants which activate B cells to secrete RF 
(Pisko et al., 1982). In addition, only prolonged immunization of mice or rabbits 
with bacterial Ags has been shown to induce RF production (Coulie and Van 
Snick, 1983; Nemazee and Sato, 1983) indicating that the production of 
pathologic RF, particularly of the IgG4 subclass, may be a secondary phenomena 
that occurs during chronic infections. These studies collectively suggest that the 
production of RF may be a physiological phenomena which potentiates the 
clearance of primary ICs.
As reviewed in part I of Chapter 1 HRG has been shown to bind several plasma 
proteins. As outlined in Chapter 3, I identified two previously undescribed 
ligands for HRG, namely IgG and Clq. My additional studies indicated that 
HRG inhibits the formation of insoluble ICs by maintaining ICs in a soluble 
form, thus implicating HRG as a key endogenous regulator of the formation of 
ICs (Gorgani et al., 1997), In fact, recent studies indicate that when HRG is 
incorporated in ICs the ICs more effectively interact with macrophages (Chapter 
5 ).
In the present work, experiments were designed to mimic the interaction of RFs 
with ICs in order to examine the effect of HRG on the binding of RF to ICs. 
Additional experiments using an IAsys biosensor studied the binding of RF to 
immobilized human IgGlx and the effect of the plasma protein HRG on this 
interaction. The results show that physiological concentrations of HRG can 
block the formation of insoluble ICs between aggregated human IgG and RF in 
vitro. Furthermore, the biosensor studies show that the binding of RF to IgGlx is 
blocked by HRG, indicating that HRG masks the epitope on IgG recognized by 
RFs. The findings suggest a novel mechanism by which the binding of RF to 
autologous IgG containing ICs can be regulated. HRG also was found to 
solubilise already formed insoluble ICs.
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6.2.1 Formation of insoluble ICs containing human IgG and anti­
human IgG antibodies
Previous studies have shown that the formation of insoluble ICs between 
ovalbumin and anti-ovalbumin IgG can be studied in vitro by monitoring 
changes in insoluble IC particle size by absorbance measurements at 350 nm 
(Gorgani et al., 1997). In the present work insoluble ICs containing human IgG 
and anti-human IgG Abs were formed by: (1) the incubation of polyclonal rabbit 
anti-human IgG (specific for the Fc region of human IgG) with monomeric 
human IgG, (2) the incubation of human RF with heat-aggregated human IgG, 
and (3) the incubation of human RF with monomeric human IgG.
To study the formation of insoluble ICs between rabbit anti-human IgG and 
monomeric human IgG, rabbit anti-human IgG (69 pig/ml) was incubated in 
PBS-BSA buffer and the formation of insoluble ICs was initiated by the addition 
of human IgG at different concentrations in the range 3.9 - 15.5 jug/ml (Ag : Ab 
ratio between ~ 0.056 - 0.22). The increase in the average size of the insoluble 
ICs formed in the suspension was monitored by measuring the absorbance of 
the turbid suspension at 350 nm (as described in Materials and Methods) for 20 
minutes (see Figure 6.1A). These data show that incubation of rabbit anti­
human IgG with monomeric human IgG (from pooled human serum) resulted 
in the formation of insoluble ICs, with maximum formation occuring at an Ag : 
Ab ratio of 0.1. To determine whether the nature of the light chain of human 
IgG (k or X), as Ag, affects the formation of insoluble ICs, insoluble IC formation 
also was carried out by mixing human IgGlic or IgGl>. with rabbit anti-human 
IgG. These experiments indicated that the light chain of human IgG (as Ag) has 
no effect on the formation and precipitation of insoluble ICs (not shown).
The formation of insoluble ICs between human RF and aggregated human IgG 
was carried out by the addition of RF (8 IU/ml) to different concentrations of 
aggregated human IgG (20 -120 jug/ml) in PBS-BSA buffer. SDS-PAGE analysis 
showed that the majority of RF used in these studies is the IgG form (not 
shown). As can be seen from the data in Figure 6.IB the formation of insoluble 
ICs under these conditions was dependent on the concentration of aggregated 
IgG used in the incubations. Interestingly, these experiments also indicate that 
little if any insolubilisation and formation of insoluble ICs between RF and 
monomeric human IgG occurs in this system (see Figure 6.1C).
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FIGURE 6.1 Formation of insoluble ICs between human IgG and 
either rabbit anti-human IgG antibodies or RF as 
measured by light scattering at 350 nm.
The results in (A) show the increase in absorbance as a function of time 
due to form ation of insoluble ICs containing rabbit anti-human IgG (69 
^ig/ml) and hum an IgG at the Ag : Ab ratios of 0.056 (■), 0.1 (□). 0.17 (•) and 
0.22 (o). The results in (B) show the increase in absorbance as a function 
of tim e due to form ation of insoluble ICs containing hum an RF (8 
IU /m l) and aggregated hum an IgG at concentrations of 20 (■), 40 (□), 60 (•), 
80 (o) and 120 (a) jig /m l. The results in (C) show the increase in 
absorbance as a function of time due to form ation of insoluble ICs 
contain ing  hum an  RF (8 IU /m l) and m onom eric hum an IgG at 
concentrations of 60 (■), 120 (□) and 240 (•) M-g/ml. D ata are a 
representative of three separate experiments.
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6.2.2 HRG blocks the formation of insoluble ICs between human IgG
and anti-human IgG antibodies
The effect of HRG on the formation of insoluble ICs between rabbit anti-human 
IgG (69 (ig/ml) and monomeric human IgG (6.9 p.g/ml) was examined. As 
shown in Figure 6.2A pre-incubation of rabbit anti-human IgG and human IgG 
with HRG at 22.5, 45 and 60 fig/ml inhibited the formation of insoluble ICs in a 
dose-dependent manner. Whereas little effect was seen at 22.5 p-g/ml HRG, 
higher concentrations (75 and 150 ng/ml) of HRG resulted in an almost 
complete blockage of the formation of insoluble ICs in this system.
Interestingly, the pre-incubation of RF (8 IU/ml) with different concentrations 
of HRG in the range 37.5 - 300 ng/ml resulted in a HRG concentration- 
dependent inhibition of the formation of insoluble ICs between RF and 
aggregated human IgG (~ 120 (ig/ml) (see Figure 6.2B). However, HRG was 
much less effective at inhibiting insoluble IC formation in this system (compare 
Figures 6.2A and 6.2 B)
6.2.3 HRG blocks the formation of insoluble ICs between RF and
STP aggregated biotinylated human IgG
Since HRG was relatively ineffective at blocking the formation of insoluble ICs 
between human RF and heat aggregated human IgG, another form of 
aggregated human IgG was investigated as Ag. In particular, there was the 
concern that heat treatment may destroy HRG binding sites on human IgG. 
Thus it was considered essential to establish whether HRG could block the 
formation of insoluble ICs between RF and biotinylated human IgG aggregated 
with STP.
Experiments were conducted to determine the optimum ratio of STP : b-IgG to 
produce aggregated b-IgG which subsequently formed insoluble ICs upon 
addition of RF (8 IU/ml). The b-IgG (30 |ig/ml) was incubated with different 
concentrations of STP (6 - 60 ^ig/ml) in PBS-BSA-Zn in a quartz reaction cuvette 
for 20 minutes at 37 °C. It should be noted that crosslinking b-IgG with STP 
resulted in no significant detectable light scattering (Figure 6.3A). However, 
addition of RF to some solutions of STP-b-IgG resulted in an increase in 
absorbance due to light scattering by insoluble ICs. These experiments 
indicated that the formation of insoluble ICs with RF (8 IU/ml) and STP-b-IgG
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FIGURE 6.2 Effect of HRG on the formation of insoluble ICs between
human IgG and either rabbit anti-human IgG antibodies or 
human RF as measured by light scattering at 350 nm.
The results in (A) show the increase in absorbance as a function of time 
due to formation of insoluble ICs containing hum an IgG and rabbit anti­
hum an IgG (69 (ig/m l) at equivalence Ag : Ab ratio for a control 
experim ent (■, no additions), and for experiments carried out in the 
presence of 22.5 (□), 45 (•), 60 (o), 75 (a) and 150 (a) ng/m l of hum an HRG. 
The results in (B) show the increase in absorbance as a function of time 
due to formation of insoluble ICs containing RF (8 IU /m l) and aggregated 
hum an IgG (120 |ig/m l) for a control experiment (■, no additions), and for 
experiments carried out in the presence of 37.5 (□), 75 (•), 150 (o) and 300 (a) 
lig /m l of hum an HRG. Data are a representative of three separate 
experim ents.
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FIGURE 6.3 Effect of HRG on the formation of insoluble ICs between 
RF and streptavidin-aggregated biotinylated human IgG 
(b-IgG).
In (A) b-IgG (30 ^ig/ml) was incubated with STP at 6 (■), 12 (□), 18 (•), 24 (o) 
and 60 (A) ^ig/ml for 20 minutes, then RF (8 IU/ml) was added to the STP- 
b-IgG complexes and insoluble IC formation was monitored by light 
scattering. In (B) b-IgG was pre-incubated without (■) or with human 
HRG at 15 (□), 30 (•), 75 (o), and 150 (a) ng/ml for 20 minutes before 
aggregation by STP (18 fig/ml) for 20 minutes and the addition of RF (8 
IU) to form insoluble ICs. Data are a representative of three separate 
experiments.
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is optimal when 18 ng/ml of STP is used for b-IgG crosslinking (see Figure 
6.3A).
The effect of HRG on the formation of insoluble ICs between RF and STP-b-IgG 
was examined by preincubating b-IgG (30 pig/ml) with different concentrations 
of HRG (15 -150 p-g/ml) for 20 min before the addition of STP (18 p.g/ ml). After 
incubating this mixture for 20 min RF was added to initiate the formation of 
insoluble ICs. Gel filtration studies showed that the presence of HRG had no 
effect on the cross-linking of b-IgG by STP (data not shown). The data show 
that preincubation of IgG with HRG inhibits formation of insoluble ICs; 
inhibition was significant at 15 and 30 |ig/m l HRG, with over 60% to 80% 
blockage of insoluble IC formation occurring at 75 and 150 ng/ml HRG, 
respectively (see Figure 6.3B). This is similar to the inhibitory effect of HRG on 
the formation of insoluble IC between human IgG and rabbit anti-human IgG 
(compare Figure 6.2 A and Figure 6.3B).
6.2.4 Use of optical biosensor to examine the effect of HRG on RF-
IgG interaction
Since HRG is an IgG binding protein, it may mask epitopes on IgG recognized 
by RF. Thus an lAsys optical biosensor was used to study the binding of human 
RF to IgG and the effect of human HRG on this interaction. Human IgGlic was 
biotinylated and bound to STP immobilized onto the sensing surface of an 
IAsys dextran cuvette. The binding of RF to immobilized IgGlic, which may 
resemble immobilized ICs, was carried out by the addition of RF to the cuvette 
at different concentrations in the range 2-16 IU/ml in PBS-T-BSA. In this study, 
the concentration of RF is expressed as IU/ml (instead of molarity) since most 
published work and clinical evaluations of RF levels in patients use this unit. 
As shown in Figure 6.4A the binding of RF to IgGlic over a 10 minute period 
exhibited saturation kinetics with near maximal binding occurring at ~ 16 
IU/ml RF. The biosensor signal obtained was specific for the binding of RF to 
the immobilized IgGlic since pre-incubation of the RF (8 IU/ml) with 120 |ig/ml 
of soluble IgGlic inhibited the binding of RF to immobilized IgGlic (not shown). 
Analysis of the data using the "Fast Fit" program showed that the association 
curves could be fitted to a single exponential. For each binding curve the 
observed rate constant (kQbs) was determined and plotted against the titer of RF. 
As shown in Figure 6.4B the plot of kQbs against the RF concentration (IU/ml) 
approximated a straight line with the slope or on-rate being 14.92 ± 2.43 x 10~5
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FIGURE 6.4 Interaction of RF with immobilized human IgGlx
(A) H um an IgGlic immobilized onto the sensing surface of a biosensor 
cuvette was reacted w ith different concentrations (2-16 IU /m l) of RF, the 
overlay plots representing the binding of different RF concentrations to 
the immobilized IgGlx. (B) The value of k0bs for the binding curve for 
each RF titer was determined using the linearization m ethod (FAST FIT 
program) and each value plotted against the concentration of RF. The 
plot of k0bs against RF concentration (IU/ml) approximates a straight line 
(•); the slope represents k0n and the y-intercept represents k0ff for this 
interaction. (C) In some experiments before m onitoring the binding of 
RF (8 IU /m l) to IgGlK the cuvette was either untreated (no HRG) or pre­
treated (+HRG) with HRG (15 ^ig/ml) for 5 minutes. Each data point in
(B) represents the mean ± SEM obtained from three separate experiments. 
The data in (A) and (C) are a representative of three separate experiments.
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IU/mh1 s'1 and the y-intercept (off-rate) for the interaction being 1.69 ± 0.41xlO3
S’1.
The ability of HRG to bind with high affinity to immobilized IgG (Gorgani et al., 
1997) raised the question of whether HRG can mask epitopes on IgGlic 
recognized by RF. Consistent with the data shown in Figure 6.4A, the addition 
of 8 IU/ml RF in PBS-T-BSA to the cuvette increased the binding signal 
(association pattern, no HRG) (see Figure 6.4C). However, the addition of RF (8 
IU/ml) to a cuvette containing immobilized IgGlic that had been pretreated 
with 15 }ig/ml HRG did not result in an increased binding signal, suggesting 
that HRG blocks the binding of RF to immobilized IgGlic. Interestingly, under 
these conditions the addition of RF to the HRG pretreated-cuvette actually 
showed a dissociation response, rather than the expected association (see Figure 
6.4C, + HRG). This result may be due to RF displacing some of the HRG bound 
to the immobilized IgGlic. Collectively, since the immobilization of b-IgG on 
the sensing surface may have created cross-linked IgG molecules resembling 
ICs, the biosensor data further supports the view that HRG has the ability to 
block the binding of RF to IgG containing ICs.
6.2.5 HRG promotes solubilisation of already formed insoluble ICs
Activation of the classical and alternative complement pathways has been 
shown to inhibit the formation of insoluble ICs and to promote solubilisation of 
already formed insoluble ICs (Schifferli et al., 1986). Therefore, it was important 
to examine whether HRG, apart from inhibiting the formation of insoluble ICs 
and regulating the binding of RF to IgG containing ICs, could promote the 
solubilisation of already formed insoluble ICs. Different concentrations of 
ovalbumin were added to rabbit anti-ovalbumin IgG (900 jig/ml) to form 
insoluble ICs and the insoluble ICs either left untreated, or treated with HRG 
(150 |ig/ml), and then incubated overnight at 37°C. After incubation, the 
insoluble ICs that remained in each sample were collected by centrifugation, 
dissolved in NaOH, and the absorbance of each solution was measured to 
determine the percent IgG precipitation as described in the Materials and 
Methods. A comparison of the precipitin curves shown in Figure 6.5A indicates 
that there was slightly less precipitate in the incubations in which HRG was 
included with the preformed insoluble ICs at almost all Ag : Ab ratios.
To explore whether the effect of HRG on the solubilisation of already formed 
insoluble ICs is dependent on the concentration of HRG, insoluble ICs were
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FIGURE 6.5 Effect of HRG on solubilization of already formed 
insoluble ICs.
In (A) insoluble ICs w ere form ed betw een ovalbum in and an ti­
ovalbum in IgG (900 ^ig/ml) at different Ag : Ab ratios (0.005 - 0.05) and 
then HRG (150 (ig/ml) examined for its ability to solubilize the insoluble 
ICs overnight at 37°C (■), insoluble IC incubated in the absence of HRG 
indicated as (•) . Data expressed as percent precipitation of an ti­
ovalbum in IgG (for details see Materials and Methods). (B) shows the 
ability  of d ifferen t concentrations of HRG, follow ing incubation 
overnight at 37°C, to solubilize ovalbum in anti-ovalbum in IgG (900 
(ig/ml) insoluble IC formed at an equivalence (0.03) Ag : Ab ratio. Each 
data point in (B) represents mean ± SEM of three experiments. Asterisks 
indicate the ability of different concentrations of HRG to significantly 
solubilize the preform ed insoluble ICs when compared to insoluble IC 
formation in the absence of HRG, i.e. * P = 0.02, ** P = 0.006.
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formed at the equivalence Ag : Ab ratio (ie. 0.03), and then incubated with 
different concentrations (56 - 450 (ig/ml) of HRG. The results indicate that HRG 
promotes solubilisation of already formed insoluble ICs, and that the 
solubilisation is dependent on the concentration of HRG (Figure 6.5B), with very 
significant solubilisation (P < 0.006) occurring when the molar ratio of HRG : 
IgG is ~ 1, i.e., 450 M-g/ml HRG. There was also significant solubilisation of 
insoluble ICs at 225 |ig/ml (P=0.02) of HRG, with 150 (ig/ml of HRG producing 
almost significant solubilisation (P=0.07).
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Earlier studies described in Chapter 3 demonstrated that HRG can inhibit the 
formation of insoluble ICs. Thus it was important to examine whether HRG 
could also inhibit formation of insoluble ICs resulting from the interaction of 
RFs with human IgG. In order to answer this question three RF models were 
used. The first involved a xenogeneic system, namely the interaction of rabbit 
IgG specific for human IgG (Fc region-specific) with monomeric human IgG. 
The other two systems entailed the formation of insoluble ICs between human 
RF and human IgG aggregated either by heat or by crosslinking with STP 
following biotinylation. It was found that, in order for RF to form insoluble ICs, 
the human IgG needed to be aggregated (Figure 6.1C), indicating that RF may 
bind weakly to monomeric IgG, and that multimeric interactions may be 
required for the formation of insoluble ICs. These results are consistent with the 
reported binding affinity of RF for ICs being 100-fold higher than for monomeric 
IgG (Johnson and Page Faulk, 1976; Normansell, 1971).
A major finding from the present work is that in all three models of the RF- 
human IgG interaction, HRG blocks the formation of insoluble ICs. It is 
interesting to note that with the rabbit anti-human IgG-human IgG interaction 
and the RF-STP aggregated b-IgG interaction, HRG could completely inhibit 
insoluble IC formation (see Figures 6.2A and 6.3B). This effect was not observed 
in the rabbit anti-ovalbumin/ovalbumin interaction, where HRG only partially 
inhibited insoluble IC formation (Gorgani et al., 1997). This difference is 
probably due to HRG both directly blocking the epitopes on human IgG 
recognized by RF and inhibiting insolubilisation of RF-human IgG containing 
ICs. In the case of the ovalbumin/anti-ovalbumin system HRG would only 
inhibit IC insolubilisation. The failure of high concentrations (300 jig/ml) of 
HRG to completely block the formation of insoluble ICs between human RF and 
heat aggregated human IgG (see Figure 6.2B) may be an indication of inefficient 
binding of the HRG to aggregated human IgG and/or possible alterations in the 
HRG binding site upon exposure to heat.
To clarify whether HRG inhibits insoluble IC formation by masking epitopes on 
IgG recognized by RF, additional studies were performed using the optical 
biosensor. These studies indicated that human RF binds to immobilized human 
IgGlx (presumably mimicing immobilized ICs) in a concentration-dependent 
and saturable manner (Figure 6.4A). In contrast, preincubation of IgGlx 
immobilized on the biosensor surface with HRG resulted in a total inhibition of
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RF binding and, in fact, significant dissociation of bound HRG was observed. 
Dissociation of HRG presumably occurs through the competitive binding of the 
HRG to RF in solution. These biosensor data are consistent with HRG masking 
the site on IgGlx recognized by the RF used in this study.
Another major finding from the present work is that the presence of HRG can 
promote solubilisation of already formed insoluble ICs. HRG was much more 
effective at inhibiting the formation of insoluble ICs (50 % inhibition when the 
HRG : IgG molar ratio was ~ 1) (Gorgani et al., 1997), than at promoting 
solubilisation (15 % solubilisation occurred when the HRG was incubated with 
insoluble ICs at a HRG : IgG molar ratio of ~ 1) (see Figure 6.5B), although such 
a result is not that surprising when one considers the poor accessibility of HRG 
to insoluble ICs. Nevertheless, the ability of HRG to promote solubilisation of 
already formed insoluble ICs in vitro, suggests that HRG may play an important 
role in the solubilisation and subsequent clearance of insoluble ICs in vivo. 
Furthermore, I have recently shown that the incorporation of HRG into ICs 
leads to enhanced uptake of the ICs by monocytes (Chapter 5).
The present work represents the first report that a plasma protein (i.e. HRG) is 
able to block the binding of RF to ICs. The results also suggest that when it is 
incorporated in ICs, HRG may prevent ICs from being recognized by the 
surface Igs on RF-producing B cells. This proposal, therefore, suggests that 
HRG may directly interfere with the production of RFs in vivo. These findings 
have major implications for the role of HRG in regulating the production of RF 
and hence the regulation of the humoral immune response. Similarly, HRG- 
mediated solubilisation of already formed insoluble ICs has major implications 
for the prevention of the deposition of pathogenic insoluble ICs in tissues (eg. 
synovia, kidney, blood vessel wall) in some ICD. The presence of HRG, by 
promoting the solubilisation and enhanced clearance of the insoluble ICs 
trapped in tissues, may reduce the pathogenic effects and immunological 
consequences associated with the deposition of insoluble ICs.
CHAPTER 7
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7 General Discussion
As reviewed in part II of Chapter 1, the formation and clearance of ICs from the 
circulation has been shown to be largely regulated by plasma complement 
proteins, erythrocyte CR1 and FcRs on cells associated with the RES. This thesis 
describes an additional abundant plasma protein, HRG, which plays an 
important role in regulating the formation and clearance of ICs in a number of 
unique ways. Initially the results outlined in Chapter 3 indicated that HRG is 
the dominant endogenous inhibitor in normal plasma of insoluble IC formation 
and may represent a natural mechanism for controlling IC size. My additional 
studies have shown that HRG (i) binds differentially to Igs which carry k and X 
light chains, thus providing a possible functional role for the k and X light 
chains of Igs (Chapter 4), (ii) can solubilise already formed insoluble ICs 
(Chapter 6), and (iii) regulates the interaction of monomeric IgG and ICs with 
monocytes by inhibiting the binding of monomeric IgG to FcyRI and enhancing 
the binding of ICs to FcyR on monocytes (Chapter 5). These latter data imply 
that when HRG is bound to IgG in ICs it does not interfere with the Fc : FcR 
interaction but can augment macrophage binding of ICs, presumably via other 
domains of the HRG molecule which bind to cells. Furthermore, studies 
described in Chapter 6 showed that when HRG is incorporated in ICs it blocks 
the binding of RF to ICs. This finding suggests that the major IgG epitope 
recognised by RF could be masked in vivo by HRG. Additional studies in 
Chapter 3 showed, for the first time, that Clq is a high affinity HRG ligand. By 
binding to Clq, HRG may regulate activation of the classical complement 
cascade by either inhibiting or enhancing Cl binding to ICs and subsequent 
activation of the classical complement pathway.
My findings, together with the published report showing that the level of HRG 
is dramatically decreased in the plasma of patients with SLE (Castel et al., 1983), 
has led me to hypothesise that HRG represents a key molecule for controlling 
IC-mediated tissue injury observed in syndromes such as vasculitis, arthritis 
and GN by (a) regulating the size of ICs and keeping ICs in a soluble form, (b) 
enhancing the clearance of ICs from the circulation by the RES, (c) solubilizing 
already formed insoluble ICs, (d) preventing the action of RF and (e) inhibiting 
the inflammatory effects of complement. Thus, as discussed below in more 
detail, HRG appears to play an important role in preventing IC-mediated tissue 
injury.
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7.1 Regulation of the size of ICs by HRG
A key feature of IC formation is that, following the initial Ag-dependent cross- 
linking of Ag and Ab, there is an Ag-independent phase of IC insolubilisation 
(Gorgani et al., 1996). The Ag-independent insolubilisation of ICs (which leads 
to the formation of very large hydrophobic particles millimetres in size) appears 
to be an important phenomenon for efficient clearance of Ags from the 
circulation, as ICs need to be kept within a critical size range for optimal 
ingestion by macrophages.
Hitherto, the size of ICs has been shown to be regulated largely by complement 
proteins (as outlined in Chapter 1). Chapter 3 of this thesis presents evidence 
that the plasma protein HRG also regulates the size of ICs. This function of 
HRG may provide two important protective mechanisms. First, as a plasma 
protein which is always present in the circulation, unlike the complement 
components which require activation, HRG is immediately available to regulate 
the size of ICs. Second, by binding Clq HRG may inhibit activation of the 
classical complement pathway by ICs, thus decreasing the inflammatory effects 
of complement activation, although further work is required to validate this 
point.
7.2 Differential binding of HRG to IgG
An unexpected finding described in Chapter 4 of this thesis is that changing the 
light chain type of IgG from k to X has a profound effect on the kinetics of 
interaction of HRG with all IgG subclasses. Thus the ability of IgG molecules to 
interact with HRG and, consequently, form soluble versus insoluble ICs is 
dependent on the light chain isotype they express. In addition, HRG also 
interacts with the IgGlK and IgG2K subclasses faster and stronger, compared to 
other IgG subclasses, suggesting that HRG also would be more efficient in 
inhibiting the formation of insoluble ICs containing IgGlK and IgG2K, these two 
subclasses constituting the majority of IgG in human plasma. Since HRG is 
found to enhance the uptake of ICs by macrophages (Chapter 5), the differential 
binding of HRG to IgG subclasses may indicate that the light chain and the IgG 
isotype are important factors in determining whether ICs are eliminated by the 
RES or are deposited in tissues, possibly providing an Ag depot. Interestingly, 
HRG binds to human IgG4K with the lowest affinity. Thus, the finding that the 
majority of pathogenic ICs in some ICD (eg. ICs in the synovium of RA patients
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or anti-ANCA Abs in patients with vasculitis) contain Abs of the IgG4 subclass 
is particularly relevant.
7.3 Regulation by HRG of the uptake of ICs by monocytes
The uptake of ICs by the RES is the major process for elimination of foreign Ags 
and has been proposed to involve two mechanisms, namely the binding of ICs 
to FcRs, and the binding of ICs complexed with complement C3b to CRs. The 
study presented in Chapter 5 provides evidence for the existence of a third 
mechanism for enhancing the uptake of ICs by monocytes, namely by the 
incorporation of HRG in ICs. Furthermore, the finding that HRG inhibits the 
binding of monomeric IgG to monocytes has major implications for the role of 
HRG in regulating immune function. Depletion of HRG in plasma may lead to 
the complete saturation of FcyRI on mononuclear cells by monomeric IgG and 
hence to a serious disruption of the clearance of ICs by the RES. The deposition 
of CICs in various organs (eg. kidney, joint and the blood vessel wall) has been 
shown to lead to the development of pathological conditions such as GN, 
arthritis and vasculitis (Abrass, 1997; Haynes, 1992). The finding that tissue IC 
deposits are in equilibrium with CICs (Abrass, 1997; Abrass, 1984) and that a 
reduction of ICs in the circulation is necessary to limit IC-mediated tissue injury 
(Balint, 1996; Charlesworth et al., 1982) has led me to the hypothesise that, in 
vivo, HRG may play an important role in reducing the pathogenic effects of ICs 
by keeping ICs at an optimal size for ingestion and enhancing FcyR-mediated 
uptake of ICs by the RES.
7.4 Regulation of binding of RF to ICs by HRG
Chapter 6 of this thesis represents the first report that a plasma protein (i.e. 
HRG) is able to block the binding of RF to ICs. Based on these results it is 
tempting to hypothesise that when it is incorporated in ICs, HRG may prevent 
ICs from being recognized by the surface Igs on RF-producing B cells. This 
proposal, therefore, suggests that HRG may directly interfere with the 
production of RFs in vivo. These findings have major implications for the role of 
HRG in regulating the production of RF, an Ab type which may play an 
important immunoregulatory as well as a pathological role.
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7.5 Ability of HRG to solubilise already formed insoluble ICs
The ability of HRG to promote solubilisation of already formed insoluble ICs in 
vitro, suggests that HRG may play an important role in the solubilisation and 
subsequent clearance of insoluble ICs in vivo. Thus HRG, by promoting the 
solubilisation and clearance of insoluble ICs trapped in tissues, may reduce the 
pathogenic effects and immunological consequences associated with the 
deposition of insoluble ICs.
7.6 Summary
In summary, HRG appears to play a crucial role in IC clearance at several levels 
in both health and disease, its major function being to prevent IC-mediated 
tissue injury. First, HRG is the dominant plasma protein which prevents Ag- 
independent insolubilisation of ICs, thereby maintaining the complexes in a 
soluble form and optimal size that can be more readily cleared by the RES. 
Second, when associated with ICs, HRG enhances uptake of the complexes by 
macrophages. Third, when bound to IgG, HRG masks the IgG epitope 
recognised by RF, thereby limiting potential pathogenic effects of RF. Fourth, 
HRG binds Clq and may well inhibit complement activation by ICs and reduce 
the inflammatory action of complement, a point yet to be established. Fifth, 
HRG can promote the solubilisation of insoluble ICs, and this may reduce the 
pathogenic effects associated with insoluble ICs trapped in tissues.
8 FUTURE DIRECTIONS
With a multifunctional protein such as HRG there are many questions that need 
to be answered. An obvious one is the location of various ligand binding sites 
on the molecule. At the functional level, the role of HRG in coagulation and 
fibrinolysis clearly needs to be clarified. However, in this final discussion I will 
concentrate on the IC-associated functions of HRG, basing my discussion on a 
general hypothesis which is outlined below.
8.1 Hypothesis
Studies presented in this thesis have demonstrated that HRG, a relatively 
abundant plasma protein, may represent a key endogenous protein for 
controlling IC-mediated tissue injury by directing ICs for clearance by the RES. 
Thus, it is hypothesized that (i) since HRG binds ICs, plasma HRG (~ 2 nM)
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may be depleted in severe or chronic infections, (ii) a primary genetic defect in 
patients with syndromes such as vasculitis, arthritis and GN may be the 
presence of HRG molecules which have lost their ability to bind IgG and/or 
Clq, and (iii) a secondary defect in RA may be the presence of IgG glycoforms 
and/or the IgG4 subclass that are unable to interact efficiently with HRG. 
Under such circumstances defective clearance of ICs would be anticipated. 
Depending on their structure, ICs may accumulate in blood vessel walls, renal 
glomeruli or synovia.
Future studies can be designed to explore whether the ability of HRG to 
potentiate the clearance of ICs is physiologically relevant and whether there is a 
functional defect in the IgG and Clq binding capacity of HRG in patients with 
ICD. This can be done by (a) examining the effect of HRG on the clearance of 
ICs in vivo in mice, (b) examining the IC handling ability of plasma from SLE or 
RA patients, (c) clarifying whether HRG from humans with SLE or RA are 
defective in IgG and/or Clq binding, and (d) examining the ability of normal 
HRG to bind pathogenic IgG associated with RA. Future experiments are 
discussed below.
8.2 Assessment of the role of HRG in IC clearance in vivo.
The effect of HRG on the clearance of ICs in vivo can be examined in an IC 
model (eg. using C57BL/6J mice) (Gauthier et al., 1996; Haakenstad and 
Mannik, 1974). ICs can be injected into animals and plasma at different times 
after injection can be examined for HRG depletion using an ELISA assay. If 
HRG is depleted by IC administration this would be consistent with HRG 
interacting with ICs in vivo. Subsequent experiments, if HRG is depleted by IC 
injection, can assess in HRG depleted animals the clearance and tissue 
localization of radiolabelled ICs which have or have not been preincubated with 
HRG. If HRG is found to prevent the tissue localization and to potentiate the 
clearance of ICs, genetically engineered fragments of HRG can be examined for 
their activity in this system. These experiments will provide insights into the 
importance of HRG in regulating the handling of ICs in vivo. This information 
also will be useful in the future design of synthetic HRG molecules that may 
well have therapeutic potential.
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Effect of HRG on activation of the classical complement 
pathway by ICs
As detailed in Chapter 3, optical biosensor experiments clearly demonstrated 
that human HRG binds Clq with high affinity, with a Kd of ~ 10 nM. These 
findings suggest that HRG, by binding to Cl, the first complement component, 
may regulate activation of the classical complement pathway by ICs, a point 
which needs to be clarified, although there is one study which suggests that 
HRG can modulate the activation of complement by opsonised erythrocytes.
In an attempt to define whether HRG is a pro-inflammatory or anti­
inflammatory protein, experiments can be designed to test the effects of HRG 
on complement activation via the classical pathway. Briefly, ovalbumin can be 
immobilised on plastic, reacted with polyclonal rabbit anti-ovalbumin IgG and 
exposed at 37°C to HRG-depleted human plasma. The fixation of human Clq, 
C3 and C5 by the immobilised IgG could be monitored by ELISA using mAbs 
against these complement components. The effect of HRG on complement 
activation, when preincubated with the IgG or added back to the human 
plasma, can then be assessed. By examining Clq, C3 and C5 fixation the effect 
of HRG on early and late events in complement activation can be ascertained.
8.4 Effect of HRG on the uptake of ICs by other Fc receptors
Potentially one of the most important functions of HRG may be to direct CICs 
for clearance by the RES. As described in Chapter 5, HRG enhances uptake of 
ICs by monocytes. Although three lines of evidences indicate that HRG binds 
to FcyRI and inhibits monomeric IgG binding, it is important to examine the 
interaction of HRG with transfected cell lines expressing FcyRI (eg. Cos-7 cells 
expressing FcyRI). In addition, examination of the binding of HRG to FcyRII, 
FcyRIII and FcaRI transfected cells would establish whether HRG can interact 
with other FcR family members. If binding to other FcR is detected it would be 
important to examine the effect of HRG, when incorporated in ICs, on the 
ingestion of ICs by cells expressing these FcRs.
8.5 Assessment of IC handling ability of HRG in SLE/RA-plasma.
As outlined in Part II of Chapter 1, two major mechanisms have been shown to 
inhibit IC-mediated tissue injury, namely removal of ICs from the circulation 
and attenuation of complement activation. Since a series of findings outlined in
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this thesis indicate that HRG may play an important role in the clearance of ICs 
in healthy states, this raises the intriguing possibility that a genetic defect in 
HRG's function or the dramatic depletion of HRG in severe infections may lead, 
at least in part, to deranged clearance of ICs and initiation of diseases such as 
GN, vasculitis and arthritis.
At the genetic level, mutations in the HRG molecule which destroy its IgG or 
Clq binding site could represent a risk factor for the development of some ICD. 
A major aim of future work would be to test this hypothesis by examining the 
IgG and Clq binding activity of HRG from SLE and RA patients. Initially the 
effect of different HRG preparations on the formation of insoluble ICs can be 
examined using turbidity assays (Gorgani et al., 1997) and on the potentiation of 
uptake of fluoresceinated ICs by macrophages (Chapter 5). The interaction 
between IgG and different HRG preparations also can be assessed using both 
ELISA and biosensor techniques (Gorgani et al., 1997). Biosensor or ELISA 
binding studies can examine whether HRG from SLE/RA patients can bind 
Clq. The assays can be identical to those performed with IgG except that Clq, 
rather than IgG, can be immobilised on the biosensor surface/ELISA plates.
Although the HRG molecule itself may be defective in certain ICD, another 
possibility is that HRG is functionally active but the IgG molecules are defective 
in their binding to HRG. A degalactosyl form of IgG has been noted in RA 
patients which may be unable to interact with HRG. The circulating IgG 
molecules in patients with RA are glycosylated differently, the oligosaccharide 
sidechain on the Fc portion of IgG lacking terminal galactose (Parekh et al., 
1985). Recently it was demonstrated that this degalactosyl-IgG can directly 
activate the lectin complement cascade via interaction with the MBP in plasma 
(Malhotra et al., 1995). Based on this finding it has been proposed that IgG 
containing ICs in RA are highly pathogenic due to their dramatically increased 
ability to activate complement (Malhotra et al., 1995). Recent studies have also 
shown that the degalactosyl glycans expressed on IgG in RA, rather than being 
immobilised in a pocket on the surface of the Fc region of IgG, are highly 
mobile and extend away from the surface of the Fc region (Wormald et al., 
1997). Thus the degalactosyl glycan is much more likely to sterically interfere 
with the interaction of proteins, such as HRG, with IgG. If this was the case, 
HRG would be unable to prevent the formation of insoluble ICs and to 
potentiate the clearance of ICs containing agalactosyl IgG in RA patients, with a 
resultant accumulation of potentially pathogenic ICs in tissues. In order to 
investigate this possibility, normal IgG can be enzymatically degalactosylated
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with Streptococcus ß-galactosidase as previously described (Wormald et al., 
1997) and the binding of normal HRG to this degalactosyl-IgG assessed on the 
biosensor or by ELISA assays. Since only approximately 30-50% of circulating 
IgG from rheumatoid patients bears the abnormal glycoform, the binding of 
HRG to purified preparations of this abnormal IgG can be examined.
On the other hand, based on my recent findings that HRG binds to IgG4x with 
the lowest affinity (Chapter 4) and since IgG4x is the predominant Ig in 
pathogenic ICs in ICD (eg. RF in the synovium of patients with RA), this may 
indicate that HRG does not regulate the formation and clearance of ICs 
containing IgG4x. Interestingly, recent studies also have shown that Fc : Fc 
interactions can occur between purified IgG4x and other IgG subclasses in the 
absence of Ag, suggesting that this Ag-independent Fc : Fc interaction can result 
in the formation of pathogenic ICs in RA (Zach et al., 1995). Thus, HRG also can 
be examined for its ability to block the Ag-independent interaction of IgG4x 
with other subclasses of Igs.
9 FUTURE CLINICAL SIGNIFICANCE
In this final section I would like to speculate about the future clinical 
significance of HRG in ICDs. ICs are an important pathogenic feature of both 
SLE and RA. In RA the ICs appear in the joints whereas in SLE they are 
predominant in the circulation. Both RA and SLE have a strong genetic 
component but the genes which are associated with disease susceptibility have 
only been partially characterized. However, it would be anticipated that the 
genes which regulate the pathogenic effects of ICs would be important.
It is important to note, however, that HRG is likely to be more relevant in SLE 
than RA patients since ICs are believed to be fundamental in the pathogenesis 
of SLE, whereas their role in the joint manifestations associated with RA is 
much less clear. Thus, serum complement levels are invariably high in RA and 
low in active SLE. Similarly, ICGN is common in SLE, but does not occur in RA 
suggesting that the pathogenesis of SLE is different from that of RA. However, 
since my in vitro studies suggest that HRG blocks the binding of RF to ICs and 
may inhibit the pathogenic effects of RFs in vivo it also would be important to 
test the function of HRG in RA patients.
If it is established that HRG is able to potentiate the clearance of ICs in an in vivo 
model, this will provide the first physiologically relevant evidence that a
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plasma protein is able to control, by a complement-independent mechanism, 
the pathogenic effects of ICs and may have therapeutic potential in IC-mediated 
tissue injury. In addition, if it is found that HRG from autoimmune patients is 
defective in IgG or Clq binding, this has profound implications for both the 
diagnosis and treatment of these diseases. First, it implies that "mutated" HRG 
may be a risk factor for diseases such as SLE and thus patients at risk from the 
development of ICD could be readily identified. Second, since HRG is a plasma 
protein, replacement of the defective protein by administration of normal HRG 
may be a viable treatment strategy, analogous to Factor VIII replacement 
therapy in haemophiliacs or administration of insulin in patients with diabetes 
mellitus. At a more theoretical level, if HRG function is found to be seriously 
compromised in SLE or RA patients, it will strongly suggest that deranged 
clearance of ICs is an initiating factor in these autoimmune diseases. If the HRG 
is not defective but is depleted in patients with ICDs, administration of HRG 
will be a viable treatment strategy to direct pathogenic ICs for clearance by the 
RES and therefore limit IC-mediated tissue injury. If HRG is normal but the 
IgG associated with RA is defective in HRG binding, genetically engineered 
forms of HRG-like molecules with higher affinity for IgG isoform associated 
with RA may be a viable strategy to potentiate the clearance of ICs from the 
synovium.
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